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Abstract 
Small molecules containing fluorescent moieties can be used as a means of studying cell 
structure and function, as a result of the high sensitivity of fluorescence microscopy. This 
technique allows one to obtain specific information about the cell and has recently 
attracted considerable interest by many research groups. This work presents three projects 
in which the main aim was to develop multi-modal imaging agents. They will possess a 
fluorescent group and also another moiety which provides predictable biological 
properties. Our interest is centred on two types of fluorophore: Polycyclic Aromatic 
Hydrocarbons (PAHs) and 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY). 
The first project describes the synthesis of the phosphorus analogues of the biologically-
active indazole core which remain rare in the literature. The synthesis presented here 
shows the versatility of our approach and allows for substitution on the phenyl ring of the 
newly formed phosphindole core simply by changing the nitrile used. Position 3 of the 
phosphindoles was also varied to bear different aromatic groups; the chosen aromatic 
systems were phenyl, naphthyl and anthracyl. These were chosen in order to prepare a 
fluorescent and biologically-active core. 
Synthesis of novel phosphindoles containing a PAH 
 
In practice, the phosphindoles showed near zero quantum yields. Photoinduced Electron 
Transfer and Dexter Energy Transfer seem to be the plausible responsible phenomena 
behind this lack of fluorescence. Temperature was found to be a key variable in the 
synthesis of phosphindoles since a temperature below 110 °C in the last step led to the 
formation of two chlorothiophosphonates. One of these unexpected 
chlorothiophosphonates showed strong activity against Bacillus subtilis and 
Streptococcus pyogenes. 
The second project describes the synthesis of the pyrene-based ligand 109, which is 
significant as it was based on an air-stable alkyl primary phosphine. This remarkable 
stability is provided by the electronic properties that both the pyrene and the butyl linker 
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confer on the corresponding primary phosphine. The tridentate ligand 109 was obtained 
following a double hydrophosphination reaction of the primary phosphine, and 109 was 
subsequently used to create complexes with the transition metals from groups 9 and 10. 
These demonstrated demonstrated weak fluorescence despite the presence of a metallic 
core. The presence of the DNA intercalating pyrene unit and the presence of the square-
planar Pt centre in complex 116 required an assessment of the cytotoxicity of the complex. 
In assays, 116 was shown to exert similar cytotoxicity towards bone osteosarcoma (U2OS) 
and transformed mammary cancer (HMLER) cell lines as the anticancer drug Cisplatin. 
The advantage of complex 116 is that it contains an intercalating function, a potential 
cytotoxic platinum centre and moderate/mild loss of fluorescence for cell imaging by 
optical microscopy. 
 
Ligand 109 and its Pt(II) complex 116 
 
The final project discussed in this thesis is the synthesis of a phosphonium salt containing 
BODIPY as fluorophore, bound to a macrocycle which is able to undergo complexation 
reactions with d-block metals. This is another example of a molecule capable of multi-
modal functionality, since phosphonium salts have been shown to target mitochondria. 
Positively charged compounds freely diffuse across the negatively charged mitochondrial 
membrane and the BODIPY moiety allows for imaging of the compound’s fate by optical 
microscopy. Finally, the tetraamine macrocycle of the molecule allowed ligand 154 to be 
reacted with [Cu(OAc)2] which gave the fluorescent Cu(II) complex 155. This complex 
is interesting because it proves that coorduination to Cu is possible. The next step in this 
research would be to prepare the 64Cu analogue, which would be a candidate for Positron 
Emission Tomography (PET) imaging. In this manner, 64Cu-154 would be a fluorescent 
organelle-specific PET imaging agent. 
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Ligand 154 and the BODIPY-phosphonium Cu(II) complex 155 
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Abbreviations 
General: 
α Alpha particle 
CT Computed Tomography 
DLC Delocalised Lipophilic Cation 
DFT Density Functional Theory 
Eγ Gamma Energy  
γ Gamma-ray 
t1/2  Half-life 
HOMO Highest Occupied Molecular Orbital 
HPLC High-Performance Liquid Chromatography 
LUMO Lowest Unoccupied Molecular Orbital 
m Metastable 
MP Melting Point 
MIC Minimum Inhibitory Concentration 
MDR Multidrug Resistant 
MRI Nuclear Magnetic Resonance Imaging 
PeT Photoinduced Electron Transfer 
PAH Polycyclic Aromatic Hydrocarbon 
β+ Positron 
PET Positron Emission Tomography 
RC Radical cation 
rt Room Temperature 
SOMO Singly Occupied Molecular Orbital 
TLC Thin Layer Chromatography 
ΔΨm Transmembrane Potential 
 
Chemicals: 
Ac Acetate 
Ac2O Acetic anhydride 
MeCN Acetonitrile 
ATP Adenosine Triphosphate 
Bn Benzyl 
Triphos Bis(2-diphenylphosphinoethyl)phenylphosphine 
Ct Calf thymus 
DCM Dichloromethane 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
BODIPY 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene 
DIPEA N,N-Diisopropylethylamine 
CDCl3 Deuterated chloroform 
CD2Cl2 Deuterated dichloromethane 
cod 1,5-Cyclooctadiene 
Cp Cyclopentadienyl 
Cy Cyclohexyl 
DAPI 4',6-Diamidino-2-phenylindole 
DCM Dichloromethane 
DDQ 2,3-Dicyano-5,6-dichloroparabenzoquinone 
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DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
DPH 1,6-Diphenyl-1,3,5-hexatriene 
EtOH Ethanol 
Fc Fe(η5-C5H4)2 
NAD Nicotinamide Adenine Dinucleotide 
MeOH Methanol 
MeI Methyl Iodide 
KOH Potassium Hydroxide 
(R)-MOPH2 2-Phosphino-2’-methoxy-1,1’-binaphthyl 
Nbd Norbornadiene 
nb Norbornene 
PBr3 Phosphorus Tribromide 
pTol para-Tolyl 
Ph Phenyl 
Pr Propyl 
py Pyridine 
TFA Trifluoroacetic Acid 
THF Tetrahydrofuran 
TMSCl Trimethylsilyl Chloride 
 
Units: 
Å Angstroms 
cm Centimetres  
° Degrees 
°C Degrees Celsius  
Ci Curies 
eq Equivalents 
eV Electron Volts 
g Grams 
Hz Hertz 
H Hours 
IU International Unit 
Kcal/mol Kilocalorie per mole 
L Litre 
MeV Megaelectron Volts 
mg Milligrams 
mV Millivolt 
MHz Megahertz 
mmol Millimolar 
min Minutes 
M Molar 
nm Nanometres  
ns Nanoseconds 
ppm Parts per million 
s Seconds 
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NMR: 
br Broad 
δ Chemical Shift 
d Doublet 
I Nuclear Spin  
J Coupling Constant 
m Multiplet 
NMR Nuclear Magnetic Resonance 
NOE Nuclear Overhausser Effect 
q Quartet 
s Singlet 
t Triplet 
 
Infrared: 
br Broad 
FT-IR Fourier Transform Infrared Spectroscopy 
m Medium 
NIR Near-Infrared Region 
s Strong 
w Weak 
 
Mass spectrometry: 
AP Atmospheric Pressure 
CI Chemical Ionisation 
EI Electron Ionisation  
ESI Electrospray 
FAB Fast Atom Bombardment  
HRMS High Resolution Mass Spectrometry 
 
Photophysical Parameters: 
λabs Absorption Maxima 
λem Emission Maxima 
S1 First Excited State 
T1 First Triplet State 
S0 Ground State 
τ Lifetime 
ε Molar Absorption Coefficient  
ΦF Quantum Yield  
S2 Second Excited State 
Δνst Stokes Shift 
UV Ultra-Violet 
  
  
viii 
 
Table of Contents 
1 Contents 
1 Introduction ............................................................................................................. 13 
1.1 Overview .......................................................................................................... 13 
1.2 Targets .............................................................................................................. 13 
1.3 Primary phosphines .......................................................................................... 14 
1.3.1 Predicting the air-stability of primary phosphines .................................... 16 
1.4 Origins of luminescence ................................................................................... 20 
1.4.1 Fluorescence quenching ............................................................................ 22 
1.5 Fluorophores ..................................................................................................... 25 
1.5.1 Polycyclic Aromatic Hydrocarbons (PAH) .............................................. 25 
1.5.2 BODIPY .................................................................................................... 34 
1.5.3 DNA probes .............................................................................................. 38 
1.6 Radiotracers ...................................................................................................... 40 
1.6.1 Positron Emission Tomography (PET) ..................................................... 40 
1.6.2 Isotopes of copper: 64Cu and 62Cu ............................................................. 42 
2 Novel 1,2-azaphosphindoles ................................................................................... 44 
2.1 Introduction ...................................................................................................... 44 
2.1.1 1H-indazole ............................................................................................... 44 
2.1.2 Synthetic routes towards indazoles ........................................................... 46 
2.2 Synthetic target ................................................................................................. 48 
2.3 Synthesis of 1,2-azaphosphindoles ................................................................... 49 
2.4 Structural and electronic properties of 1,2-azaphosphindoles .......................... 54 
2.4.1 Phosphorus-selenium coupling constants in NMR ................................... 54 
2.4.2 X-ray crystallographic analysis and molecular structures ........................ 56 
2.4.3 Chlorothiophosphonates 80-81 ................................................................. 59 
  
ix 
 
2.4.4 An investigation to the torsional angles between the phosphindole backbone 
and the PAH ancillary group ................................................................................... 61 
2.5 Photophysical data ............................................................................................ 63 
2.5.1 UV-Vis absorption spectroscopy .............................................................. 63 
2.5.2 Quantum yield ........................................................................................... 66 
2.6 Biological activity of the novel synthesised phosphindazoles ......................... 73 
2.6.1 Determination of Minimum Inhibitory Concentration (MIC) .................. 74 
2.7 Summary .......................................................................................................... 77 
2.8 Experimental .................................................................................................... 79 
2.8.1 General Procedure ..................................................................................... 79 
2.8.2 Diphenyl zirconocene 67........................................................................... 79 
2.8.3 3-Anthracen-9-yl-(phenyl-azazirconacyclopentene) 69 ............................ 80 
2.8.4 3-Anthracen-9-yl-((1-tert-butyl)-1-sulfide-1H-1,2-azaphosphindole) 73 . 80 
2.8.5 3-Naphthalen-1-yl-(phenyl-azazirconacyclopentene) 70 .......................... 81 
2.8.6 3-Naphthalen-1-yl-((1-tert-butyl)-1-sulfide-1H-1,2-azaphosphindole) 74
 81 
2.8.7 3-Phenyl-(phenyl-azazirconacyclopentene) 71 ......................................... 82 
2.8.8 3-Phenyl-((1-tert-butyl)-1-sulfide-1H-1,2-azaphosphindole) 75 .............. 83 
2.8.9 Bis(p-tolyl) zirconocene 68 ....................................................................... 83 
2.8.10 3-Anthracen-9-yl-(p-tolyl-azazirconacyclopentene) 72a/b ...................... 84 
2.8.11 3-Anthracen-9-yl-((1-tert-butyl)-(4-methyl)-1-sulfide-1H-1,2-
azaphosphindole) / 3-Anthracen-9-yl-((1-tert-butyl)-(5-methyl)-1-sulfide-1H-1,2-
azaphosphindole) 76a/b .......................................................................................... 85 
2.8.12 3-Anthracen-9-yl-((1-tert-butyl)-1-selenide-1H-1,2-azaphosphindole) 77
 86 
2.8.13 3-Naphth-1-yl-((1-tert-butyl)-1-selenide-1H-1,2-azaphosphindole) 78 ... 86 
2.8.14 3-Phenyl-((1-tert-butyl)-1-selenide-1H-1,2-azaphosphindole) 79 ............ 87 
  
x 
 
2.8.15 N-(Anthracen-9-yl(phenyl)methylene)-P-(tert-butyl)phosphonamidothioic 
chloride 80 ............................................................................................................... 88 
2.8.16 N-(Anthracen-9-yl(p-tolyl)methylene)-P-(tert-butyl)phosphonamidothioic 
chloride / N-(anthracen-9-yl(m-tolyl)methylene)-P-(tert-
butyl)phosphonamidothioic chloride 81a/b ............................................................ 89 
3 Synthesis of a pyrene-based tridentate phosphine and its coordination chemistry in 
complexes of biological interest ..................................................................................... 90 
3.1 Primary phosphines on aromatic backbones .................................................... 90 
3.2 Quantum chemical calculations ........................................................................ 91 
3.3 Synthesis of air-stable phosphines pyrene-based 93-95 ................................... 93 
3.3.1 NMR experiments to determine the air stability of PyrCH2PH2 94 and 
Pyr(CH2)4PH2 95 ................................................................................................... 102 
3.4 Synthesis of the pyrene-based ligand 109 ...................................................... 104 
3.4.1 Group 10 coordination chemistry of tridentate phosphine 109 ............... 106 
3.4.2 Group 9 coordination chemistry of tridentate phosphine 109 ................. 116 
3.5 Photophysical data .......................................................................................... 120 
3.6 Cell studies with [PtCl(109)][Cl] 116 ............................................................ 125 
3.7 Summary ........................................................................................................ 130 
3.8 Experimental .................................................................................................. 131 
3.8.1 General Procedure ................................................................................... 131 
3.8.2 Diethyl 1-pyrenylmethylene phosphonate 100 ....................................... 132 
3.8.3 1-Pyrenylmethylene phosphine 94 .......................................................... 132 
3.8.4 1-(4-Bromobutyl)-pyrene 102 ................................................................. 133 
3.8.5 Diethyl (4-(pyren-1-yl)butyl)phosphonate 103 ....................................... 134 
3.8.6 4-(Pyren-1-yl)butylphosphine 95 ............................................................ 134 
3.8.7 4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine 109 .. 135 
3.8.8 [PtCl(109)][Cl] 116 ................................................................................. 136 
3.8.9 [PdCl(109)][Cl] 120 ................................................................................ 136 
  
xi 
 
3.8.10 [NiCl2(109)] 121 ..................................................................................... 137 
3.8.11 [RhCl(109)] 125 ...................................................................................... 137 
3.8.12 [IrCl(109)] 129 ........................................................................................ 138 
3.8.13 Absorption and Emission Spectroscopy ................................................. 138 
3.8.14 Quantum Yield Method........................................................................... 138 
3.8.15 UV/Vis titration ....................................................................................... 139 
3.8.16 Ethidium bromide displacement assay .................................................... 139 
3.8.17 ct-DNA precipitation assay ..................................................................... 140 
3.8.18 Cell lines and cell culture conditions ...................................................... 140 
3.8.19 Cytotoxicity MTT assay .......................................................................... 140 
4 Synthesis of a fluorescent chelator ligand derived from 8-((4-
dicyclohexylphosphino)phenyl)-4,4-diphenyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene .................................................................................................. 142 
4.1 Mitochondria .................................................................................................. 142 
4.1.1 Mitochondria as a drug target ................................................................. 143 
4.2 Phosphonium cations capable of binding Cu(II) ............................................ 145 
4.3 BODIPY-derived ligand target ....................................................................... 148 
4.4 Synthesis of BODIPY-Cu(II) complex derived from a phosphonium cation 151 
4.5 Photophysical Data ......................................................................................... 161 
4.6 Summary ........................................................................................................ 165 
4.7 Experimental .................................................................................................. 166 
4.7.1 General procedure ................................................................................... 166 
4.7.2 8-(4-Bromophenyl)-4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 149 ................................................................................... 166 
4.7.3 8-(4-Bromophenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 150 ................................................................................... 167 
4.7.4 8-((4-Dicyclohexylphosphino)phenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-
2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 151 .................................................... 168 
  
xii 
 
4.7.5 9-(4-(Bromomethyl)benzyl)-8-((4-dicyclohexyl)phenyl)-4,4-dimethyl-
1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene phosphonium 
bromide 152 .......................................................................................................... 169 
4.7.6 9-(4-((4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)methyl)benzyl)-8-((4-dicyclohexyl)phenyl)-4,4-
dimethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 
phosphonium bromide 154 .................................................................................... 170 
4.7.7 [CuBr(154)][Br]2 155 .............................................................................. 171 
5 Future Work .......................................................................................................... 172 
 
 
 
  
13 
 
1 Introduction 
1.1 Overview 
The use of fluorescent molecules in biological applications is a useful tool in 
contemporary research, and their ever increasing due to their flexibility, sensitivity and  
ability to provide data. Fluorescence methods are predominantly valuable due to the 
widespread use of confocal,1, 2 two-photon3 and epifluorescence light microscopy.4 
Furthermore, the development of new functional fluorescent compounds that can monitor 
intra- and extracellular events with high chemoselectivity is a promising avenue. The use 
of confocal5 and multiphoton microscopy6 provides optical sectioning (the process by 
which a suitable microscope can record clear images of cells in a thick sample). This type 
of probe uses fluorescent compounds that improve image quality. This thesis describes 
the results obtained during the development of three projects where the main objective 
was to prepare multi-modality organophosphorus fluorescent probes for use in the fields 
of bioscience. During the development of this work, the synthesis of novel primary 
phosphines was required in order to synthesise some of the essential phosphorus-
containing compounds. 
1.2 Targets 
This thesis explores three main topics: 
1) 1,2-Azaphosphindoles containing aromatic moieties and the biological 
characterization of 73, 76 and 80: 
This type of compound is interesting as N-heterocycles are a common scaffold in 
medicine, while the analogous P-heterocycles have been much less studied. The Higham 
research group is interested in the use of primary phosphines as precursors − can be used 
to prepare organodichlorophosphines RPCl2 which in turn can be used to prepare the P−N 
heterocycles found in azaphosphindoles. Thus, the primary phosphine route offers a new 
avenue for the preparation of bioactive molecules. 
2) Synthesis of a fluorescent pyrene-based tridentate phosphine with DNA 
intercalating properties: 
The Higham research group has reported a BODIPY-based tridentate phosphine that was 
synthesised from the primary phosphine BODIPY-PH2. The tridentate BODIPY ligand 
proved to be a potential Single-Photon Emission Computed Tomography (SPECT) 
imaging agent. In this section, a fundamental question will be addressed − is 
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pyrene(CH2)4PH2 air-stable? If so, this would be the first example of an alkyl primary 
phosphine which is air-stable, by virtue of remote π-conjugation. The synthesis of such a 
primary phosphine would also allow for the synthesis of a tridentate derivative capable 
of binding or intercalating with DNA. The pyrene-based ligand and its resulting 
complexes then had their biological and photophysical properties assessed, with 
promising results. 
3) 64Cu-BODIPY complex – synthesis of a mitochondria specific fluorescent PET 
imaging agent: 
There have been previous reports of non-fluorescent phosphonium salt chelators of 64Cu 
that are interesting in PET applications because they are selective for mitochondria. The 
nature of the mitochondrial membrane means that it possesses an electric potential, Δψm; 
it has been shown that this potential is higher in cancer cells than in healthy cells. This 
enhanced gradient in cancer cells offers an opportunity to target tumours. 64Cu is an 
isotope used in radiotracing agents, therefore, phosphonium-64Cu compounds have been 
developed as radiotracer that can selectively accumulate in the mitochondria of cancerous 
cells. In this section, the development of a BODIPY-phosphonium-64Cu complex which 
could take advantage of the selective absorption of a phosphonium ion is described. This 
complex will allow for both PET and fluorescent cell imaging studies to be undertaken. 
The features that make these molecules significant are discussed in the following sections. 
1.3 Primary phosphines 
Primary phosphines are the keystone of the development of the proposed compounds. 
Primary phosphines7-24 have two hydrogens bonded to a phosphorus that is connected to 
an alkyl or aryl group. They are known for being unstable in air, as a number of examples 
decompose into an often random mixture of oxides and acids, due to the high enthalpy of 
formation of the P=O bond (bond dissociation energy of 128 to 139 kcal/mol). Some of 
these compounds can spontaneously ignite in the presence of air due to this high 
reactivity, making their handling a complicated procedure.25, 26 Common protocols for the 
synthesis of primary phosphines include the reduction of dichloroalkyl/arylphosphines, 
phosphonic acid, phosphonate or their derivatives. The usual reducing reagent used is 
lithium aluminium hydride (Figure 1.1).8, 27 The reduction of phosphonates often proceeds 
in a quantitative fashion using an equivalent of chlorotrimethylsilane as a co-reductant. 
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Figure 1.1 Synthesis of primary phosphines starting from different phosphorus-containing 
compounds. The reducing agent is LiAlH4 in this approach. 
 
Despite their air-sensitivity, primary phosphines are flexible starting materials due to the 
possibility of functionalising the two phosphorus-hydrogen bonds. However, the low air 
stability of many such compounds has made them an under-utilised class of ligand. This 
kind of useful functional group can be employed in many different reactions including 
hydrophosphination additions to unsaturated hydrocarbon chains. They can also be 
substituted with acid halides and undergo alkylation and amination. These different 
reactions opened the door to new compounds, which have been shown to have 
applications in numerous fields, including medicinal chemistry,15, 28, 29 polymer science,30 
carbohydrate modification,31 macrocyclic research32 and catalysis.33 
 
Figure 1.2 Functionalisation of primary phosphines showing a broad variety of reactions that 
primary phosphines can undergo. 
 
Due to their reactive nature towards oxygen from the atmosphere, it is important to take 
into account the air stability of compounds containing this functional group. 
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1.3.1 Predicting the air-stability of primary phosphines 
There are however a small number of air-stable primary phosphines which make synthetic 
preparations and purifications more time efficient and simpler technically, especially 
regarding a large scale synthesis. From the air-stable primary phosphines reported (Figure 
1.3), there appears to be a range of structural types, including supermesitylphosphine 1,9, 
10 triptycylphosphine 2,11 (R)-MOPH2 3,
34 diprimary 4,14 thioether 58 and the ferrocene 
derivative 6.12 The first two compounds, 1-2, are protected from oxidation due to steric 
encumbrance provided by the bulky substituents. However, the same argument cannot be 
used to rationalise the air-stability of the remaining compounds, 3-6. 
 
Figure 1.3 Air-stable primary phosphines.34 
 
On the other hand, Figure 1.4 provides examples of primary phosphines that have proved 
to be unstable to air oxidation, which can lead them to spontaneously ignite if not handled 
under an inert atmosphere. 
 
Figure 1.4 Air-sensitive primary phosphines.7 
 
To understand the air-stability of the primary phosphines, where steric hindrance cannot 
be the protecting factor, the electronic nature of the molecule must be taken into account. 
The mechanism for the air-oxidation of phosphines has not yet been fully elucidated. 
However, it has been demonstrated that the generation of the corresponding radical cation 
of a given phosphine by photolysis35 or radiolysis36 led to its oxidation via the radical 
pathway shown below (Figure 1.5), which was confirmed spectroscopically. 
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Figure 1.5 Postulated steps in the photolytic/radiolytic oxidation of phosphines.35, 36 
 
Our research group therefore modelled the neutral phosphine and its radical cation in a 
series of Density Functional Theory (DFT) calculations using the B3LYP function with 
a 6-31G* basis set, in an attempt to explain the observed stability/sensitivity of the 
different phosphines to aerobic oxidation. It was possible to observe a trend involving the 
highest occupied molecular orbital (HOMO), which corresponded to the experimental 
findings.  
 
Figure 1.6 HOMO distributions of air-stable primary phosphines (top) and air-sensitive primary 
phosphines (bottom), obtained from B3LYP/6-31G* DFT calculations.37 Note that the phosphine 
does not participate in the HOMO of the air-stable compounds. 
 
  
18 
 
 
Air-stable primary phosphines with extended conjugation have a HOMO with no 
phosphorus character, whereas the primary phosphines shown to be sensitive to air 
oxidation demonstrate phosphorus character in the HOMO (Figure 1.6).37 However, this 
trend does not predict the stability of triphenylphosphine since its HOMO is located on 
the phosphorus atom. Therefore, the location of the HOMO with respect to phosphorus is 
unlikely to be the causative factor of air-stability (unless the mechanism of oxidation of 
primary and tertiary phosphorus is due to different mechanisms). Increasing π-
conjugation in the different compounds corresponded with increased stability towards 
oxidation, also producing higher energy HOMO orbitals (as expected). This indicates that 
a radical mechanism is likely to be involved. A radical cation generated from lower 
energy orbital would be more reactive than one generated from a compound with high π-
conjugation. The radical cation Singly Occupied Molecular Orbital (SOMO) energies 
were therefore also calculated for each primary phosphine. The SOMO energies of the 
primary phosphines showed that those that are resistant towards air oxidation have a 
SOMO energy above an apparent threshold of −10 eV, as depicted in Figure 1.7.37 This 
infers that a radical cation produced from a more stable HOMO is reactive enough to 
combine with oxygen from the atmosphere and generate a peroxy radical, which 
ultimately results in irreversibly oxidation to the phosphine oxide.37 This DFT model is a 
useful predictive tool which allows for new primary phosphines that may be air-stable to 
be modelled before synthesising them in the laboratory. Figure 1.7 contains examples of 
a wide variety of primary phosphines. The compounds above a SOMO energy of −10 eV, 
represented by a red line in the figure below, are air-stable whereas those below this 
energy are unstable in the presence of air. Compounds 1 and 2 are stable due to the steric 
hindrance provoked by the structures in which the phosphine function is placed. However, 
compounds 4-6 do not contain bulky groups around their phosphorus atoms. In these 
cases, the air-stability is attributed to their electronic properties, since the three of them 
have SOMO values that are above the stability threshold of −10 eV. Phosphines 7-10 do 
not contain any bulky groups around their phosphine functional groups and their SOMO 
energy is below the stability threshold. Therefore, it is no surprise that they are sensitive 
to air-oxidation. 
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Figure 1.7 Plot of the radical cation SOMO energies for primary phosphines 2-10.37 
 
A part of the research presented in this thesis is based on an air-stable primary phosphine 
that has as backbone pyrene 11, which is separated from the phosphine by an alkyl chain. 
One important feature of the phosphines stabilised electronically is that they either 
contain heteroatoms, such as sulfur, oxygen or nitrogen, or have a direct aryl bond to 
phosphorus. This research group has previously synthesised stable fluorescent primary 
phosphines based on the known fluorophore 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
13 (BODIPY). The high conjugation of the BODIPY 13 core was key to the stability of 
the resulting phosphines 14a and 14b and this generated the first fluorescent air-stable 
primary phosphines.38 The air-stability of these compounds is provided by the π-
conjugation of the system. Nevertheless, this conjugation also confers a useful property, 
which has been subsequently exploited in medical imaging.39 
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Figure 1.8 Fluorophores pyrene 11 and BODIPY 13; phosphines 14a and 14b developed using 13 as 
fluorophore and the theoretical air-stable phosphine 12 using pyrene as core. 
 
Both cores, pyrene 11 and BODIPY 13, have a useful feature in common: fluorescence. 
Fluorescence has a special place in the life sciences, as many non-destructive techniques 
take advantage of this phenomenon in order to track or analyse biological molecules. This 
is possible because there are relatively few cellular components that are naturally 
fluorescent, which makes “non-labelled” cells invisible to fluorescence microscopy. By 
“labelling” a cell or a protein with a fluorescent compound which has a known emission 
wavelength, it is possible to follow it within the biological system. Fluorescent 
compounds which are used in this way are known as fluorescent probes.40 
One of the main objectives of our research was to functionalise pyrene with a phosphino 
group to answer two related questions: does the conjugation provide the phosphine air-
stability? Does the presence of the pyrene, a known DNA intercalator, allow for the 
development of new medicinal agents? 
1.4 Origins of luminescence 
Pyrene is fluorescent which may be a feature we can exploit in medicinal imaging; 
therefore, a brief introduction to it will be discussed next. 
Luminescence is the emission of light from an electronically excited species and it can 
occur in two different forms, fluorescence and phosphorescence. Which type of emission 
is given off by any given molecule is determined by the nature of its excited state. These 
processes are usually illustrated by the Jablonski diagram (Figure 1.9). The Jablonski 
diagram describes the excitation of an electron from the ground state (S0) to the first 
excitation state (S1) due to the absorption of light (hνA), followed by the emission of 
energy in the form of fluorescence (hνF) back to S0 (S1-S0). Other processes can take place 
such as the excitation from S0 to the second excited state (S2). Following this, an internal 
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conversion allows the molecule to relax to S1. At each of these electronic levels the 
fluorophores can exist in different vibrational energy levels (0, 1, 2, etc.). Electrons in the 
S1 state can also undergo intersystem crossing to the first triplet state T1. Emission from 
T1 is called phosphorescence (hνP) and is usually found at longer wavelengths than 
fluorescence. An interesting feature of emission is that its energy and its wavelength are 
extremely related, as Equation 1 shows.40 E is the energy of emission, h is the Planck’s 
constant, c is the speed of light and λ is the wavelength of the emission. 
𝐸 =
ℎ𝑐
𝜆
 
Equation 1 
The conversion between S1 to T1 is irreversible, since T1 to S1 is a spin forbidden 
transition. Molecules containing heavy atoms like bromine and iodine are more prone to 
undergo S1-T1 transitions. Heavy atoms facilitate intersystem crossing enhancing the 
phosphorescence quantum yields of the molecules which contain them. A phosphorescent 
material does not immediately re-emit the radiation it absorbs. The slower time scales of 
phosphorescence emission are associated with forbidden energy state transitions in 
quantum mechanics. As these transitions occur extremely slowly in certain materials, 
absorbed radiation is emitted at a lower intensity for up to several hours after the original 
excitation. This phenomenon occurs when an electron in S1 migrates to a separate excited 
state known as the triplet excited state (T1) by intercrossing system.
40 
The photophysical phenomenon of interest for the purposes of this project is fluorescence, 
which is the emission of a photon from S1-S0.
 
 
Figure 1.9 Jablonski diagram; internal conversion depicted by thick arrows, excitation by solid 
arrows, and radiative processes by wavy arrows. 
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The emission spectrum of a fluorescent molecule is usually found at higher wavelength 
(lower energy) than the absorption spectrum due to internal conversions that take place 
when the excitation leads to an energy level higher than the lowest vibrational level of S1. 
The Stokes shift (Δνst) is the energy gap between the maximum of the first absorption 
band and the maximum of the fluorescence spectrum.41 The quantum yield (ΦF) and 
lifetime (τ) of fluorescent compounds are important features found in this type of 
molecule. The value given by ΦF is a measure of the efficiency of a fluorescent molecule 
comparing the total number of photons emitted to the total number of photons absorbed. 
The nature of this comparison allows a maximum ΦF value of 1. In terms of an instrument, 
a ΦF value of 1 would mean that each absorbed photon was emitted back without the 
occurrence of any side processes, such as heat emission, phosphorescence or increasing 
the kinetic energy of the sample. Therefore, efficiency would be equal to 1 in a perfect 
fluorescence system.41 The fluorescence procedure can be dramatically diminished under 
certain circumstances, a phenomenon called fluorescence quenching and there are several 
reasons why it may occur, which are discussed in the next section. 
In biological systems, it is possible to find molecules and proteins that are naturally 
fluorescent. This phenomenon is called autofluorescence or intrinsic fluorescence. 
Nicotinamide adenine dinucleotide (NAD),42 tryptophan,43 chlorophyll44 and certain 
proteins are known for being fluorescent.45 
When developing fluorescence compounds with biological activity, it is important to keep 
in mind the effects that different substituents can exert on fluorescence, such as 
fluorescence quenching, which is discussed in the next section. 
1.4.1 Fluorescence quenching 
Dioxygen has shown the capacity to provoke fluorescence quenching by colliding with 
the fluorophore − this interaction reduces the emission of photons from S1. This has been 
corroborated by performing fluorescence and absorbance measurements on solutions 
equilibrated with pressures of oxygen up to 100 atm.46 In order to avoid this undesirable 
effect, it is recommended to purge solvents with an inert gas prior to use. 
Non-radiative processes can be augmented when increasing the temperature of the sample 
to be measured − this effect is known as thermal agitation. The formation of excimers47, 
48 (i.e. dimers in the excited state formed by the collision of an excited molecule and an 
identical unexcited molecule) and exciplexes (i.e. excited state complexes formed by 
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collision of an excited molecule with an unlike unexcited molecule) can also lower 
fluorescence − it is diffusion controlled and therefore more pronounced in more highly 
concentrated solutions. This is especially common in concentrated solutions since the 
possibility of an excited molecule interacting with a molecule in its ground state is 
statistically higher.48 
 
Figure 1.10 Structures of the anthracene sandwich dimer, and its photodimer 9-substituted 
anthracenes form photodimers andsandwich dimers in the trans conformation.48 
 
Intersystem crossing occurs between isoenergetic vibrational levels belonging to 
electronic states of different multiplicities e.g. S1-Tn as shown in Figure 1.9.This process 
is spin forbidden but occurs due to spin orbit coupling (coupling between the orbital 
magnetic moment and the spin magnetic moment). Heavy atoms or triplet oxygen 
molecules promote intersystem crossing and therefore a decrease in fluorescence is often 
observed.40, 41 
Another mechanism by which fluorescence quenching can occur is known as 
Photoinduced Electron Transfer (PeT). This mechanism is caused by the presence of an 
electron donor or electron acceptor in the vicinity of the fluorophore when the latter has 
been excited to S1. This step is crucial since it allows for the formation of a donor-electron 
complex (D+A-) that can return to its ground state by means of a process in which no 
photons are emitted. Lastly, the added electron in the acceptor can return to the electron 
donor. The excited fluorophore can act either as the electron donor or the acceptor; this 
depends on the oxidation and reduction potential of the ground and excited states.40 The 
fluorescence of molecules can be modified by the transfer of electrons between nonplanar 
parts of the molecule.49 Nagano et al. used orbital energy levels calculations and 
experimental electrochemical data in order to explain quantum yields. They started their 
investigations with fluorescein50, 51 systems, and then expanded it in order to also explain 
BODIPY systems.52 The oxidation potentials of some substituents in relation to the 
excited-state of their BODIPY core can make them act as electron donors or acceptors 
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producing Photoinduced Electron Transfer (PeT). This process diminishes fluorescence 
when the fluorescent group in its excited-state is reduced. In this case, the fluorescent 
group is an acceptor of electrons, and can thus be called reductive-PeT or a-PeT (“a” for 
acceptor). On the other hand, if the fluorescent group donates electrons to the substituent 
LUMO, an oxidative process takes place (oxidative-PeT or d-PeT, “d” for donor). 
 
 
Figure 1.11 Molecular orbital schematic for Photoinduced Electron Transfer (PeT). BODIPY, a 
known fluorophore, is used to exemplify the phenomenon.40 
 
Fluorescence quenching phenomena can be caused by the Dexter electron transfer process. 
This is a fluorescence quenching mechanism provoked by an excited electron that is 
transferred from a donor to an acceptor via a non-radiative path.53, 54 This type of effect 
requires a wave function overlap between the donor and acceptor, which usually occurs 
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at short distances. In this process an electron in S1 is transferred from the donor moiety to 
the acceptor moiety. In a Dexter electron transfer with an efficiency of 100%, there would 
be no trace of emission from the donor. Relative short separations between chromophores 
have shown efficient energy transfer via the Dexter mechanism when the chromophores 
are orthogonally aligned to avoid an interaction between their electronic systems which 
would lead them to act as one single fluorophore.55, 56  
 
Figure 1.12 Schematic for Dexter electron transfer process. 
 
The groups that provide fluorescence in a molecule are known as fluorophores and have 
different chemical structures. The next section provides a description of the fluorophores 
used in this research. 
1.5 Fluorophores 
This section will provide an introduction to the specific fluorophore compounds that were 
used during the development of this project. 
1.5.1 Polycyclic Aromatic Hydrocarbons (PAH) 
Two of the three aforementioned research projects involved the synthesis of compounds 
containing three important PAHs, naphthalene 15, anthracene 16 and pyrene 17. 
PAHs are composed of multiple aromatic rings, which means that they have the following 
characteristics: 1) a delocalized conjugated π system (usually an alternate arrangement of 
single and double bonds); 2) a coplanar structure, with all the contributing atoms in the 
same plane; 3) the contributing atoms are arranged in one or more rings; 4) a number of 
π-delocalized electrons that is even, but not a multiple of 4. That is, 4n + 2 π-electrons, 
where n = 0, 1, 2, 3, and so on, this is known as Hückel's rule.57 Interestingly, this rule 
loses its validity for PAH formed by more than 3 fused aromatic rings in a cyclic 
arrangement. Examples of this behaviour are pyrene 17, since it contains 16 conjugated 
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electrons distributed in 8 different double bonds, and coronene 19, with 24 conjugated 
electrons in 12 double bonds. Although both PAHs are aromatic, they fail to fulfil the 4n 
+ 2 rule;58 their degree of aromaticity is given by independent rings within the PAH.59 
This kind of compound can be formed during human productive activities via the 
incomplete combustion of organic materials or other organic substances such as tobacco 
and plants.60 PAHs can be also found in fossil fuels such as oil and coal.61 Their presence 
in the environment is significant since previous research has shown that they can be 
related to the development of chemical carcinogenesis due to environmental 
contaminants.62 
 
Figure 1.13 Examples of PAHs: naphthalene 15, anthracene 16, pyrene 17, benzo(c)phenanthrene 
18, coronene 19, benz(a)anthracene 20 and acenaphthene 21. 
 
 
 PAHs and DNA 
The different structures of PAHs influence the biological effect that they can exert on 
DNA. This structure-effect relationship can determine whether or not a PAH can be 
carcinogenic.63, 64 Interactions between PAHs and DNA can lead to different outcomes 
since some carcinogenic PAHs are genotoxic and produce DNA lesions that induce 
cancer; on the other hand, other types are not genotoxic but can affect cancer processes.63, 
64 The compounds that have been shown to positively start carcinogenic processes require 
activation. This is caused by oxidations catalysed by the P450 enzymes (CYPs) that 
ultimately produces vicinal diol-epoxides. These compounds are electrophiles capable of 
binding to DNA, while some of the diol epoxide stereoisomers of PAHs are found to be 
ultimate carcinogens.65 These carcinogens are usually PAHs that contain four or more 
aromatic rings and a “bay region” or a structural pocket where the oxidation will take 
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place. Mutagenic metabolites of PAHs include diol epoxides, quinones, and radical PAH 
cations.65 
 
Figure 1.14 Carcinogenic metabolites of 18 and 20. 
 
The metabolites produced by CYP have the capacity to bind to DNA in certain sites, 
creating bulky complexes known as DNA adducts. When the formed adducts are stable, 
they might provoke DNA replication errors that can transform genes allowing for the 
production of cancer–causing oncogenes.63 Another mechanism by which PAHs disrupt 
normal cell development is the dysregulation of DNA gap junctions, intercellular 
connections between different cells.66 This affects intercellular communication with 
enzymes in charge of activating transcription factors involved in cell proliferation, 
producing an excessive replication of certain cells.67 Benzo(c)phenanthrene 18 is an 
example of the mechanism by which PAHs intercalate with DNA forming DNA adducts. 
Intercalation is the insertion of molecules between the planar bases of DNA. Intercalation 
occurs when a molecule with the appropriate size and chemical features puts itself 
between base pairs of DNA. These molecules are mostly polycyclic, aromatic, and planar. 
Benzo(c)phenanthrene 18 is oxidized by the CYP enzymes creating a diol epoxide, which 
undergoes a nucleophilic attack by an exocyclic amino group of deoxyadenosine 
generating an adduct where the PAH is attached to the major groove edge of DNA.68 
Cosman et al.69 identified that after the amino group of deoxyadenosine became 
covalently attached to oxidised form of 18, the PAH intercalates to the helix without 
disrupting other base pairs. This phenomena is called intercalation. They observed a 
buckling of the intercalation cavity reflecting the selective overlap of the intercalated 
PAH 18. They determined that in spite of the covalent bond formed, the major groove 
edge of deoxyadenosine can still intercalate into the helix without further disruption of 
the modified base pair. 
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Figure 1.15 Left: Intercalation of oxidised 18 to DNA. Right: Benzo(c)phenanthrene 18, its oxidised 
metabolite, and the adduct derived from trans-opening of this epoxide by the exocyclic 2-amino 
group of deoxyguanosine. 
 
Naphthalene 15 has useful fluorescent features such as a very low self-quenching effect 
in solutions.70 These features have a niche in fluorescent microscopy and its 
applications.71 The dependence of the fluorescence intensity of naphthalene has been 
studied, demonstrating that it initially decreases with increasing concentrations. However, 
above a certain concentration, the fluorescence, surprisingly, remains constant.72 The 
photophysical features of naphthalene, such as its fluorescence quantum yield (ΦF = 0.23) 
and good photo- and chemo-stability, make it a significant candidate for the development 
of different fluorescent probes. This PAH has therefore been used in probes to determine 
the presence of toxic pollutants,73 the concentration of endogenous compounds of 
physiological importance,74, 75 protein tagging76 and to identify metallic ions in living 
cells.77, 78  
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Figure 1.16 Naphthalene-based probe for determining the presence of H2S, signalling compound 
involved in different physiological processes in living cells79, 80. H2S reduces the azide group and the 
naphthalene recovers its fluorescence at 320 nm emitting a blue colour.75 
 
Naphthalene-based 22 is a probe for developed by Mao et al.79, 80 detecting the cellular 
presence of SH2 exhibiting a wide linear response concentration range (0−5 μM) with 
high selectivity. Compound 22 is not fluorescent due to the presence of an electron 
withdrawing group (N3), which disrupts the π-conjugation of naphthalene. When the 
naphthalene-azide 22 as is placed in a solution containing 10 equivalents of SH2 in water, 
the naphthalene derivative is turned into 23 increasing its fluorescence 67-fold after 60 
min. 
In the same fashion as other PAHs, anthracene is frequently used as a fluorophore for 
sensors for organic and inorganic analytes and as probes and markers in biological or 
supramolecular systems49 due to its quantum yield (ΦF = 0.36).81-83 In addition, 
anthracene can insert itself between the planar bases of DNA (intercalation),84 which 
forms the core base of anthracyclines85, 86 and provides a possible fluorophore core for 
DNA probes.87 The anthracene derivative 24 was developed by Ostaszewski et al.88 using 
calf thymus DNA (ct-DNA) to measure the affinity of this compound for the 
macromolecule. Using UV-Vis spectroscopy, they determined the affinity of 24 for 
intercalating with DNA and they established that the complex 24-ct-DNA is not 
fluorescent.  
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Figure 1.17 Anthracene derivative 24 developed by Ostaszewski et al.88 24 is an efficient DNA 
intercalator agent. 
 
Pyrene 17 is a PAH that consists of four fused benzene rings, resulting in a flat aromatic 
system. This colourless solid is the smallest peri-fused PAH, which means that the rings 
that form its structure are fused through more than one face. 
Pyrene 17 is a PAH that is widely exploited for its quantum yield (ΦF = 0.36),83 and for 
its capacity to take part in non-covalent interactions. For example, poly(pyrenebutyric 
acid) is used as a noncovalent stabilising unit for single-walled carbon nanotubes, 
preventing the formation of bundles and enabling dispersion in solvents.89 This 
fluorophore possesses an outstandingly long fluorescence lifetime, and the vibrionic band 
structure of its emission shows dependence on the polarity in which the solution takes 
place.90 These photophysical features have led to the development of pyrene-based 
oligonucleotides that have been studied in DNA and RNA hybridization assays.91-94 
While pyrene is now used extensively, its current applications seem to be limited. The 
main limitation is a lack of reliable procedures for the synthesis of pyrenes with various 
substitution patterns. Thus, while pyrene is easily appended to a system, the generation 
of structures with pyrenyl cores is much less straightforward when polysubstituted 
pyrenes are required.95 
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Figure 1.18 Pyrene is activated towards electrophilic aromatic substitutionat the 1, 3, 6 and 8 
positions only. Some bulky electrophiles are forced by steric hindrance to react at the 2 and 7 
positions.95 
 
 Drugs based on PAHs 
Drugs have been developed around these PAH characteristics. Topoisomerase inhibitors 
are compounds used in chemotherapy96 since they inhibit enzymes that restore the 
topological integrity of DNA. DNA replication and transcription processes can be stopped 
due to the presence of molecular torsion lesions. Furthermore, their presence gets 
intensified ahead of a replication process. In order to repair these types of topological 
problems caused by double helix spatial distribution, topoisomerases cut the phosphate 
backbone in DNA strands, which allows the structure to redistribute its spatial 
arrangement by untangling or unwinding. At the end of this process, the DNA backbone 
is resealed again. This process does not change the chemical structure or the connectivity 
of DNA.97 Topoisomerase inhibitors block the activity of topoisomerases − in this group 
it is possible to find different structures that are based on the PAHs having a flat moiety 
made by fused rings. Their mechanism of action is thought to inhibit the step in which 
the DNA strands are resealed again which leads to single and double stranded breaks 
undermining the integrity of the genome. These lesions subsequently provoke apoptosis, 
or cell death.98 Due to their mechanism of action, this type of compound has been shown 
to exhibit antibacterial activity.99 
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Figure 1.19 Dunorubicin 2585, 86 and Amsacrine 26100 are different topoisomerase inhibitors 
containing PAH moieties. 
 
 Phosphorus containing PAHs derivatives 
As we have already seen, PAHs offer a versatile tool for developing compounds with 
useful properties. Their reactivity allows them to add phosphorus atoms to their structures, 
which adds extra features to the resulting molecules as will be shown in this section. 
An interesting type of phosphorus-containing compound is the phosphonium cation. 
These molecules have the general chemical formula PR4
+, they are common intermediate 
products in the Wittig reaction.101 In addition, mitochondria is a good target for 
phosphonium ions with anticancer activity. The electron transport chain contained within 
the impermeable inner mitochondrial membrane provides a negative membrane potential 
(ca. 150 mV to 170 mV) in healthy cells.102 In cancerous and ischaemic heart cells, 
mitochondrial dysfunction can significantly disrupt the membrane potential,103 causing a 
tenfold increase in accumulation of membrane potential-dependent compounds.102  
The phosphonium salt 27 is an innovative compound containing a naphthalene moiety, 
which was synthesised by the reaction of 1,8-dibromomethylnaphthalene with 
triphenylphosphine. The phosphonium salt 27 exhibits colour in the presence of fluoride 
ions. Yeo et al. attributed the high selectivity for fluoride to the acidity of the methylene 
protons and the small size of fluoride ions.104 As discussed, anthracene is a well-known 
-electron rich fluorophore whose photophysical properties are frequently used in the 
fluorescence sensors field.105 Fascinating work carried out by Yamaguchi et al. compared 
the fluorescence of phosphine 28a (ΦF = 0), phosphonium ion 28b (ΦF = 0.0077), 
phosphonium oxide 28c (ΦF = <10-3) and fluorophosphine 28d (ΦF = 0.28). Interestingly, 
the fluorophosphine 28d exerted the highest fluorescence, which was comparable with 
the fluorescence of the parent anthracene.105 Compound 29 is a pyrene based 
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phosphonium ion reported by Real et al.106 whose photophysical measurements proved 
that the sample did not undergo dimers formation during excitation for measuring 
fluorescence. This was attributed to the charge of the phosphonium ion which should 
increase the repulsion forces between each independent molecule in the solution. The 
positively charged pyrene derivative 29 has the advantage of being water soluble, while 
avoiding affecting the pyrene fluorescence. The pyrene moiety gives it the capacity to 
intercalate with DNA. The positive charge and the butyl groups, contribute to a weak 
binding interaction in the external groove of the double helix. The importance of this 
compound resides on its capability to discriminate between a double helix and a strand 
due to its incomplete intercalation originated by the butyl chains.106 
 
Figure 1.20 Different examples of PAHs containing a phosphorus-based functional group. These 
compounds exert interesting photophysical properties. 
 
PAHs are not the only fluorophores that have been used to take advantage of the high 
absorption of phosphonium ions in the mitochondria of abnormal cells. Our group has 
reported the development of BODIPY based agents for mitochondrial imaging. 
Compounds 30 and 31 were shown to be taken up in a mitochondrial membrane potential-
dependent manner in both cancer and heart cells. The BODIPY-cyclohexane 30 
derivative demonstrated a better absorption in mitochondria than its phenyl analogue 31. 
DFT calculations showed that the positive charge in 30 is mainly held by the P-atom. 
Since the absorption is regulated by a difference of potentials, this might be the factor that 
differentiates the absorption of both compounds.107  
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Figure 1.21 The synthesis of the BODIPY analogues 30 and 31 has shown the importance of the 
positive charge in relation to mitochondrial absorption. 
 
Therefore, BODIPY is another significant fluorophore when developing compounds with 
biological activity. 
The first project presented in this thesis will describe the synthesis of novel 1,2-
azaphosphindoles, which are P-containing heterocycles that include the coupling of either 
naphthalene or anthracene moieties. The second project describes the synthesis of a 
pyrene-based tridentate ligand that was used to obtain complexes with possible biological 
applications. The final project presented here describes the obtaining of a fluorescent 
BODIPY-based ligand that was used to produce a fluorescent BODIPY-64Cu complex 
intended for use as a fluorescent imaging agent and a radiotracer. This entire project 
involved fluorophores, which is the reason behind the short overview of this topic. 
1.5.2 BODIPY 
The compound 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (abbreviated to F- BODIPY), 
is a versatile fluorophore. The characteristics that make this a useful fluorophore are: 
strong UV absorption profile, sharp fluorescence emission peak, high quantum yields, 
high thermal and photochemical stability, negligible triplet state formation and high 
solubility in different solvents.108-110 Although BODIPY derivatives have been known 
since 1968,111 BODIPY 13 has not been reported in the literature (Figure 1.22). This 
might be due to synthetic difficulties since none of the pyrrole carbons on the core are 
blocked towards an electrophilic attack. The synthesis of the symmetrical tetramethyl-
substituted BODIPY 32 established a reference for other alkylated BODIPYs. It also 
suggests that alkylating the carbon positions on the pyrrole moiety increases the stability 
of this type of compound.112 The unsymmetrically substituted systems 33 and 34 suggests 
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that there are minimal differences in the photophysical behaviour of the different 
BODIPY systems synthesised. 113 
 
Figure 1.22 Different BODIPY systems and the difference in stability provoked by their alkyl 
substituents. BODIPY and its different positions.108 
 
There are different synthetic routes to produce BODIPY molecules. One of these routes 
involves a pyrrole condensation; an electrophilic carbonyl forms a bridge between the 
two pyrrole units forming C–C bonds with this carbon atom in the newly formed meso 
position (Figure 1.22). The newly formed dipyrromethane 35 is then transformed to 
dipyrromethene 36 by the action of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). 
The boron atom is then coupled to the molecule creating two N−B bonds, and a base is 
used, usually a sterically impeded amine, in order to remove a fluorine atom from the 
boron trifluoride molecule (Figure 1.23). 
 
 
Figure 1.23 A synthetic approach for the production of BODIPY compounds.109 
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The positions adjacent to the nitrogen atom in the pyrrole moiety tend to be substituted 
to avoid the formation of any undesired side products as a result of the polymerisation of 
the molecule109. Typically, the “8” carbon is the position that is substituted with aryl and 
alkyl groups. These substitutions do not change the absorption and emission profiles of 
the molecule. However, in order to maintain high quantum yields, positions “1” and “7” 
are substituted to prevent the free rotation of the substituent in the meso, which would 
reduce the energy from the excited state via non-radiative molecular motion and decrease 
the quantum yield. The BODIPY core can be modified by a variety of chemical alterations 
allowing it to accept different groups in the meso α and β positions. This gives chemical 
versatility to the core, producing several dyes for different applications, including sensors 
of particular redox active molecules,114-116 pH probes,117 metal-chelators118 and 
biomolecule conjugating groups.119 
 
 Phosphorus containing BODIPY derivatives 
The number of BODIPY compounds containing phosphorus as a substituent is highly 
limited to date.120-123 In 2009, Inoue et al. reported the first phosphorus-containing 
BODIPY compound (38a). The importance of this compound is related to its oxidation 
to the phosphine oxide 38b in the presence of lipid hydroperoxides, which have been 
connected to arteriosclerosis, hyperlipidaemia, cancer, and aging.121 
 
Figure 1.24 Probe for lipid peroxides developed by Inoue. The oxidation of the phosphorus atom 
shows a higher fluorescence.121 
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Different chronic diseases and physiological processes (i.g. inflammation and hypoxia-
reoxygenation) have proved to be governed by reactive oxygen species such as hydrogen 
peroxide. However, the mechanism of action involved in this type of process has not been 
fully elucidated yet.124 Compound 39a, in Figure 1.25, produced and increased 
fluorescence as its phosphine oxide form 39b, whose existence is dependent on the 
concentration of hydrogen peroxide.121 Reductive-PeT is thought to arise from the 
electron donating phosphine donor whose HOMO energy level is high enough for 
electron transfer to the excited BODIPY acceptor.121 Similar mechanisms have been 
proposed for compounds 40a and 40a.124, 125 As has been shown, fluorescent phosphines 
can experience PeT, a phenomenon that can be removed upon oxidation of the lone pairs 
of electrons to the phosphine oxide. 
 
Figure 1.25 Fluorescent probes for monitoring hydrogen peroxide using.124, 125 
 
When the HOMO energy of the donor is high enough to provoke electron transfer to the 
acceptor, quantum yields will be diminished. Therefore, compounds with high quantum 
yields usually contain electron donors with low HOMO energy levels. Compound 40 is a 
good example of this, since the values of HOMO energies for methyldiphenylphosphine 
and methyldiphenylphosphine oxide HOMO were calculated to be −8.33 and −9.95 eV 
respectively proving that the donor with the lowest HOMO (the phosphine oxide) 
provides the highest fluorescence.124 
The BODIPY dyes, mentioned above, were initially developed in order to replace 
fluorescein and rhodamine compounds. The structure of the specific BODIPY can change 
its emission wavelength, which is usually set in a range around 510 to 675 nm. Their 
quantum yields are also an important feature since they are high and tend to approach the 
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unit. They also possess an important insensitivity to solvent polarity and pH which make 
them good candidates for biological probes.40 Therefore, the development of new 
BODIPY-based compounds offers a niche for the development of compounds with novel 
applications. 
1.5.3 DNA probes 
Fluorescence is used as a non-destructive way of tracking or analysing biological 
processes and molecules. It is possible to label proteins, nucleic acids, lipids or other 
endogenous compounds with external fluorophores. Usually the molecules of interest in 
the body are not fluorescent or their fluorescence is not adequate for the particular 
experiment required. DNA is a target for this kind of probe since unlabelled DNA has 
shown very weak intrinsic emission. This emission is too weak and out of the UV spectra 
for practical purposes. However, a wide variety of probes have been developed which 
have affinity for DNA and, after binding to it, display enhanced emission.126-128 Ethidium 
bromide 41 is an intercalating agent, meaning that, since its geometry is flat, it can be 
inserted between the planar bases of DNA129 as it has been explained in Section 1.5.1.1. 
This characteristic turns ethidium bromide 41 into a reagent for an assay known as 
“Ethidium bromide displacement”, which tests the intercalation of novel compounds with 
DNA by measuring the concentration of displaced ethidium bromide 41 from a DNA-41 
complex. This complex is placed in a solution with the competitor compound, whose 
DNA affinity is to be tested − spectrophotometry is used to determine the amount of 41 
that was displaced by the tested compound.130  
 
Figure 1.26 Left: Different DNA probes and their excitation and emission wavelengths referred to 
the DNA-dye complex.40 Right: Intercalating of DNA and fluorescent probes (orange rectangles). 
 
Acridine orange 42 is a fluorescent dye that is highly nucleic acid-selective. Due to this 
characteristic, this compound is commonly used for cell cycle determination.131 This 
compound permeates the cell and interacts with DNA by intercalation, and with RNA by 
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electrostatic attractions.132 Rescifina et al.133 developed an isoxazolidinyl-pyrene 
molecule with the expectation that the heteroatoms in the isoxazolidinyl moiety would 
interact electrostatically with the base pairs of DNA. In order to explore the capacity of 
this compound to bind to DNA, UV spectral analysis of a mixture of the isoxazolidinyl-
pyrene 43 and ct-DNA was performed. The red shift of 13 nm for DNA134 and the binding 
constant for 43 with ct-DNA (6 x 103 M−1) were consistent with intercalation. 
Additionally, preliminary docking studies of compound 43 to the DNA fragment 
d(CGCAATTGCG)2 indicated that it preferentially intercalates into the DNA Adenosine-
Thymine (AT) region where resulting complex appears to be further stabilized by the 
formation of a hydrogen bond between the hydroxyl group of the isoxazolidinyl moiety 
and an oxygen of the phosphate group.133 
 
Figure 1.27 Isoxazolidinyl-pyrene 43 developed by Rescifina et al.133 
 
As discussed above, intercalation is an important mechanism for DNA-binding agents, 
such as DNA probes. Intercalators bind by inserting a planar aromatic chromophore 
between adjacent DNA base pairs causing little perturbation of the DNA structure.135 This 
mechanism is usually followed by PAHs Therefore, it would be possible to develop a 
PAH as intercalator which includes a second moiety that interacts with DNA in order to 
increase its efficiency. An example of this hypothetical second moiety is platinum. This 
metal is the main core of many anticancer treatments currently in use. The main example 
of this type of compounds is cisplatin “cis-[Pt(NH3)2Cl2]”.136 Therefore, in this thesis, we 
present the development of a pyrene-platinum complex. Fluorescent compounds are not 
the only tool for studying living systems. Radiotracers can be also used for this particular 
purpose. 
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1.6 Radiotracers 
A radioactive tracer is a chemical compound in which one or more atoms have been 
replaced by a radioisotope which can be monitored using different techniques such as 
Photon Emission Tomography (PET) and (Single-Photon Emission Tomography). 
1.6.1 Positron Emission Tomography (PET) 
Radiotracers are molecules in which one or more atoms are replaced by a radioactive 
isotope giving an agent that can be traced via biological systems. In Positron Emission 
Tomography (PET), certain isotopes with an excess of nuclear energy make them unstable. 
The excess energy can be released by the emission of a positively charged particle, called 
a positron, which travels a short distance (known as the positron range) around the tissue 
before it combines with an electron causing its anhilation.137 After this process, the mass 
of both particles is converted into energy producing 511 keV -rays which are emitted 
simultaneously and follow opposite trajectories at 180° to each other. These -rays are 
detected by detectors located in the periphery of the location of the event, which collect 
and record information about the positron annihilation. Collecting data from a large 
number of annihilations provides information about the spatial distribution of 
radioactivity as a function of time that can be reconstructed into an image.137 The energy 
of the positron is highly important, since the positron will travel further in the tissue and 
the spatial resolution will be diminished if the amount of energy is too high. 
 
Figure 1.28 Representation of annihilation process used in PET. 
 
Typically PET nuclides are incorporated into molecules with biological activity. Usually, 
the isotopes used as PET imaging agents have half-lives comparable to the half-time of 
the imaging process. The main mode of decay used in this technique is positron emission. 
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However, other decay modes can be accepted as long as their energies do not approach 
511 keV. Table 1.1 shows the most commonly used nuclides.  
Nuclide Half-live/min Mode of Decay Eβ (max) MeV 
11C 20 β+ (99%) 0.97 
13N 10 β+ (100%) 1.20 
15O 2 β+ (100%) 1.74 
18F 110 β+ (97%), EC (3%) 0.64 
64Cu 762 β+ (19%), EC (41%), β− (40%) 0.66 
68Ga 68 β+ (89%), EC (11%) 1.90 
124I 60,192 β+ (25%), EC (75%) 2.14 
94mTc 53 β+ (72%), EC (28%) 2.47 
EC: Electron Capture 
Table 1.1 Radionuclides used for PET imaging.137 
 
The development of a radiotracer requires the study of the non-radioactive (or “cold”) 
molecular analogue and its interaction with the target that it was designed for.137 Synthetic 
routes for the preparation of a small library of analogues are then designed which 
incorporate the isotopic label at a late stage of the synthesis. The ‘cold’ (non-radioactive) 
compounds are initially tested for affinity with the receptor. 
A popular compound used in cancer PET imaging is 2-[18F]fluoro-2-deoxyglucose 44. 
This compound is transported into the cells by membrane glucose transporters, it then 
undergoes phosphorylation which traps it irreversibly in the interior of the cell. This 
confers selectivity to this compound towards the tissue that forms tumours, since many 
of them have unregulated glucose transport and glycolysis. This selectivity turned 44 into 
a popular option as a biomarker of many human malignancies. 
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Figure 1.29 Synthesis of the radiotracer 2-[18F]fluoro-2-deoxyglucose 44 used in PET imaging.138 
 
The synthetic cyclic monosaccharide 44 has some limitations as an imaging agent, 
including high uptake in healthy tissues, such as the brain and bladder, which limits its 
use for the identification of gliomas and prostate cancers. Additionally, inflammatory 
conditions can provoke an increase in the uptake of 44, creating false positives. These 
limitations have prompted the continuous development of specific biomarkers with higher 
specificity.139 
1.6.2 Isotopes of copper: 64Cu and 62Cu 
The utility of PET has not been fully exploited due to the limited availability of relevant 
isotopes, which require the construction of nuclear reactors or particle accelerators. The 
invention of different techniques for the development of a wider variety of radionuclides, 
such as the small biomedical cyclotron, increased the demand of PET for research and 
clinical purposes.140 
The isotopes 18F, 15O, 13N, and 11C have been traditionally used for their ability to 
integrate into small molecules. However, short half-lives, and rapid clearance make them 
more suited to studies that do not require extended periods of time, which makes it 
difficult to explore biological phenomena that have a duration of hours or days. Given the 
development of compounds that have specific biological targets, it was clear that new 
radionuclides needed to be produced with half-lives that could be appropriate for the 
challenges faced by biological investigation. There are a few transition metals and post-
transition metal elements whose radionuclides have been developed to fulfil these new 
requirements of biological research. Copper, Gallium, Indium, Yttrium, and Zirconium 
complexes have been used before for PET imaging.140 This section will refer mainly to 
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Copper. Table 1.1 gives an example of some interesting radionuclides that have been 
studied, as well as providing the long half-live of 64Cu in comparison with other 
radionuclides of commercial importance.137 
Copper nuclides are an important area of research due to the variety of half-lives and 
decay energies, which can be useful in diagnostic imaging and radiotherapeutic 
applications.141 Specifically, 64Cu has a half-life of 762 minutes and a + emission of 18%, 
(Emax = 0.655 meV). The low + abundance is a deficiency that is compensated by its long 
half-life, since this makes it easier to be transported, prepared and delivered for clinical 
applications.142 The isotope 64Cu is a plausible alternative to 18F, maintaining a high 
sensitivity and high spatial resolution of PET without maintaining expensive radionuclide 
production facilities. Since 64Cu is a transition metal, it would be possible to attach it to a 
myriad of ligand carriers that would not work with 18F due to its chemistry. 62Cu is 
produced in generators. Its short half-life (9.7 minutes), allows the patient to receive 
consecutive doses without resulting in a dangerous exposure to radiation and allows 
radiotracers made with this radionuclide to obtain similar imaging results as other 
radiotracers containing radionuclides produced with more expensive methods.143 The 
production of 62Cu requires the use of a zinc-62/copper-62 radionuclide generator144 
while the production of 64Cu requires a cyclotron.145 This radionuclide exerts a + 
emission of 98%, (Emax = 2.93 meV), which is lower than the + emission of 64Cu. 
Kobayashi et al.146 compared the performance of 62Cu and 64Cu radionuclides for PET. 
They found that 64Cu produced images of higher quality and better definition when the 
3D acquisition mode was used. The definition of the images produced using 64Cu was 
more accurate than for those obtained using 62Cu, because the latter has a higher 
maximum + emission energy. This results in a longer positron range than 64Cu.147 
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2 Novel 1,2-azaphosphindoles 
2.1 Introduction 
2.1.1 1H-indazole 
Indazole derivatives display a broad variety of bioactivity. These type of compounds are 
rare in nature.148 The plant Nigella sativa contains the alkaloids nigellicine 45, 
nigeglanine 46, and nigellidine 47, which are examples of indazoles produced in nature. 
 
Figure 2.1 Nigella sativa (commonly known as black cumin) flowers. 
 
The synthesis of these indazoles has been accomplished by different methods and their 
biological, chemical and physical properties have been recently studied.149 
 
Figure 2.2 The indazole alkaloids nigellicine 45, nigeglanine 46, and nigellidine 47. 
 
There has been recent interest in the pharmacological properties of indazoles.150 Since the 
electronic properties and geometry of small molecules play an important role in their 
interaction with biological receptors, there have been studies on these aspects in a 
collection of different chemical cores, including indazoles. These studies are aimed to 
support the development of new drugs.151 The use of indazole in medicinal chemistry led 
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to the development of tumour inhibiting and redox-active antineoplastic ruthenium 
complexes.152 There is a broad horizon for the use of derivatives of indazoles. The 
iodobenzamide derivative 48 has demonstrated antifungal activity153 and compound 49 
has been studied as a β3-adrenergic receptor agonist in an attempt to treat type II diabetes. 
Indazole 50 has been studied due to its properties as a dopamine D2 receptor antagonist.154 
The compound 7-nitroindazole 51 is an indirect inhibitor of nitric oxide (NO), since it 
selectively inhibits the enzyme that produces this compound in the brain.155 These 
features led to the research of 7-nitroindazole 51 as a possible protective agent against 
nerve damage caused by excitotoxicity or neurodegenerative diseases.156 
 
Figure 2.3 Different synthetic indazole analogues with interesting biological properties. 
 
The biological properties of certain disubstituted indazoles have been already reported, 
suggesting that the biological properties found in the indazole core cannot only be 
retained but also modified according to the different substituents placed on the core. There 
are published examples of N(1)–C(3)-disubstituted indazoles showing pharmacological 
properties. Granisetron 52 is an clinically used antiemetic for treating nausea and emesis 
provoked by chemotherapy, and works by inhibiting the 5-HT3 receptor.
157 By changing 
the methyl group to a carboxylic acid on the amine compound 53 was obtained, which is 
a gastrointestinal prokinetic and dopamine D2 receptor antagonist.158 Benzydamine 54 is 
an anti-inflammatory agent used topically,159 although, it also exhibits antifungal 
properties. The indazole derivative 55 has shown to be an activator of the cardiovascular 
and central nervous system by interacting with specific receptors. Interestingly, it also 
can inhibit endothelial cell functions that are activated by angiogenic factors in vitro and 
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angiogenesis in vivo.160 The indazole core has also been reported as an interesting ligand. 
Complexes 56-59 have been reported in a study showing their interconversion between 
cis and trans isomers induced by high temperatures.161 
 
Figure 2.4 Examples of disubstituted indazoles that have shown biological activity. 
 
Recently, indazoles have also shown to have antibiotic properties. Zhang et al. targeted 
bacterial DNA gyrase B, which is present in bacterial DNA making it a potent antibiotic 
target.162 The crystal structure of the enzyme showed a pocket where a pyrazole moiety 
could interact electrostatically. Cell penetration was a problem which was resolved by 
physiochemical property optimization of pyrazolopyridone 60, leading to the 
development of indazole 61. This displayed a considerable improvement in activity 
against S. aureus  and S. pneumoniae.162 
 
Figure 2.5 Development of the DNA bacterial gyrase B inhibitor indazole 60 from the 
pyrazolopyridone 61. 
 
Due to the applications that have been found for indazole analogues, different synthetic 
approaches for producing a broad variety of these compounds have been developed. 
2.1.2 Synthetic routes towards indazoles 
Indazoles can be prepared using diazo groups in phenyl rings, while o-methyl groups are 
required in order to close the newly formed 5-membered ring. The simplicity of this 
approach makes it versatile enough to produce different indazole analogues.163, 164 
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Figure 2.6 General synthesis of indazoles. 
 
Similar syntheses include the diazotation of o-alkynylanilines such as 62, producing the 
indazole 63. This is an advance in this field since the benzylic position can have 
substituents that are not sensitive to basic conditions.165, 166 The elucidation of the 
mechanism involved in this reaction led to derivatives such as five-membered pyrazole 
or six-membered pyridazine.167, 168 
A recent breakthrough involved the development of a procedure for the synthesis of 2H-
indazoles by virtue of their increasing interest in medicinal chemistry applications, most 
notably as anticancer agents.169, 170 This procedure, known as David-Beirut synthesis, is 
characterised by the formation of an N,N-bond to form the heterocycle required for the 
synthesis of 2H-indazoles and indazolones.171, 172 The group that originally developed this 
procedure made different analogues, with the intention of determining their activity 
against cystic fibrosis.173 Figure 2.7 illustrates the Davis-Beirut approach for synthesising 
compound 63, and other N-substituted indazoles.174 
 
Figure 2.7 Synthesis of an indazole using the Davis-Beirut approach. 
 
The similarity of phosphorus with nitrogen due to their positions in the periodic table had 
led to the development of different compounds where the nitrogen atom has been 
substituted with a phosphorus atom. Some of these find applications in the optoelectronic 
field, such as phospholes.175, 176 However, some phosphorus analogues of important 
nitrogen-containing natural products have also displayed interesting biological properties 
themselves. An example of which can be found in -amino acids, being these are the 
building blocks of life, they are a natural target for developing phosphorus-based 
analogues.177 
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The field of phosphorus-based analogues of indazoles requires a more resourceful 
synthetic approach in comparison with its nitrogen counterparts due to the different 
reactivity of phosphorus. An organometallic approach has been employed to overcome 
this problem. J. P. Majoral and group178 used the metallacyles obtained with zirconium in 
order to synthesise azaphosphindoles. In their methodology, they relied upon the 
thermolysis of diphenylzirconocene to generate a benzyne intermediate, which in the 
presence of a wide variety of nitriles, formed the required azazirconacyclopentanes. The 
zirconocene complex formed was reacted with the nitriles (i-Pr2N)2PCN and (Cy2N)2PCN, 
forming azaphosphindoles 64 in high yields (80-90%). Then, they were reacted with 
phenyldichlorophosphine and tert-butylchlorophosphine, leading to elimination of 
Cp2ZrCl2 in order to produce novel 1,2-azaphosphindoles 65. Finally, elemental sulfur 
was added in order to produce the monosulfide 66. 
 
Figure 2.8 Synthesis of Majoral et al. by 2H-1,2-Azaphosphindoles.178 
 
2.2 Synthetic target 
The synthesis developed by Majoral and his group178 allows the incorporation of different 
aromatic rings in the 3-position of the phosphindole in order to incorporate functionality; 
the only requirement is that the group that will be added must be a nitrile in order to 
perform the coupling to achieve the phosphindole ring. The chosen aromatic systems are 
phenyl, naphthyl and anthracyl, since polyaromatic hydrocarbons are well known for 
interacting with DNA.63  
To our knowledge, there are no examples of 1,2-azaphosphindoles with an electron 
donating group in the phenyl ring; therefore, a methyl group will be added in the para 
position. Sulfur and selenium will be added to oxidize the phosphorus atom to making it 
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more stable towards oxidation and the electronic differences between the two chalcogen-
containing derivatives will be measured. 
 
Figure 2.9 Proposed substitutions on 1,2-azaphosphindoles core. 
 
2.3 Synthesis of 1,2-azaphosphindoles 
 
The synthesis of the 1,2-azaphosphindoles began with commercially available 
zirconocene dichloride. The addition of 2 equivalents of a Grignard reagent to the 
zirconocene dichloride solution formed the desired disubstituted zirconocene complexes 
67 and 68. The resulting complexes 67 and 68 were handled under dinitrogen to avoid 
their interaction of the Zr metal centre with oxygen or moisture from the air. The excess 
Grignard reagent was quenched using 1,4-dioxane since the normal hydrolysis using 
water would lead to the formation of oxygen-bridged products.179 In order to remove the 
salts formed by the reaction of dioxane with the Grignard reagent, THF was evaporated 
and the resulting mixture was redissolved in toluene, leading to a pale yellow suspension 
that was then filtered under dinitrogen using a cannula. The solvent from the resulting 
solution was evaporated and no further form of purification was performed. 1H and 13C 
NMR were obtained and were in agreement with structures 67 and 68. 
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Figure 2.10 Synthesis of zirconocene compounds 67 and 68. 
 
The zirconocenes obtained were heated to 80 °C in toluene in order to induce a 
thermolysis reaction, obtaining a reactive zirconocene benzyne complex. Our study was 
focused on the use of anthracene, naphthalene and benzene nitriles in order to successfully 
form azazirconacyclopentenes. As it can be seen in Figure 2.11, this reaction, 4 different 
products using exactly the same procedure were produced. Diphenyl zirconocene 67 was 
used as starting material to produce the azaphosphindoles 69-71 and di-p-tolyl 
zirconocene 68 was used to produce the azaphosphindole 72a/b. Each reaction was 
allowed to stir at 80 °C overnight, producing a suspension which was filtered under 
dinitrogen. The resulting mixtures were evaporated under dinitrogen and washed with 
pentane in order to remove traces of unreacted aromatic nitriles. The resulting compounds 
contained an imine, which was identified by 13C and by infrared spectroscopy (Table 2.1). 
Figure 2.11 Synthesis of Azaphosphindoles 69-72. The resulting products contained different 
substituents. 
 
Electron donating groups, such as methyl groups, in benzyne mediated reactions, have 
previously proven to be poor regioselective substituents;180 which explains why 
compound 72a/b shows two different peaks at δ 2.31 and 2.27 ppm in 1H NMR. This is 
intrinsic of the reaction mechanism, in which the benzyne adduct is trapped by the nitrile. 
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Due to the electronic environment and the lack of steric hindrance, the nitrile can trap the 
benzyne intermediate in two different spatial arrangements, as shown in Figure 2.12.181 
 
Figure 2.12 Formation of complexes 69-72. The different positions of the benzene intermediate is 
not important when R = H. 
 
Purifying the compound at this stage proved to be impractical due to the formation of 
different products in the chromatography column inferring decomposition of the product. 
However, it was possible to obtain a crystal of 69 suitable for X-ray crystallographic 
analysis. 
 
Figure 2.13 X-ray crystal structure view of 69 (50% probability ellipsoids with bromine, carbon, 
chlorine, nitrogen and zirconium atoms labelled. Carbon atoms in grey). Hydrogen atoms have 
been omitted for clarity. Selected bond distances [Å] and angles [°]: Zr1–N1 2.2901(17), Zr1–C1 
2.3788(18), Zr1–C22 2.524(2), Zr1–C23 2.521(2), Zr1–C24 2.523(2), Zr1–C25 2.5280(19), Zr1–C26 
2.503(2), Zr1–C27 2.536(2), Zr1–C28 2.536(2), Zr1–C29 2.541(2), Zr1–C30 2.4984(18), Zr1–C31 
2.5067(19), N1–C7 1.291(2); N1–Zr1–C1 68.36(6), N1–Zr1–C22 137.17(7), N1–Zr1–C23 110.21(8). 
 
After reacting the imino zirconocycle with tert-butyldichlorophosphine, it was possible 
to obtain spectroscopic data of the constitutional isomers proposed. 
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Treatment of compounds 69-72a/b with tert-butyldichlorophosphine led to the 
elimination of zirconocene dichloride, producing a five-membered phosphole that was 
immediately oxidized by reaction with a chalcogen. The resulting 1,2-azaphosphindoles 
were all purified via column chromatography. Table 2.1 contains the IR and 13C NMR 
spectroscopic data, showing that the imine function remained intact after displacement of 
the zirconocene dichloride. This table also contains the general structure of compounds 
69-79, highlighted with different colours to indicate the positions that allow for 
substitutions to occur. 
 
Compound ν C=N (cm-1) δ C=N (ppm) 
HZrAnth 69 1589 191.2 
HZrNaph 70 1593 188.9 
HZrPh 71 1593 186.2 
MeZrAnth 72a/b 1578 179.1 
HPSAnth 73 1531 182.2 (d, 2JCP = 8.3 Hz) 
HPSNaph 74 1593 181.1 (d, 2JCP = 8.3 Hz) 
HPSPh 75 1531 180.0 (d, 2JCP = 7.2 Hz) 
MePSAnth 76a/b 1577 182.4 (d, 2JCP = 7.7 Hz), 
182.1 (d, 2JCP = 8.5 Hz) 
HPSeAnth 77 1537 182.2 (d, 2JCP = 11.2 Hz) 
HPSeNaph 78 1532 181.2 (d, 2JCP = 10.4 Hz) 
HPSePh 79 1531 179.1 (d, 2JCP = 9.8 Hz) 
Table 2.1 IR stretching frequencies and 13C{1H} NMR, key data for the imine functional group. PS: 
P=S, PSe: P=Se, Anth: Anthracenyl, Naph: Naphthyl, Ph: Phenyl. 
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During the experimental procedure, it was noted that temperature played a key role in 
attaining the closure of the five membered ring when the phosphorus atom displaces the 
zirconocene. When this reaction is heated to 110 °C, the target is obtained; however, if 
the reaction is heated to 80 °C, the isolated compound instead contains a P–Cl bond that 
is attached to the phenyl ring by a C–C bond with the carbon of the imine. This interesting 
result shows that the chlorothiophosphonates obtained are the kinetic products of this 
reaction, which means that the activation energy required to close the ring was not reached 
and must be higher than the energy barrier at 80 °C. The ring-closed compounds are the 
thermodynamic products, which means that while they are more thermodynamically 
stable, they require more energy to be attained. Interestingly, Majoral reported reflux 
temperatures were used only for the benzyne production step. Substitution of the 
zirconocene group by the phosphine chloride and its further oxidation with sulfur were 
performed at room temperature (Section 2.1.2). The different compounds obtained with 
this procedure are listed in Figure 2.14. The final compounds were purified by column 
chromatography and traces of zirconocene dichloride were recovered. 
 
Figure 2.14 Novel 1,2-azaphosphindoles 73-79 and chlorothiophosphonates 80 and 81. 
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The structure of novel chlorothiophosphonates 80 and 81a/b was determined by X-ray 
crystallographic analysis − this will be explained in further detail in Section 2.4.2. There 
are examples of reported crystal structures of compounds containing N–P–Cl bonds;182, 
183 however, fewer examples exist with the addition of sulfur on the phosphorus atom. 
Synthesis of chlorothiophosphonates has been already reported, with the intention of 
feveloping chiral phosphorus compounds with insecticidal activity.184 
2.4 Structural and electronic properties of 1,2-azaphosphindoles 
2.4.1 Phosphorus-selenium coupling constants in NMR 
The magnitude of 1JPSe is highly dependent upon the nature of the organic groups bound 
to the phosphorus atom; electron-withdrawing groups cause the 1JPSe coupling constant 
to increase whereas electron-donating and bulky groups cause it to decrease. It is well 
known that coupling constants between directly bonded atoms arise predominantly from 
the Fermi-contact interaction between nuclear moments and electron spins in s orbitals,185 
and there have been a number of postulations in the literature that is a correlation exists 
between the magnitude of these coupling constants and the lengths of the bonds between 
adjacent atoms.186 Sterically demanding substituents can indirectly influence the coupling 
if the intervalence angles of the phosphorus are widened; the s-character of the 
phosphorus lone pair is therefore reduced, resulting in increased Lewis basicity.187 This 
lowers the 1JPSe magnitude also. Identifying the isolated effect caused on 
1JPSe by steric 
and electronic effects has proven to be a difficult endeavour.188 Thus, electronic 
information about the compounds synthesised in this work can be acquired by inspection 
of the 1JPSe magnitude.  
 
Figure 2.15 HOMO diagrams with accompanying energies of 77-79 (in that order) calculated at the 
B3LYP/6-31G* level of theory. 
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Compounds 77-79 were obtained by adding KSeCN to the corresponding phosphole 
solution in toluene and heating it to 110 °C. Their 1JPSe were measured and contrasted 
with the values of calculated HOMO energies (calculated at the B3LYP/6-31G* level of 
theory) of their respective phosphole parents. The anthracenyl substituent decreases the 
value of 1JPSe. However, this might be related to its size rather than its electronic features, 
since anthracene is a polyaromatic hydrocarbon. In comparison, the anthracenyl group 
seems to have a more extended conjugated π-electron system, which gives it more 
stability than the naphthyl or phenyl substituents. There have been previous attempts to 
relate theoretical data with the behaviour of tertiary phosphines as ligands using DFT-
generated data.189, 190 It has been found in a set of tertiary phosphines that there is a linear 
relationship between the activation energy and the energy of the tertiary phosphines’ 
HOMO.189 The DFT calculations in Figure 2.15 show that the HOMO is more dispersed 
in 77, which contains the anthracenyl group. For the naphthyl and phenyl derivatives, we 
can determine that the HOMO contains a higher selenium character. The calculated 
energy for the HOMO energies shows that the compound 77 is the highest in energy and 
gives the lowest 1JPSe coupling constant experimentally. The difference in the 
1JPSe 
magnitudes of 77-79 must therefore be related to the HOMO distribution. 
Magnitude 77 78 79 
1JPSe (Hz) 749.5 756.9 777.4 
HOMO (eV) −5.4 −5.5 −5.4 
Table 2.2 Values of 1JPSe (Hz) and the HOMO energy calculated for the selenides 77-79 
Previous reports of selenides 82a,b191 provide an example to contrast these results, since 
the phosphorus atom forms part of a five-membered ring. The reported 1JPSe for 
phospholanes 82a,b is 693 Hz, which suggests that these compounds are stronger σ-
donors in comparison with the phosphindoles 77-79. 
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Figure 2.16 Phosphindole 77-79 and phospholanes 82a,b. 
 
2.4.2 X-ray crystallographic analysis and molecular structures 
Crystal structures were obtained for compounds 73-79; the measurement of their P=Z and 
P–N bonds show very little variations. Compound 76a/b presents an interesting case, 
since the P=S bond is shorter than in 73-75 and the P–N bond is longer. Compounds 73-
75 show very little variation in their P=S and P–N bonds, with the former one being the 
longest of the two in all the compounds.  
 
Compound P=Z* (Å) P–N (Å) 
73 1.9425(6) 1.7189(14) 
74 1.9401(7) 1.714(1) 
75 1.9417(5) 1.715(1) 
76a/b 1.9354(7) 1.7259(13) 
77 2.0910(5) 1.7193(16) 
78 2.0910(5) 1.7142(16) 
79 2.0974(10) 1.715(3) 
Table 2.3 Selected P=Z and P–N bond lengths of compounds 73-79 (Å). 
 
The methyl group in 76a/b is exerting an effect that shortens the P–N bond and elongates 
the P=S bond. Aladzheva et al.192 reported crystallographic data showing the elongation 
of P=S bonds of Pd(II) and Pt(II) complexes with the sulfur directly coordinated to the 
metallic core. However, this does not affect the P–N bond. The electron withdrawing 
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effect of the metal centres does not resemble the effect provided by the methyl group in 
76ab; therefore, the electron donating effect that the methyl group can provide does not 
satisfactorily explain this effect. For compounds 73-79, slow diffusion of diethyl ether 
into a saturated toluene solution yielded crystals suitable for X-ray crystallographic 
analysis. Compound 76a/b is an interesting case since the mechanism that produces it 
allows a mixture of regioisomers. The formation of benzyne allows for two different sites 
where the addition of 9-anthracenecarbonitrile can occur. 
 
Figure 2.17 Depiction of the formation of regioisomers 72. 
 
Regioselective reactions using benzyne derivatives have been reported using inductive or 
steric effects in order to control the selectivity.193 However, the methyl group in this case 
was used to prove that it is possible to have different substituents using the zirconocene 
approach developed by Majoral et al.178 X-ray crystallographic analysis showed the 
presence of two methyl groups in the phenyl ring of compound 76a/b. The presence of 
these two methyl groups was expected since the p-tolyl zirconozene 72a/b used to 
produce 76a/b does not possess strong inductive effects, nor is it sterically demanding 
enough to provide high regioselectivity. Groups providing this character include O-
protected groups193, 194 and fused heterocycles;195, 196 however, the development of 
regioselective benzyne derivatives is an ongoing process. 
The crystallographic analysis corroborated the NMR data that suggests that the compound 
76 exists as a mixture of two regioisomers, with the methyl group (C22, C22A) in the 
phosphindole ring occupying the para or meta positions. 
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The crystal structure provided information on the sulfides 73-76, the selenides 77-79 and 
the chlorides 80-81a/b. It was found that the length of the P–Se bond is larger than those 
of their P–S analogues. The P=S is shorter than the P=Se bond, which is a normal trend 
when compared to other crystal structures in the literature.197, 198 P=Te is the longest 
bond,199 which makes sense if one considers the electronegativity and radii. 
 
Figure 2.18 View of the molecular structures of regioisomers 76a/b (50% probability ellipsoids with 
notable carbon, chlorine, nitrogen, phosphorus and sulfur atoms labelled. Carbon atoms are in 
grey). Hydrogen atoms have been omitted for clarity. Disordered structure in the solid state with 
major component A (C22 occupancy = 0.5452) and minor component B (C22A occupancy = 
0.4548). 
 
The bond lengths found agree with the data reported in the literature regarding similar 
systems where the phosphorus atom is in a five membered-ring with different 
substituents.200-202 Table 2.4 shows the average P=Z bond lengths found for sulfides 73-
76a/b and selenides 77-79 and those of similar compounds reported in the Cambridge 
Structural Database (CSD). The average P=Z bond length of 73-76a/b is quite similar to 
the average found in the CSD. Considering the standard deviation, the difference between 
the two values might be regarded as insignificant. On the other hand, the average P=Z 
bond length for selenides 77-79 differs considerably from the average values from the 
CSD. This difference might be explained by the presence of the nitrogen atom, since there 
are no reported examples of phosphindole selenides containing a nitrogen atom in that 
position. Therefore, the average was calculated using five-membered ring phosphindole 
selenides containing a carbon atom instead of the nitrogen. The effect exerted by the 
nitrogen seems to induce the shortening of the P=Se bond when compared with the 
average P=Se bond length obtained from the CSD. 
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P=Z bond Experimental bond 
length (Average) Å 
*Reported bond 
length (Average) Å 
Z = S 1.940(7) (73-76) 1.948(5) 
Z = Se 2.0931(7) (77-79) 2.134(17) 
* There are no reports of crystal structures in CSD of selenides containing a nitrogen in that position, 
therefore the search was performed with a carbon atom. 
Table 2.4 Comparison of average values of P=Z bond lengths for compounds 73-79 and the average 
P=Z bond length found in the CSD. 
 
2.4.3 Chlorothiophosphonates 80-81 
The synthesis of sulfides 73-76a/b led to the serendipitous synthesis of phosphinothioic 
chlorides 80 and 81a/b that were identified after purification. Phosphinothioic chloride 
systems have been synthesised before because of their interesting synthetic properties.203-
205 Compound 83 was developed by Gholivand et al.206 as an acetylcholinesterase 
inhibitor, predicting that the chlorine would act as a leaving group. This would result in 
the phosphorylation of acetylcholinesterase leading to its irreversible inhibition. 
 
Figure 2.19 Acetylcholinesterase inhibitor developed by Gholivand.206 
 
31P{1H} NMR is a useful technique for identifying compounds and monitoring reactions 
where phosphorus is involved. In this case, the technique was useful in the form of 
providing information about changes in the starting material, tBuPCl2. The 
31P{1H} NMR 
spectrum obtained was originally compared to that obtained by Majoral et al.178 Their 
results showed that the phosphindole sulfide 66 (Figure 2.8) produced a signal at 100 ppm. 
Compounds 80 and 81a/b show singlets at 97.4 and 96.7 ppm; therefore, it was thought 
that the desired phosphindoles had been synthesised, while X-crystallographic data 
unambiguously assigned the structures of compounds 80 and 81a/b. 1H NMR data was 
similar to their closed ring analogues; although, the integration suggested the presence of 
one more hydrogen for both compounds. X-ray analysis helped to elucidate that this extra 
hydrogen came from the loss of the phosphindolic system. As was mentioned in Section 
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2.3, the temperature at which this reaction takes place seems to be the controlling factor 
for obtaining the phosphindole or the phosphinothioic chloride. Compound 81a/b 
contains the same mixture of regioisomers where the methyl group in the phenyl ring can 
be found in para and meta positions in the same way as the phosphindole 76. This is not 
surprising, since the information available suggests that the regioisomers are formed 
during the benzyne formation. Therefore, replacement of the zirconocene moiety by the 
tert-butyl phosphine has no effect. 
 
Figure 2.20 View of the molecular structure of 80 (50% probability ellipsoids with interesting 
carbon, chlorine, nitrogen, phosphorus and sulfur atoms labelled. Carbon atoms in grey). 
Hydrogen atoms have been omitted for clarity. 
 
 
Figure 2.21 View of the molecular structure of regioisomers 81 (50% probability ellipsoids with 
interesting carbon, chlorine, nitrogen, phosphorus and sulfur atoms labelled. Carbon atoms in 
grey). Hydrogen atoms have been omitted for clarity. Disordered structure in the solid state with 
major component A (C26 occupancy = 0.511(3)) and minor component B (C26’ occupancy = 
0.489(3)). 
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The crystallographic data for compounds 80 and 81a/b shows that carbons, which serve 
as a link between the phenyl ring and the anthracenyl group, has retained its sp2 
hybridization. Moreover, the imine also retained the  bond between the nitrogen and the 
carbon in the benzylic position.  
It is interesting to highlight that in the phosphinothioic chlorides 80 and 81a/b, there are 
two planes where the phenyl ring and the anthracenyl groups are located. These planes 
have a perpendicular relationship to each other (101.66° (19) for 80 and 99.2° (4) for 
81a/b). 
2.4.4 An investigation to the torsional angles between the phosphindole backbone 
and the PAH ancillary group 
Phosphindoles 73-79 contain two adjacent aromatic groups linked by the C7–C8 bond. 
This bond is interesting as it represents the junction of the two adjacent aromatic groups 
and is affected by the PAH attached to the phosphindole moiety. The results collected in 
Table 2.5 show that the C7–C8 bond length follows the pattern: 73>74>75. This trend 
suggests that the phenyl ring is shortening the bond. It is not clear why this happens unless 
the torsional angle formed by the two aromatic rings, the phosphindole and the PAH, is 
taken into account. As compounds 73-79 contain two aromatic rings attached by a -bond, 
a dihedral angle can be measured between the two planes formed in the solid state.  
 
Figure 2.22 An overlay diagram of 73 (red), 74 (grey) and 75 (green) showing the variation in the 
conformation of the PAH substituent. 
 
Figure 2.22 illustrates the angles a and b formed by the spatial arrangement of these 
compounds when measured in their solid state. For all of the derivatives synthesised 73-
79, b is larger when the PAH is smaller, suggesting a relationship between the C7–C8 
bond length and the PAH attached to the phosphindole. This relationship is also present 
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for the sulfides 73-75. A larger value of b implies a more parallel relationship between 
the phosphindole and the corresponding PAH. Therefore, the level of π-conjugation 
between the two aromatic moieties will increase. This conjugation could be used to 
rationalise the C7–C8 bond length pattern found for sulfides 73-75. This trend in the C7–
C8 bond length is not followed by the selenides 77-79, suggesting that the selenium atom 
is exerting an effect on the π-conjugation or directly on the C7–C8 bond length. On the 
other hand, the selenides, 77-79, follow the trend that b increases as the PAH gets 
smaller. 
 
Figure 2.23 Spatial representation of the measured dihedral angles a and b. 
 
Entry C7–C8 (Å) P=Z* (Å) 
Experimental 
(average) 
Calculated 
a (°) b (°) a (°) b (°) 
73 1.495(2) 1.9425(6) 77.9(2) 101.6(2) 82.5 97.5 
74 1.488(2) 1.9401(7) 54.7(2) 126.5(2) 56.7 123.3 
75 1.482(2) 1.9417(5) 42.9(2) 139.0(2) 35.2 144.8 
76 1.4868(5) 1.9354(7) 74.4(2) 103.8(2) 67.9 112.1 
77 1.495(5) 2.0910(5) 76.8(2) 103.2(2) 67.2 112.8 
78 1.487(4) 2.0910(5) 51.2(5) 128.8(6) 54.2 125.6 
79 1.488(7) 2.0974(10) 35.0(5) 145.0(7) 45.3 134.76 
* Z = S for 73-76 and Z = Se for 77-79 
Table 2.5 Crystallographic and DFT (B3YLP) calculated data of compounds 73-79. 
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At first glance, it seems that the tert-butyl group exerts a repulsion effect on the PAH due 
to steric hindrance, yielding a larger b than a as a result. However, Figure 2.22 shows 
that the tert-butyl group is too far away from the PAH group. On the other hand, analysis 
the crystal structure of sulfide 74 shows that most of the asymmetrical naphthyl group is 
in the quadrant near the S atom, suggesting a repulsion effect exerted by the tert-butyl 
group. This may not be definite evidence because, as it has been mentioned before, the 
tert-butyl and the naphthyl group, are too far away from each other in this molecule 
(Figure 2.24). 
 
Figure 2.24 View of the molecular structure of 74 (50% probability ellipsoids with nitrogen, 
phosphorus and sulfur atoms labelled. Carbon atoms in grey). Hydrogen atoms have been omitted 
for clarity. The majority of the naphthyl group is located in the same quadrant as the S1 atom. 
 
Comparing angles a and b from sulfides 73-75 to selenides 77-79, it is possible to 
appreciate that there are no changes in the trend. The larger the PAH, the more acute the 
b. Therefore, the phenyl ring produced the biggest values for the angle b. The size of 
the S and Se atoms do not provoke any changes in the trend of the two sets of compounds. 
DFT calculations obtained via the B3YLP functional (with the 6-31G* basis set) of the 
spatial arrangement show the same pattern and similar values. 
2.5  Photophysical data 
2.5.1 UV-Vis absorption spectroscopy 
After characterising the novel synthesised compounds 73-79, their absorption spectra was 
measured. The absorption profile of the novel 1,2-azaphosphindoles 73-79 was compared 
to the absorption profile of the different PAHs contained in them. For ease of viewing, 
the different absorption spectra obtained will be placed next to their corresponding 
molecules in the following section. Anthracene produces an absorption spectrum with 
five sharp bands between 300-400 nm that are attributed to →* transitions.40 Sulfides 
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73, 76 and selenide 77 produce four visible bands that are slightly redshifted. The three 
novel compounds show a broad band at around 300 nm with a medium intensity that 
overlaps one of the bands visible in the anthracene absorption spectrum. Another visible 
difference is the broad shoulder that is visible at around 400-450 nm (Figure 2.25).  
 
Figure 2.25 Absorption spectrum of anthracene and anthracene derivatives 73, 76 and 77, recorded 
in cyclohexane at room temperature at a 7.5 x 10 −6 M concentration. 
 
The absorption spectrum of naphthalene shows bands corresponding to →* transitions 
of the  system in the aromatic molecule between 250-300 nm. The absorption spectra of 
the sulfide 74 and the selenide 78 show a broad band at around 250-300 nm, as in the case 
of naphthalene; however, there is a second broad band in both cases. This is located at 
around 300-350 nm (Figure 2.26).  
 
Figure 2.26 Absorption spectrum of naphthalene and naphthalene derivatives 74 and 78 recorded 
in cyclohexane at room temperature at a 1.3 x 10 −5 M concentration. 
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It is important to note that the second band might correspond to the absorption produced 
in the phosphindole core, since they contain heteroatoms and double bonds that can 
undergo n→* and →* transitions. Figure 2.27 shows a visible shoulder at around 
400-450 nm which can be also explained by the presence of the new phosphindole core 
and its electronic transitions. 
 
Figure 2.27 Absorption spectrum of benzene and benzene derivatives 75 and 79 recorded in 
cyclohexane at room temperature at a 2.8 x 10 −4 M concentration. 
 
The absorption spectrum of benzene shows well defined bands at around 220-270 nm. 
The novel compounds 75 and 79 produced broad bands at around 230-320 nm which 
suggests the absorption produced by the phenyl ring contained in them absorbs at a longer 
wavelength. As with the other compounds, it is possible to observe a second band that is 
attributed to the novel phosphindole core. When comparing the different absorption 
spectra for the compounds 73-79, it is clear that the band we assumed is produced by the 
phosphindole absorbs at the same wavelength, around 350-400 nm. Benzene is the PAH 
with the least extended aromaticity; therefore, its HOMO-LUMO gap is higher which 
makes it to require more energy to absorb a photon.  
Molecule HOMO (eV) LUMO (eV) ∆E (eV) 
Benzene −6.7 0.1 6.8 
Naphthalene −5.8 −1.0 4.8 
Anthracene −5.2 −1.6 3.6 
Table 2.6 HOMO and LUMO energies of anthracene, naphthalene and benzene calculated at the 
B3LYP/6-31G* level of theory. 
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Anthracene is the PAH with the highest extended aromaticity which makes the opposite 
effect occur, allowing it to absorb photons with a less energetic wavelength. There are no 
differences in the phosphindole core of the different compounds which suggests that there 
should not be any difference in its HOMO-LUMO gap and absorption wavelength. Table 
2.6 shows the DFT-calculated values for the HOMO-LUMO gaps of the PAHs. 
2.5.2 Quantum yield 
The measurement of the photophysical properties of the novel compounds showed that 
their fluorescence quantum yields were quenched. The reference used in each case was 
the fluorophore itself, so for compounds 73, 76 and 77 the reference used was anthracene 
For 74 and 78 naphthalene was used, and benzene was used for 75 and 79. In order to 
prove that the quenching was not due to a solvent effect, photophysical measurements 
were performed in solvents with varying polarities. 
Table 2.7 demonstrates that the fluorescence of compounds 73-79 is virtually 0. It is also 
possible to ascertain that the solvent effect does not improve the quantum yields, even 
though the solvents used here have a wide range of polarities. This must be related to the 
fact that the fluorophore group of the molecules synthesised are not polar enough to 
interact with the molecules of polar solvents. The solvent effect can have a dramatic 
influence on emission spectra when the fluorophore is highly polar.207, 208 
 ΦF in: 
Compound Cy DCM MeOH MeCN 
73 54 x 10−5 0 41 x 10−5 0 
74 0 0 30 x 10−4 41 x 10−5 
75 26 x 10−5 0 14 x 10−5 2 x 10−5 
76 45 x 10−3 0 13 x 10−3 0 
77 31 x 10−4 96 x 10−5 28 x 10−4 17 x 10−5 
78 54 x 10−3 19 x 10−3 23 x 10−3 50 x 10−3 
79 0 0 20 x 10−4 23 x 10−5 
Table 2.7 The quantum yield values of compounds 73-79 obtained in cyclohexane, dichloromethane, 
methanol and acetonitrile solvents. Measurements were performed in dry degassed solvents at 
room temperature. 
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It has been reported that the interconversion of 9-anthraldehyde azine 88 into its isomers 
results in low quantum yield (Figure 2.28).209 The interconversion in the 73-79 systems 
is not possible due to the fact that the imine group forms part of a five-membered ring. 
This forms a highly restrained framework where exchange of substituents on the imine 
double bond is highly unlikely without first breaking the five membered ring of the 
phosphindole core. Therefore, although the electronic environment is more similar, this 
explanation does not satisfy this particular system. 
 
Figure 2.28 9-Anthraldehyde azine 88 and the isomerization that leads to a decrease in 
fluorescence. 
 
Compounds 73-79 contain an imine group and a chalcogenide atom. Both groups could 
act as donors and produce Photoinduced Electron Transfer (PeT), a process that has been 
detailed in Section 1.4.1. It is proposed that the lack of fluorescence in compounds 73-79 
might be due to this phenomena since the PAH moieties can act as acceptors and the lone 
pair of electrons on the nitrogen atom can act as a donor. Shinkai et al.210 have reported 
that the fluorescent sensors 84 and 85 whose fluorescence is quenched by the pair of 
electrons of its benzylamine moiety. Ghosh et al.211 synthesised 86 and 87, which are 
anthracenyl-containing compounds that contained a benzylamine which dramatically 
decreased their quantum yields. The addition of an organic acid to a solution of these 
compounds increased their quantum yields. The structure is similar to compounds 73 and 
77. However, the main difference is that, in the case of 73 and 77, the electron donor is 
an imine, not an amine as shown in Figure 2.29. 
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Figure 2.29 Compounds 73 and 77 compared to previously reported analogous compounds that 
experience PeT. 
 
The electronic environment of Shinkai and Ghosh’s amines and the novel compounds 73-
79 reported here are quite different. Compound more similar to73-79 would better explain 
the behaviour of their fluorescence. 
In the literature there are many examples of molecules containing anthracene with a 
benzylic amine212-216 or imine,217, 218 quenching the fluorescence of the molecule via a 
PeT effect. These types of molecules are commonly used as sensors that increase their 
fluorescence when the nitrogen atom in the amine or imine group is no longer able to act 
as a PeT donor. Therefore, this mechanism could be a candidate to explain the 
fluorescence quenching suffered by compounds 73-79.  
The protonated form of the compounds should be free of PeT effects if they exist. 
Compounds 73-75 were therefore dissolved in methanol and citric acid was added to the 
resulting solution. However, the solutions proved to be non-fluorescent under the UV 
light. This might not necessarily mean that the PeT did not cause this fluorescence 
quenching, since the citric acid might not have being strong enough to protonate the imine. 
Therefore, hydrochloric acid was added (The pka in water of the different protons in citric 
acid is 3.13, 4.76 and 6.39 whereas for hydrochloric acid the value is −6.13). 
Unfortunately, the result regarding fluorescence quenching was the same as with citric 
acid. However, the colour of the solutions did change. It is noticeable that compounds 73 
and 74 were more affected than compound 75. The lack of fluorescence in these solutions 
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suggests that the lone pair of electrons in the phosphindole core is not producing a 
quenching effect by PeT. However, the change of colour supports the idea that the imine 
is involved in the absorption of these compounds providing an n→* transition.  
 
Figure 2.30 Left: Compounds 73, 75 and 74 (in that order) in a solution with CDCl3. Right: 
Compounds 73, 75 and 74 in CDCl3 after the addition of 0.1 ml of 2 M solution of HCl in ethereal 
HCl. 
 
Imines can be hydrolysed in acidic conditions;219 therefore, it was a concern that the 
change of colour in the solution was due to a change in the molecular structure of 
compounds 73-75. 
 
Figure 2.31 Possible product from hydrolysis of the imine in compounds 73-75. 
 
However, this possibility seems unlikely due to the stability provided by the aromaticity 
of the phosphindole core. NMR spectroscopy demonstrated that there was no formation 
of a new product. The 31P{1H} NMR showed that the compounds retained the same 
chemical shift for the phosphorus atom as before addition of the acid. 13C{1H} NMR 
spectra of the compounds showed the same signal for the carbonyl of the imine which 
was definitive proof that the imine was unaffected (Table 2.8). 
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Compound δ C=N (ppm) δ P (ppm) 
73 182.2 (d, 2JCP = 8.4 Hz) 107.8 
73 + HCl 181.5 (d, 2JCP = 7.9 Hz) 106.7 
74 181.1 (d, 2JCP = 8.3 Hz) 106.3 
74 + HCl 181.3 (d, 2JCP = 8.3 Hz) 105.8 
75 180.0 (d, 2JCP = 7.2 Hz) 104.6 
75 + HCl 181.2 (d, 2JCP = 4.2 Hz) 101.8 
Table 2.8 C=N signal in 13C{1H} NMR and P signal in 31P{1H} NMR. The chemical shifts were 
constant for compounds 73-75 before and after the addition of ethereal HCl. 
 
The presence of the imine is proven by the lack of C=N shift; therefore, the results suggest 
that the change of colour is a pH-dependant bathochromic shift. This experiment proved 
that the PeT mechanism seems a weak explanation for the fluorescence quenching of 
compounds 73-79. 
Another explanation for the fluorescence quenching of compounds 73-79 can be given by 
the Dexter electron transfer process. As was described in Section 1.4.1, short separations 
between chromophores and chromophores arranged orthogonally aligned to each other 
favour this fluorescence quenching process. The X-ray analysis of the crystal structures 
of compounds 73-79 shows this kind of spatial disposition; however, the crystal structures 
do not necessarily represent the behaviour of the molecule in solution. In this type of 
molecules where two fluorophores are attached via covalent bonds, the donor is the 
fluorophore that absorbs at the shorter wavelength, whereas the acceptor is the moiety 
that absorbs at higher wavelength. Figure 2.32 depicts examples of compounds with these 
features. Compound 89 is contains anthracene and a BODIPY analogue. In this compound, 
anthracene donates the energy received when excited to the BODIPY moiety and this 
releases the energy in the form of photons. This molecule has a large Stokes shift which 
is necessary to avoid self-quenching.55 In compound 90 Fluorescein is the donor and 
Rhodamine 123 is the acceptor. 
  
71 
 
 
Figure 2.32 Anthracene- BODIPY (89)55 and Fluorescein-Rhodamine 123 (90)56. The dye with the 
shorter λabs wavelength works as the donor and the dye with the longest λabs works as the acceptor. 
 
Taking in account the Dexter electron transfer effect, DFT calculations (calculated at the 
B3LYP/6-31G* level of theory) were carried out in order to compare the HOMO-LUMO 
orbitals of the PAHs contained in compounds 73-79 with the novel phosphindole cores 
synthesised (Figure 2.33). The results showed that all of the PAHs have higher LUMO 
energies than those in the novel phosphindole cores. Therefore, it is sensible to propose 
that Dexter electron transfer is occurring in compounds 73-79 since the distance 
separating the two aromatic moieties is one C–C bond. In addition, the LUMO energies 
suggest that it is possible that after the electronic system of the PAHs become excited, the 
energy is transferred to the LUMO of the corresponding phosphindole core. However, 
this energy is not released as photons but in other forms of decay such as vibration of the 
moiety or heat. Therefore, the fluorescence quenching might occur due to the intrinsic 
lack of fluorescence in the phosphindole core despite the chalcogen atom contained in it 
(O, S or Se). Figure 2.33 shows the HOMO and LUMO surfaces calculated using DFT at 
the B3LYP/6-31G* level of theory. The phosphindole cores synthesised in this work 
contained S and Se; however, in order obtain a better explanation, the O analogue was 
calculated as well. 
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Figure 2.33 HOMO and LUMO energies obtained using DFT calculations (calculated at the 
B3LYP/6-31G* level of theory). 
 
Figure 2.33 also shows the effect exerted on the HOMO by the chalcogenides on the 
phosphindole core. The size of these HOMO energies decreases in the order of O-
phosphindole < S-phosphindole < Se-phosphindole. The LUMO energies do not seem to 
be as affected for the different chalcogenides as the HOMO energies. It is important to 
highlight that the O-phosphindole core also has lower LUMO than any of the PAHs 
(anthracene, naphthalene or benzene); therefore, it is highly probable that the oxide 
version of the novel phosphindoles 73-79 would be non-fluorescent as well since the 
Dexter electron transfer could also occur, according to the DFT calculations of HOMO 
energies (Table 2.9). Figure 2.34 depicts the electron exchange proposed for explaining 
the fluorescence quenching of compounds 73-79 based on the theory of Dexter electron 
transfer process. 
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Table 2.9 HOMO and LUMO surfaces of the different aromatic moieties present in compounds 73-
79 (calculated at the B3LYP/6-31G* level of theory). 
 
 
Figure 2.34 Graphical interpretation of the fluorescence quenching provoked by the Dexter 
electron transfer process. 
 
2.6 Biological activity of the novel synthesised phosphindazoles  
As mentioned previously in Section 2.1.1 (Figure 2.5), indazole-containing compounds 
have shown biological activity. The antibiotic activity of the compounds prepared by 
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Zhang et al.162 gave us impetus to measure the biological activity of the novel 
phosphindoles presented in this work. Therefore, it was decided to measure the Minimum 
Inhibitory Concentration (MIC) of these compounds.  
2.6.1 Determination of Minimum Inhibitory Concentration (MIC) 
In the next section, different procedures for defining the susceptibility of bacterial 
pathogens to compounds 73, 76 and 80 are presented. Quantitative in vitro determinations 
are usually expressed as the MIC. This measures the lowest concentration of a compound 
that inhibits the growth of the microbiological agent being tested.220 The MIC of 
compounds 73, 76 and 80 was determined by the agar diffusion test (Kirby–Bauer 
antibiotic testing), which tests the antibiotic sensitivity of bacteria. It was performed by 
impregnating paper wafers with solutions of different concentrations of the compounds 
of interest, dissolved in DMSO, to test the extent to which the bacteria were affected by 
them. Impregnated wafers were placed on a blood agar plate onto which bacteria were 
inoculated, and the plate was left to incubate at 35°C overnight. The aim of this test is to 
determine the compound concentration that inhibits microbial growth on the plate by 
measuring the zone that is free of bacteria after incubation − this is called the zone of 
inhibition. 
The concentrations used were 0, 1, 2, 4, 8, 16, 32, 64, 128 and 256 mg/L. The first 
concentration is used as baseline, in order to assure that the effect seen is not due to the 
solvent (in this case DMSO which was used to dissolve the compound). A compound 
with a higher MIC is not as potent against that particular microorganism compared to a 
compound with a lower MIC value. 
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Group Bacteria 73 76 80 
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Acinetobacter baumannii >256 >256 >256 
Burkholderia cepacia >256 >256 >256 
Enterobacter cloacae >256 >256 >256 
Escherichia coli >256 >256 >256 
Klebsiella pneumoniae >256 >256 >256 
Providencia rettgeri >256 >256 >256 
Pseudomonas aeruginosa >256 >256 >256 
Salmonella typhimurium >256 >256 >256 
Serratia marcescens >256 >256 >256 
Yersinia enterocolitica >256 >256 >256 
G
ra
m
-p
o
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e 
B
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Bacillus subtilis >256 >256 8 
Enterococcus faecalis >256 >256 128 
Enterococcus faecium >256 >256 >256 
Listeria monocytogenes >256 >256 128 
Staphylococci epidermidis >256 >256 32 
Staphylococcus aureus >256 >256 16 
Staphylococcus aureus (MRSA) >256 >256 32 
Streptococcus pyogenes >256 >256 4 
Y
ea
st
s Candida albicans >256 >256 128 
Candida glabrata >256 >256 256 
Table 2.10 Results of the Kirby Bauer test to determine MIC of bacteria to compounds 73, 76 and 
80. Concentrations given in mg/L. 
 
Table 2.10 shows that compounds 73 and 76 did not inhibit the growth of any 
microorganisms; however, compound 80 was effective in this regard. The best result for 
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80 was against Bacillus subtilis and Streptococcus pyogenes, the latter being a pathogenic 
microorganism221 that has shown antibiotic resistance to tetracycline in the past.222 
 
Figure 2.35 Left: Bacillus subtibilis. Right: Streptococcus pyogenes 
 
Zhang162 synthesised nearly 40 different compounds to obtain the promising bacterial 
gyrase B inhibitor 91. This compound was most effective against Staphylococcus aureus 
and Streptococcus pneumoniae with a MIC = 0.06 μg/ml (or 0.06 mg/mL × 10−3) for both. 
Compound 80 showed activity against Staphylococcus aureus with a MIC = 16 mg/mL; 
it is visibly less potent than compound 91. Their mechanism of action must be different 
since compound 80 does not contain a similar core to the indazole in 91. However, the 
results obtained for compounds 73 and 76 do not necessarily mean that the novel 
phosphindole core does not have biological activity against microorganisms. As the 
research carried out by Zhang162 showed, the absorption of the core inside the bacteria is 
quite important; therefore, in order to assure that the phosphindole core does not exert 
any antibiotic activity, it would be necessary to create analogues with different lipophilic 
values and compare their results. To our knowledge, there are no examples of reported 
antibiotic activity of similar compounds to phosphonamidothioic chloride 80 containing 
P−N, P= S and P−Cl bonds as in the compound presented here. It could be argued that its 
activity might come from the chloride atoms, since Cl is a good leaving group, as in the 
case of different alkylating agents used in chemotherapy such as cyclophosphamide 92.223 
However, current alkylating agents contain a C−Cl bond, not a P−Cl bond; therefore, a 
direct comparison of the biological activity of phosphonamidothioic chlorides reported to 
80 is not feasible at this point. 
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Figure 2.36 Structure of bacterial gyrase B inhibitor 91 developed by Zhang compared with the 
novel compounds 73 and 76. The core phosphindole core in phosphonamidothioic chloride 80 is 
clearly lost; therefore its antibiotic activity might be related to its P−Cl bond as in the case of the 
anticancer agent cyclophosphamide 92. 
 
2.7  Summary 
Seven novel phosphindoles 73-79 were successfully synthesised. They contain a novel 
core that resembles the one found in the natural product indazole, with phosphorus in the 
position of nitrogen in the natural product. The starting material for this synthesis was 
zirconocene dichloride, which is a metallocene that contains zirconium as the central 
metal. Using Grignard reagents, it was possible to create two Zr−aryl bonds from which 
a benzyne intermediate could be formed. Benzyne has a biradical character, 
demonstrating a highly reactive nature.224 The benzyne formation, from compounds 67 
and 68, allowed the addition of aromatic rings, anthracene, naphthalene and benzene, in 
the 3-position of the ring that were later transformed into the azaphosphindole core. 
Addition of the corresponding nitriles (9-anthracenecarbonitrile, 1-cyanonaphthalene or 
benzonitrile) led to the formation of the azazirconocycles 69-72, which were then reacted 
with tert-butyl dichlorophosphine to give the phosphindoles 73-79. 
Phosphindole 76a/b exists as a mixture of regioisomers that are formed due to the nature 
of the benzyne adduct, which is a highly reactive transition state. The coupling of the 
benzyne adduct of the zirconacycle 68 with 9-anthracenecarbonitrile allows for two 
different spatial rearrangements to be adopted (Figure 2.17), which explains the outcome 
of two different regioisomers, whose NMR data proved that the formation occurred after 
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the coupling of the 9-anthracenecarbonitrile. Finally, the substitution of zirconocene in 
the five-membered ring using the sterically hindered tert-butyl dichlorophosphine as the 
electrophile and its further oxidation with the chalcogenides, sulfur and selenium, led to 
the synthesis of compounds 73-79. Temperature was found to be a key variable in the last 
step since a temperature bellow 110 °C led to the formation of chlorothiophosphonates 
80 and 81a/b where the σ-bond between the phosphorus atom and the benzene ring never 
formed. 
Furthermore, spectroscopic analysis of compounds 73-79 showed that their quantum 
yields were virtually zero. Different hypotheses were tested in order to elucidate why the 
quantum yields of these molecules displayed such a dramatic drop. The distance between 
the phosphindole core and the corresponding PAH (a C−C bond) in compounds 73-79 
suggests that the possible mechanism is Dexter electron transfer. This mechanism usually 
takes place in compounds containing two different dyes. One dye acts as the donor of an 
electron and the other one as the acceptor. The LUMO energies calculated using DFT of 
the PAHs and different phosphindole cores (Figure 2.33) shows that the LUMO energies 
of the PAHs is higher than those of the phosphindole cores. This suggests that the Dexter 
electron transfer is energetically possible, and that this data could mean that compounds 
73-79 absorb the energy from light in the PAH moiety. The energy promotes an electron 
in the PAH orbital from a ground state to an excited state, and the electron is then 
transferred to the excited state of the acceptor phosphindole core, which in turn transfers 
an electron from its ground state to the ground state of the donor PAH. When the 
transferred electron returns to the ground state of the phosphindole, there is no emission 
due to loss of energy in the other routes but by simple emission (such as vibration or heat). 
This would mean that the phosphindole moiety is intrinsically non-fluorescent. 
The antibiotic activity demonstrated by the indazole analogues162 led us to test the 
antibiotic activity of compounds 73, 76 and 80 using the Kirby–Bauer antibiotic test. The 
results showed that the phosphindoles 73 and 76 did not exhibit any antibiotic activity; 
however, the phosphonamidothioic chloride 80 showed activity against Bacillus subtilis 
and Streptococcus pyogenes. Comparison with the reported bacterial gyrase B inhibitor 
91 showed that both compounds have activity against Staphylococcus aureus but this does 
not provide a useful comparison for 80 since it is not chemically related to the indazole 
91, whereas 73 and 76 are related by the phosphindole core. 
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2.8 Experimental 
2.8.1 General Procedure 
All air- and/or water-sensitive reactions were performed under a dinitrogen atmosphere 
using standard Schlenk line techniques. Tetrahydrofuran and toluene were dried over 
sodium/benzophenone and sodium respectively and distilled prior to use. Toluene and 
petrol used for column chromatography were used as received from the suplier. All 
starting materials were purchased from Aldrich, Acros Organics, Alfa Aesar or Strem and 
used as received. Compound 67178 was prepared according to literature procedures. Flash 
chromatography was performed on silica gel from Fluorochem (silica gel, 40-63u, 60A). 
Thin-layer chromatography was carried out on Fisher aluminium-based plates with silica 
gel and fluorescent indicator (254 nm). Melting points were determined in open glass 
capillary tubes on a Stuart SMP3 melting point apparatus. 1H, 13C{1H} and 31P{1H} NMR 
spectra were recorded on a JEOL ECS-400 (1H 399.78 MHz) spectrometer at room 
temperature (21°C); 1H and 13C shifts were relative to tetramethylsilane, 31P relative to 
80% H3PO4. Infrared spectra were recorded on a Varian 800 FT-IR spectrometer. UV-
Vis absorption and emission spectra were recorded on a UV-1800 Shimadzu 
spectrophotometer and RF-6000 Shimadzu spectrofluorometer respectively. Mass 
spectrometry was carried out by the EPSRC National Mass Spectrometry Service Centre, 
Swansea. 
2.8.2 Diphenyl zirconocene 67 
 
Zirconocene dichloride (1.00 g, 3.42 mmol) was dissolved in THF (10 mL); a solution of 
phenyl magnesium bromide (2.3 ml, 6.84 mmol) was then added dropwise, giving a 
transparent brown solution. The reaction was left for 20 minutes and then anhydrous 
dioxane (1.75 mL, 20.52 mmol) was added dropwise. The solution turned into a 
suspension containing a white solid in a yellow solution. After 15 hours, the solvent was 
evaporated and the solid was dissolved again using anhydrous toluene (25 mL). The 
suspension was then filtered under dinitrogen through a fritted funnel, using a cannula. 
The yellow obtained solution was then dried under reduced pressure to give a yellow solid 
(1.02 g, 80%). MP: 150.0 °C. 1H NMR (400 MHz, CDCl3) δ 7.31 (d, 3JHH = 7.5 Hz, 4H), 
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7.18-7.13 (m, 4H), 7.07 (t, 3JHH = 7.8 Hz, 2H), 6.22 (s, 10H) ppm. 13C{1H} NMR (100 
MHz, CDCl3) δ 182.9, 135.8, 126.6, 125.4, 112.3 ppm, IR (neat): 𝜈 = 3062 (w), 2214 (s), 
1446 (s), 1015 (s), 600 (s), 731 (s) cm−1. 
2.8.3 3-Anthracen-9-yl-(phenyl-azazirconacyclopentene) 69 
 
Diphenyl zirconocence (2.16 g, 5.73 mmol) was dissolved under dinitrogen in anhydrous 
toluene (40 mL). The yellow solution then had the corresponding nitrile 9-
cyanoanthracene (1.15 g, 5.73 mmol) added to it. The resulting brown suspension was 
heated to 80 °C and left to react overnight. After that period the reaction was left to cool 
down to room temperature. The suspension was finally filtered through a fritted funnel 
using a cannula under dinitrogen, obtaining a brown solid (0.71 g, 25%). MP: 147.5 °C. 
1H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 8.07 (d, 3JHH = 7.6 Hz, 2H), 7.68 (d, 3JHH = 
7.6 Hz, 1H), 7.59-7.47 (m, 6H), 7.28 (d, 3JHH = 7.1 Hz, 1H), 6.80 (d, 
3JHH = 7.1 Hz, 1H), 
6.76 (d, 3JHH = 7.4 Hz, 1H), 6.22 (s, 10H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 190.8, 
144.4, 141.0, 131.2, 131.1, 130.4, 130.3, 129.1, 129.0, 128.9, 128.6, 127.3, 125.8, 124.9, 
124.8, 123.9, 111.0, 110.9 ppm. IR (neat): 𝜈 = 3052 (w), 2214 (s), 1589 (w), 1446 (s), 
1015 (s), 731 (s), 695 (s) cm−1. 
2.8.4 3-Anthracen-9-yl-((1-tert-butyl)-1-sulfide-1H-1,2-azaphosphindole) 73 
 
The organophosphorus compound tert-butyl dichlorophosphine (0.81 g, 5.13 mmol) was 
added to a refluxing solution of 3-anthracen-9-yl-(phenyl-azazirconacyclopentene) (69) 
(2.56 g, 5.13 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, sulfur 
(0.32 g, 10.56 mmol) was added to the black mixture which was stirred for another hour 
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during this time, the reaction was monitored by 31P NMR. The mixture cooled to room 
temperature and the solvent evaporated. The resulting mixture was purified using column 
chromatography (petrol/toluene 1:1, Rf = 0.5). The product was a bright yellow solid (0.66 
g, 33%). A sample suitable for X-ray crystallographic analysis was obtained from toluene. 
MP: 91.8 °C. 1H NMR (300 MHz, CDCl3) δ 8.53 (s, 1H), 8.01 (d, 3JHH = 8.6 Hz, 1H), 
7.98-7.90 (m, 3H), 7.58-7.48 (m, 2H), 7.42-7.35 (m, 3H), 7.32-7.24 (m, 2H), 6.85 (d, 3JHH 
= 7.8 Hz, 1H), 1.38 (d, 3JHP = 17.6 Hz, 9H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 182.2 
(d, 2JCP = 8.4 Hz), 155.0, 141.7 (d,
 JCP = 26.5 Hz), 139.5, 138.9, 131.3, 130.9 (d, JCP = 8.1 
Hz), 129.7, 129.0, 128.3, 128.1, 127.9 (d, JCP = 6.3 Hz), 127.5, 126.7 (d,
 JCP = 20.1 Hz), 
126.4, 125.5, 125.3 (d, JCP = 12.1 Hz), 124.8, 124.2 (d,
 JCP = 15.9 Hz), 123.9, 119.0, 34.4 
(d, 1JCP = 59.0 Hz), 23.7 ppm. 31P{1H} NMR (121 MHz, CDCl3) δ 107.8 ppm. IR (neat): 
𝜈 = 2972 (w), 2256 (w), 1980 (w), 1676 (s), 1531 (s), 1286 (s), 1131 (s), 889 (s), 734 (s), 
685 (s) cm−1. HRMS (ESI+) exact mass calcd. for C25H23N1P1S1 [M+H]
+ requires m/z 
400.1289, found m/z 400.1289 (0.1 ppm). 
2.8.5 3-Naphthalen-1-yl-(phenyl-azazirconacyclopentene) 70 
 
Diphenyl zirconocence (1.93 g, 5.13 mmol) was dissolved under dinitrogen in anhydrous 
toluene (40 mL) resulting in a yellow transparent solution and 1-cyanonaphthalene (0.78 
g, 5.13 mmol) was then added. The resulting brown suspension was heated to 80 °C and 
left to react overnight. After that period the reaction was left to cool down to room 
temperature. The suspension was then filtered through a fritted funnel using a cannula 
under dinitrogen, obtaining a brown solid (0.71 g, 25%). IR (neat): 𝜈 = 3059 (w), 2959 
(w), 1724 (m), 1593 (m), 1505 (s), 1275 (s), 1017 (s), 795 (s) cm−1. 
2.8.6 3-Naphthalen-1-yl-((1-tert-butyl)-1-sulfide-1H-1,2-azaphosphindole) 74 
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The organophosphorus compound tert-butyl dichlorophosphine (0.81 g, 5.13 mmol) was 
added to a refluxing solution of 3-naphtalen-1-yl-(phenyl-azazirconacyclopentene) (70) 
(2.31 g, 5.13 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, sulfur 
(0.32 g, 10.56 mmol) was added to the black mixture which was stirred for another hour 
during this period, the reaction was monitored by 31P NMR spectroscopy. The mixture 
cooled to room temperature and the solvent evaporated. The resulting mixture was 
purified using column chromatography (petrol/toluene 3:1, Rf = 0.4). The product was a 
pale yellow solid (0.71 g, 40%). A sample suitable for X-ray crystallographic analysis 
was obtained from toluene. MP: 101.3 °C. 1H NMR (300 MHz, CDCl3) δ 7.59-7.75 (m, 
4H), 7.57 (d, 3JHH = 7.1 Hz, 1H), 7.51-7.29 (m, 5H), 7.21 (d,
 3JHH = 7.5 Hz, 1H), 1.21 (d,
 
3JHP = 18.0 Hz, 9H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 181.1 (d, 2JCP = 7.9 Hz), 
141.8 (d, JCP = 31.6 Hz), 140.4 (d, JCP = 69.4 Hz), 133.8, 132.3, 132.1, 131.8 (d, JCP = 8.5 
Hz), 131.3, 130.9, 129.1 (d, JCP = 8.9 Hz), 128.7, 127.3, 127.2, 126.7, 126.6, 126.4, 125.3 
(d, JCP = 37.7 Hz), 35.5 (d, 
1JCP = 58.1 Hz), 24.6 ppm. 31P{1H} NMR (121 MHz, CDCl3) 
δ 106.3 ppm. IR (neat): 𝜈 = 2968 (s), 2928 (w), 2864 (s), 2399 (w), 2272 (w), 1538 (s), 
1294 (s), 1254 (s), 1205 (s), 1130 (s), 936 (s), 829 (s), 804 (s), 766 (s), 743 (s), 709 (s), 
688 (s) cm−1. HRMS (ESI+) exact mass calcd. for C21H21N1P1S1 [M+H]
+ requires m/z 
350.1127, found m/z 350.1130 (0.9 ppm). 
2.8.7 3-Phenyl-(phenyl-azazirconacyclopentene) 71 
 
Diphenyl zirconocence (1.93 g, 5.13 mmol) was dissolved under dinitrogen in anhydrous 
toluene (40 mL) resulting in a yellow transparent solution; 1-cyanonaphthalene (0.53 ml, 
5.13 mmol) was then added. The resulting brown suspension was heated to 80 °C and left 
to react overnight. After that period, the reaction was left to cool down to room 
temperature. The suspension was then filtered through a fritted funnel using a cannula 
under dinitrogen, obtaining a yellow solid (0.71 g, 25%). IR (neat): 𝜈 = 3292 (w), 1593 
(s), 1487 (m), 1280 (m), 1072 (s), 1019 (s), 804 (s), 756 (s), 695 (s) cm−1 
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2.8.8 3-Phenyl-((1-tert-butyl)-1-sulfide-1H-1,2-azaphosphindole) 75 
 
The organophosphorus compound tert-butyl dichlorophosphine (0.81 g, 5.13 mmol) was 
added to a refluxing solution of 3-phenyl-(phenyl-azazirconacyclopentene) (71) (2.06 g, 
5.13 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, sulfur (0.32 g, 
10.56 mmol) was added to the black mixture which was stirred for another hour during 
this time, the reaction was monitored by 31P NMR. The mixture cooled to room 
temperature and the solvent was evaporated. The resulting mixture was purified using 
column chromatography (petrol/ethyl acetate 9:1, Rf = 0.4). The product was a colourless 
crystalline solid (0.68 g, 44%). A sample suitable for X-ray crystallographic analysis was 
obtained from toluene. MP: 95.0 °C. 1H NMR (300 MHz, CDCl3) δ 7.89-7.73 (m, 4H), 
7.59-7.44 (m, 5H), 1.18 (d, 3JHP = 17.4 Hz, 9H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 
180 (d, 2JCP = 7.2 Hz),141.5, 140.8, 140.5, 140.2, 134.6 (d, JCP = 20.0 Hz), 131.9 (d, JCP 
= 32.5 Hz), 131.5 (d, JCP = 9.5 Hz), 129.4 (d, JCP = 8.8 Hz), 128.9 (d, JCP = 18.3 Hz), 126.3 
(d, JCP = 11.5 Hz), 35.5 (d, 
1JCP = 58.8 Hz), 24.5 ppm, 31P{1H} NMR (121 MHz, CDCl3) 
δ 104.6 ppm. IR (neat): 𝜈 = 2970 (s), 2955 (s), 2863 (s), 2650 (w), 2399 (w), 1972 (w), 
1531 (s), 1489 (s), 1443 (s), 1360 (s), 1328 (s), 1296 (s), 1153 (s), 1132 (s), 957 (s), 806 
(s), 792 (s), 717 (s), 686 cm−1. HRMS (ESI+) exact mass calcd. for C17H18N1P1S1 [M+H]
+ 
requires m/z 350.1127, found m/z 350.1130 (0.9 ppm). 
2.8.9 Bis(p-tolyl) zirconocene 68 
 
Zirconocene dichloride (1.50 g, 5.13 mmol) was dissolved in a Schlenk flask in THF (15 
mL); a solution of p-tolylmagnesium bromide (3.4 ml, 10.26 mmol) was then added 
dropwise, resulting in a transparent yellow solution. The solution was left to react for 20 
minutes and then anhydrous dioxane (2.6 mL, 30.79 mmol) was added dropwise; the 
solution turned into a suspension containing a white solid in a yellow solution. After 15 
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hours, the solvent was evaporated and the resulting solid was dissolved again using 
anhydrous toluene (40 mL). The resulting suspension was then filtered under dinitrogen 
through a fritted funnel, using a cannula. The yellow solution was then dried under 
reduced pressure to give a yellow solid (1.87 g, 90%). MP: 150.0 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.21 (d, 3JHH = 7.3 Hz, 4H), 6.98 (d, 3JHH = 7.3 Hz, 4H), 6.20 (s, 10H), 2.29 (s, 
6H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 179.0, 135.9, 134.8, 127.3, 112.1, 21.3 ppm. 
IR (neat): 𝜈 = 2963 (w), 1723 (w), 1599 (m), 1503 (s), 1278 (s), 1017 (m), 800 (s) cm−1. 
2.8.10 3-Anthracen-9-yl-(p-tolyl-azazirconacyclopentene) 72a/b 
 
Bis(p-tolyl) zirconocene (1.87 g, 4.63 mmol) was dissolved under dinitrogen in 
anhydrous toluene (30 mL) resulting in a yellow transparent solution; 9-cyanoanthracene 
(0.94 g, 4.63 mmol) was then added. The resulting brown suspension was heated to 80 °C 
and left to react overnight. After that time the reaction was left to cool down to room 
temperature; afterwards, the suspension was filtered through a fritted funnel using a 
cannula under dinitrogen, obtaining a brown solid. Pentane was added to the resulting 
black solution, forming a suspension which was filtered under dinitrogen. The solvent of 
the final yellow solution was evaporated under dinitrogen and the product was a yellow 
solid (0.25 g, 10%). MP: 136.8 °C. 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 8.49 (d, 
3JHH = 6.7 Hz, 1H), 8.33 (d, 
3JHH = 8.9 Hz, 1H), 8.02-7.94 (m, 6H), 7.61 (d, 
3JHH = 8.1 Hz, 
2H), 7.53-7.45 (m, 4H), 6.12 (s, 10H) ppm, 2.31 (s, 1.5H), 2.27 (s,1.5H). 13C{1H} NMR 
(75 MHz, CDCl3) δ 179.1, 136.0, 137.8, 134.8, 133.4, 133.2, 132.8, 132.3, 131.3, 130.6, 
129.4, 129.0, 128.8, 128.4, 127.4, 127.0, 126.4, 125.9, 125.7, 125.5, 125.3, 112.1, 21.4, 
21.3 ppm. IR (neat): 𝜈 = 2956 (w), 2195 (s), 1578 (w), 1436 (s), 1056 (s), 711 (s), 702 (s) 
cm−1. 
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2.8.11 3-Anthracen-9-yl-((1-tert-butyl)-(4-methyl)-1-sulfide-1H-1,2-
azaphosphindole) / 3-Anthracen-9-yl-((1-tert-butyl)-(5-methyl)-1-sulfide-1H-
1,2-azaphosphindole) 76a/b 
 
The organophosphorus compound tert-butyl dichlorophosphine (0.68 g, 4.27 mmol) was 
added to a refluxing solution of 3-anthracen-9-yl-(p-tolyl-azazirconacyclopentene) (72) 
(2.19 g, 4.27 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, sulfur 
(0.27 g, 8.54 mmol) was added to the black mixture which was stirred for another hour 
during this time, the reaction was monitored by 31P NMR. The mixture cooled to room 
temperature and the solvent was evaporated. The resulting mixture was purified using 
column chromatography (petrol/toluene 1:2, Rf = 0.4). The product was a bright yellow 
solid (0.65 g, 36%). A sample suitable for X-ray crystallographic analysis was obtained 
from toluene. MP: 106.0 °C. 1H NMR (300 MHz, CDCl3) δ 8.56 (d, 3JHH = 6.3 Hz, 1H), 
8.07-7.89 (m, 3H), 7.75 (d, 3JHH = 7.3 Hz, 1H), 7.60 (d,
 3JHH = 7.7 Hz, 1H), 7.47-7.28 (m, 
5H), 7.10 (d, 3JHH = 7.5 Hz, 1H), 2.41 (s, 1.5H), 2.13 (s, 1.5H), 1.43 (d,
 3JHP = 3.0 Hz, 
4.5H), 1.37 (d, 3JHP = 3.0 Hz, 4.5H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 182.4 (d, 
2JCP = 7.7 Hz), 182.1 (d, 
2JCP = 8.5 Hz), 141.2, 140.9, 140.6, 140.5, 137.6, 136.9, 134.2, 
133.1, 132.9 (d, JCP = 8.9 Hz), 131.6, 130.8, 130.0, 129.8 (d, 
3JHP = 9.7 Hz), 129.4 (d, JHP 
= 3.8 Hz), 129.1-128.9 (overlapped signals), 128.5, 127.5, 126.8 (d, JHP = 7.4 Hz), 126.2 
(d, JHP = 12.0 Hz), 125.3-125.1 (overlapped signals), 114.2, 35.4 (d, 
1JCP = 53.6 Hz), 24.8, 
21.5 (d, 1JHP = 28.2 Hz) ppm. 31P{1H} NMR (121 MHz, CDCl3) δ 107.2, 107.1 ppm. IR 
(neat): 𝜈 = 2967 (w), 2376 (w), 1577 (w) 1241 (s), 825 (s), 756 (s), 704 (s) cm−1. HRMS 
(ESI+) exact mass calcd. for C26H25N1P1S1 [M+H]
+ requires m/z 414.1440, found m/z 
400.1439 (0.2 ppm). 
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2.8.12 3-Anthracen-9-yl-((1-tert-butyl)-1-selenide-1H-1,2-azaphosphindole) 77 
 
The organophosphorus compound tert-butyl dichlorophosphine (0.81 g, 5.13 mmol) was 
added to a refluxing solution of 3-anthracen-9-yl-(phenyl-azazirconacyclopentene) (69) 
(2.56 g, 5.13 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, 
potassium selenocyanate (1.48 g, 10.56 mmol) was added to the black mixture which was 
stirred for another hour during this time, the reaction was monitored by 31P NMR 
spectroscopy. The mixture cooled to room temperature and the solvent was evaporated. 
The resulting mixture was purified using column chromatography (petrol/toluene 1:1, Rf 
= 0.4). The product was a brown solid (0.48 g, 24%). A sample suitable for X-ray 
crystallographic analysis was obtained from toluene/petrol. MP: 110.6 °C. 1H NMR (300 
MHz, CDCl3) δ 8.57 (s, 1H), 8.05 (d, 3JHH = 8.13 Hz, 1H), 8.02-7.89 (m, 3H), 7.61-7.52 
(m, 2H), 7.46-7.38 (m, 3H), 7.35-7.27 (m, 2H), 6.90 (d, 3JHH = 8.3 Hz, 1H), 1.41 (d,
 3JHP 
= 18.1 Hz, 9H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 182.2 (d, 2JCP = 11.2 Hz), 142.7, 
142.4, 141.1, 132.2, 132.0 (d, JCP = 7.7 Hz), 131.9, 131.7, 130.8, 130.4, 129.5-129.1 
(overlapped signals), 128.5, 127.7, 127.5, 127.2, 126.7, 126.5, 125.9, 125.3 (d, JCP = 8.9 
Hz), 124.9, 35.5 (d, 1JCP = 47.4 Hz), 24.8 ppm. 31P{1H} NMR (121 MHz, CDCl3) δ 103.0 
(s with 77Se satellites, 1JSeP = 749.5 Hz) ppm. IR (neat): 𝜈 = 2970 (w), 2394 (w), 2242 
(w), 1537 (s), 1359 (s), 1241 (s), 1131 (s), 914 (s), 889 (s), 727 (s) cm−1. HRMS (ESI+) 
exact mass calcd. for C25H23N1P1Se1 [M+H]
+ requires m/z 448.0735, found m/z 448.0727 
(0.1 ppm). 
2.8.13 3-Naphth-1-yl-((1-tert-butyl)-1-selenide-1H-1,2-azaphosphindole) 78 
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The organophosphorus compound tert-butyl dichlorophosphine (0.73 g, 4.56 mmol) was 
added to a refluxing solution of 3-naphtalen-1-yl-(phenyl-azazirconacyclopentene) (70) 
(2.06 g, 4.56 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, 
potassium selenocyanate (0.32 g, 10.56 mmol) was added to the black mixture which was 
stirred for another hour during this time, the reaction was monitored by 31P NMR. The 
mixture cooled to room temperature and the solvent evaporated. The resulting mixture 
was purified using column chromatography (petrol/toluene 5:1, Rf = 0.6). The product 
was a pale brown solid (0.76 g, 42%). A sample suitable for X-ray crystallographic 
analysis was obtained from toluene. MP: 105.6 °C. 1H NMR (300 MHz, CDCl3) δ 7.95 
(d, 3JHH = 8.5 Hz, 2H), 7.90-7.84 (m, 2H), 7.64 (d, 
3JHH = 7.3 Hz, 1H), 7.58-7.51 (m, 2H), 
7.49-7.37 (m, 3H), 7.30 (d, 3JHH = 7.5 Hz, 1H), 1.27 (d, 
3JHP = 18.2 Hz, 9H) ppm. 13C{1H} 
NMR (75 MHz, CDCl3) δ 181.2 (d, 2JCP = 10.4 Hz), 141.9, 141.5, 141.1, 133.8, 132.0-
131.7 (overlapped signals), 131.2, 131.0, 129.3, 129.2, 127.9 (d, JCP = 101.3 Hz), 127.4, 
126.8, 126.7, 125.5, 124.9, 35.6 (d, 1JCP = 48.9 Hz), 24.7 ppm. 31P{1H} NMR (121 MHz, 
CDCl3) δ 101.2 (s with 77Se satellites, 1JSeP = 756.9 Hz) ppm. IR (neat): 𝜈 = 3665 (w), 
2969 (w), 2901 (w), 2222 (w), 1953 (w), 1532 (s), 1295 (s), 1254 (s), 1130 (s), 1066 (s), 
935 (s), 803 (s), 774 (s) cm−1. HRMS (ESI+) exact mass calcd. for C21H20N1P1Se1 [M+H]
+ 
requires m/z 392.0632, found m/z 392.0636 (0.9 ppm). 
2.8.14 3-Phenyl-((1-tert-butyl)-1-selenide-1H-1,2-azaphosphindole) 79 
 
The organophosphorus compound tert-butyl dichlorophosphine (0.81 g, 5.13 mmol) was 
added to a refluxing solution of 3-Phenyl-(phenyl-azazirconacyclopentene) (71) (2.06 g, 
5.13 mmol) in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, sulfur (0.32 g, 
10.56 mmol) was added to the black mixture which was stirred for another hour; during 
this time, the reaction was monitored by 31P NMR spectroscopy. The mixture cooled to 
room temperature and the solvent evaporated. The resulting mixture was purified using 
column chromatography (petrol/ethyl acetate 9:1, Rf = 0.5), and was obtained a colourless 
crystalline solid (0.68 g, 44%). A sample suitable for X-ray crystallographic analysis was 
obtained from toluene. MP: 95.0 °C. 1H NMR (300 MHz, CDCl3) δ 7.89-7.73 (m, 4H), 
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7.59-7.44 (m, 5H), 1.18 (d, 3JHP = 17.4 Hz, 9H) ppm. 13C{1H} NMR (75 MHz, CDCl3) δ 
179.1 (d, 2JCP = 8.4 Hz), 141.4, 140.8, 139.3, 139.0, 133.5 (d,
 JCP = 21.7 Hz), 130.8 (d,
 JCP 
= 13.2 Hz), 130.5 (d, JCP = 9.7 Hz), 128.5 (d,
 JCP = 10.5 Hz), 127.9 (d,
 JCP = 30.0 Hz), 
125.5 (d, JCP = 11.9 Hz), 34.6 (d,
 1JCP = 50.5 Hz), 23.5 ppm. 31P{1H} NMR (121 MHz, 
CDCl3) δ 104.6 (s with 77Se satellites, 1JSeP = 777.4 Hz) ppm. IR (neat): 𝜈 = 2970 (s), 
2955 (s), 2863 (s), 2650 (w), 2399 (w), 1972 (w), 1531 (s), 1489 (s), 1443 (s), 1360 (s), 
1328 (s), 1296 (s), 1153 (s), 1132 (s), 957 (s), 806 (s), 792 (s), 717 (s), 686 cm−1. HRMS 
(ESI+) exact mass calcd. for C21H21N1P1S1 [M+H]
+ requires m/z 350.1127, found m/z 
350.1130 (0.9 ppm). 
2.8.15 N-(Anthracen-9-yl(phenyl)methylene)-P-(tert-butyl)phosphonamidothioic 
chloride 80 
 
The organophosphorus compound tert-butyl dichlorophosphine (0.81 g, 5.13 mmol) was 
added to a solution of 3-anthracen-9-yl-(phenyl-azazirconacyclopentene) (69) (2.56 g, 
5.13 mmol) heated at 80 °C in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, 
sulfur (0.32 g, 10.56 mmol) was added to the black mixture which was stirred for another 
hour; during this time, the reaction was monitored by 31P NMR. The mixture cooled to 
room temperature and the solvent was evaporated. The resulting mixture was purified 
using column chromatography (petrol/toluene 1:1, Rf = 0.6). The product was a bright 
yellow solid (0.63 g, 29%). A sample suitable for X-ray crystallographic analysis was 
obtained from toluene. 1H NMR (300 MHz, CDCl3) δ 8.58 (s, 1H), 8.07-8.02 
(overlapping signals, 2H), 7.80 (d, 3JHH = 8.6 Hz, 1H), 7.74 (d, 
3JHH = 8.4, 2H), 7.59-7.42 
(m, 5H), 7.36 (m, 3H), 1.44 (d, 3JHP = 21.6 Hz, 9H) ppm. 13C{1H} NMR (75 MHz, CDCl3) 
δ 181.2 (d, 2JCP = 8.2 Hz), 138.9, 138.6, 133.7, 131.2, 131.0, 130.7, 130.1, 129.8, 129.0, 
128.9, 128.8-128.7 (overlapping signals), 128.4, 127.6, 127.0, 126.6, 126.4, 126.1, 125.5, 
125.3, 43.3 (d, 1JCP = 85.9 Hz), 24.9 ppm. 31P{1H} NMR (121 MHz, CDCl3) δ 97.4 ppm. 
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2.8.16 N-(Anthracen-9-yl(p-tolyl)methylene)-P-(tert-butyl)phosphonamidothioic 
chloride / N-(anthracen-9-yl(m-tolyl)methylene)-P-(tert-
butyl)phosphonamidothioic chloride 81a/b 
 
The tertiary phosphine tert-butyl dichlorophosphine (0.68 g, 4.27 mmol) was added to a 
solution of 3-anthracen-9-yl-(p-tolyl-azazirconacyclopentene) (72) (2.19 g, 4.27 mmol) 
heated at 80 °C in anhydrous toluene (50 mL) under dinitrogen. After 3 hours, sulfur 
(0.27 g, 8.54 mmol) was added to the black mixture which was stirred for another hour, 
during this time, the reaction was monitored by 31P NMR. The mixture cooled to room 
temperature and the solvent was evaporated. The resulting mixture was purified using 
column chromatography (petrol/toluene 1:2, Rf = 0.4), which gave a bright yellow solid 
(0.65 g, 36%). A sample suitable for X-ray crystallographic analysis was obtained from 
toluene. 1H NMR (300 MHz, CDCl3) δ 8.33-8.31 (m, 2H), 7.98-7.93 (m, 3H), 7.71 (d, 
3JHH = 8.4 Hz, 1H), 7.64-7.60 (m, 1H), 7.54 (d,
 3JHH = 8.4 Hz, 1H), 7.50-7.46 (m, 2H), 
7.41-7.37 (m, 2H), 7.06 (d, 3JHH = 8.0 Hz, 1H), 2.28-2.20 (m, 3H), 1.35 (d,
 3JHP = 22.0 Hz, 
9H). 13C{1H} NMR (100 MHz, CDCl3) δ 178.3, 143.8, 133.6, 135.07, 133.1, 132.3, 131.7, 
130.1, 129.7, 129.7, 129.1, 128.6, 127.9, 127.7, 127.6, 127.4, 127.3, 126.6, 126.0, 125.4, 
125.3, 124.9, 42.1 (d, 1JCP = 90.0 Hz), 23.7, 20.7, 20.4 ppm. 31P{1H} NMR (121 MHz, 
CDCl3) δ 96.7 ppm. 
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3 Synthesis of a pyrene-based tridentate phosphine and its 
coordination chemistry in complexes of biological interest 
3.1 Primary phosphines on aromatic backbones 
The synthesis of primary phosphines is a task that requires an elevated technical effort 
due to their high reactivity towards oxidation in the presence of atmospheric oxygen 
(Section 1.3). Our research group has developed different air-stable phosphines, which 
has allowed the further synthesis of ligands with interesting properties. 
 
Figure 3.1 Primary phosphines previously reported by this group. 
 
 
The chiral primary phosphine 3188 and the fluorescent air-stable phosphine 14b225 were 
developed as required intermediates to develop different phosphine analogues. This type 
of compound are underdeveloped despite their importance in catalytic and biomedical 
applications. An example of these applications is the use of by the fluorescent phosphine 
14b to develop imaging probes containing Re and 99mTc as radionuclides.152 The 
phosphines presented in Figure 3.1 have something in common, both functional groups 
are bonded directly to the aryl group. This is important because the effect provided by the 
extended π conjugation of the aromatic rings stabilizes the −PH2 group towards air-
oxidation. Our group decided that it would be interesting to use this knowledge on a 
different fluorescent core. As it was mention in Section 1.5.1.1, Polycyclic Aromatic 
Hydrocarbons (PAHs) are not only fluorescent but are also capable of intercalating with 
DNA giving them biological activity. Therefore, it was decided to use pyrene as the 
aromatic backbone of a novel phosphine. In order to keep the intercalating activity of the 
pyrene core, it was necessary to add an alkyl chain as a spacer to avoid any interference 
of the new moieties attached to the PAH. 
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Figure 3.2 Possible primary phosphines containing pyrene as backbone.  
 
Figure 3.2 contains the structures of interest for our research. Following the success with 
BODIPY−PH2, we were interested in primary phosphines containing an R group with 
other potential biological roles. We also know that π conjugation gives stability on the 
−PH2 group. Therefore, knowing that pyrene intercalates DNA, we decided to synthesise 
a primary phosphine containing a pyrenyl group as backbone. The parent compound 
PyrPH2 93 is of interest as another aryl bound −PH2 molecule, but the commercial 
availability of starting materials, favoured the synthesis of the alkyl-chain PyrCH2PH2 94 
and Pyr(CH2)4PH2 95. This allowed us to investigate the effect of having a remote π-
stabilising group on the phosphine air-sensitivity. For compound Pyr(CH2)4PH2 95 the 
relatively large separation between the aryl and the phosphine group may facilitate DNA 
intercalation. This feature might be important when incorporating a transition metal of 
biomedical importance/significance. 
3.2 Quantum chemical calculations 
Initial calculations predict that the incorporation of the phosphino group onto a pyrene 
backbone would lead to a SOMO above −10 eV, which is an indicator of a stable primary 
phosphine. 
In order to establish the electronic nature of 93, 94 and 95 in comparison to other 
phosphines, a series of DFT calculations using the B3LYP function with a 6-31G* basis 
set were employed (theoretical groups have used the same level of theory for modelling 
phenylphosphine226). This showed that phosphines that have an extended π-electron 
structural motif possess a HOMO with no significant phosphorus character, they also 
demonstrate stability to air oxidation.37 It was anticipated from initial quantum chemical 
calculations that the incorporation of a phosphino functional group onto a pyrenyl 
skeleton would produce air-stable primary phosphines. The molecular structure of 95 
does not indicate a crowded environment in the vicinity of the P-atom since the pyrene 
structure is flat and it is four carbon atoms away from the primary phosphine, thus ruling 
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out steric hindrance as a contributor to any air-stability and isolating electronics as the 
key controlling factor.  
 
Figure 3.3 Calculated molecular orbital surfaces from the LUMO, HOMO and SOMO of the 
primary phosphines 93-95. 
 
 
The HOMOs of the neutral molecules of 93, 94 and 95 are shown in Figure 3.3. The 
compound PyrPH2 93 shows a weak phosphorus character in the HOMO and its SOMO 
energy is too near to the proposed stability threshold −10 eV. The methylene group used 
as a linker in PyrMePH2 94 does not efficiently isolate phosphorus from the HOMO that 
is on the pyrene system. On the other hand, the HOMO of Pyr(CH2)4PH2 95 do not 
incorporate the phosphorus atom and is predominately on the pyrene skeleton. It is 
possible to infer from this result that long aliphatic chains attached to a PAH such as 
pyrene could lead to more stable phosphines. In the three compounds, 93, 94 and 95, the 
SOMO energy is above the stability threshold. Following the pattern discovered in 
previous findings,37 it is possible to predict that the phosphines PyrPH2 93, PyrCH2PH2 
94 and Pyr(CH2)4PH2 95 will be resistant to air oxidation. However, it would be 
interesting to compare their stabilities since the differences shown in their HOMO and 
SOMO energies might also lead to stability differences. 
In order to have a better understanding of the effect exerted by the alkyl chain, the SOMO 
energies of a series of pyrenyl-alkyl phosphines using the B3LYP function with a 6-31G* 
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basis set were obtained. The results show that long alkyl chains increase the SOMO 
energy of the corresponding primary phosphine (Figure 3.4). 
 
Figure 3.4 Plot of the SOMO energy of the radical cations for the pyrene derivatives 93-97 and the 
primary phosphines 3 and 14b . The line indicates an apparent “air stability” threshold value of 
−10 eV; phosphines above or on this line are found to be air-stable. 
 
The calculated SOMO energies of the radical cations for PyrPH2 93, PyrCH2PH2 94 
Pyr(CH2)4PH2 95 are −9.9, −9.4 −8.6 eV and respectively, which is above the −10 eV 
threshold. The HOMO of PyrPH2 93 and PyrCH2PH2 94 shows weak phosphorus 
character. On the other hand, the HOMO of Pyr(CH2)4PH2 95 has no phosphorus 
character in it. These results could predict a comparatively lower stability towards air-
oxidation for PyrPH2 93 and PyrCH2PH2 94 than for Pyr(CH2)4PH2 95 (Section 1.3.1). It 
is also important to highlight that comparing the SOMO energy of the reported MOPH2 
3 and BODPH2 14b shows that the novel Pyr(CH2)4PH2 95 has a higher value, which 
would imply a higher degree of stability towards air-oxidation. 
3.3 Synthesis of air-stable phosphines pyrene-based 93-95 
After calculating the SOMO for different phosphines with a pyrene backbone, it was clear 
that the three proposed phosphines would be air-stable. The synthesis of PyrPH2 93 
started with the commercially available 1-bromopyrene. This approach involves the 
substitution of bromine for a source of phosphorus to produce the corresponding primary 
phosphine.  
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Aryl radicals, which have a sp2 hybridization, have been generated from aryl bromide 
precursors under standard thermal azobisisobutyronitrile (AIBN)/n-Bu3SnH conditions. 
227 When trapped by trimethyl phosphite, these aryl radicals give dimethyl 
arylphosphonates in good yields.227 Therefore, we decided to react 1-bromopyrene with 
trimethyl phosphite in the presence of 1,1'-azobis(cyclohexanecarbonitrile) (ABCN)/ n-
Bu3SnH in benzene at 80 °C. After leaving the reaction overnight (the original procedure 
reported by Yun was 6 hours227), the reaction was stopped and purified using column 
chromatography on silica gel. Unfortunately, the starting material was recovered proving 
that there was no reaction. A second attempt was carried out with the catalyst palladium(II) 
acetate with the ligand 1,4-bis(diphenylphosphinobutane) (DPPB), these conditions have 
been proven to produce aryl phosphonates from aryl bromides.228 The result was the same; 
after purification using column chromatography, the starting material was recovered. 
 
Figure 3.5 Attempted synthesis of pyrene phosphine 93. 
 
In order to compare the effect exerted by the alkyl chain, a novel primary phosphine was 
synthesised, with a methylene group linking the phosphine to the pyrene moiety. 
Commercially available 1-(bromomethylene)pyrene was used as the starting material. 
The first reaction was the synthesis of the phosphonate 100. The 1H NMR spectrum 
integrates to 9 protons in the aromatic region corresponding to the pyrene backbone. In 
addition, a multiplet signal with a chemical shift between δ 3.86-3.64 ppm indicates the 
presence of the three methylene groups in this molecule. Finally, a triplet at δ 1.42 ppm 
proves that the molecule contains two methyl groups corresponding to the ethyl groups 
on the phosphonate. The 31P NMR spectrum shows a singlet at δ 25.9 ppm which is 
characteristic of phosphonates. The phosphonate 100 was finally reduced in order to 
produce the primary phosphine 94. The 1H NMR spectrum shows that the signals 
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corresponding to the ethyl groups of phosphonate 100 had disappeared. In addition, they 
show a multiplet at δ 3.54 ppm that belongs to the methylene group. It is also possible to 
observe a doublet of multiplets that integrates to 2 protons and resembles a doublet of 
triplets with a 1JHP value of 194.0 Hz. These signals must belong to the protons of the 
phosphine group. The 13C NMR spectrum shows a doublet at δ 19.0 ppm, the alkyl region, 
with a JCP value of 12.3 Hz. The only alkyl carbon in phosphine 94 is the one in the 
methylene carbon; therefore, it is reasonable to assume that this signal belongs to the 
methylene carbon and its multiplicity is due to its position next to the P-atom. 
 
Figure 3.6 Synthetic route followed to obtain the primary phosphine 94, which contains a 
methylene group as spacer. 
 
Crystal structures appropriate for X-ray crystallography were obtained for compounds 94 
and 100. The P1–C1 bond in PyrCH2Phos 100 has a 1.7937(18) Å bond length, whereas 
the P1–C1 bond in PyrCH2PH2 94 has a P1–C1 1.847(3) Å bond length. There are 
examples of phosphonates in benzylic positions, for instance, Vilela et al.229 reported the 
compound hexaethyl ((2,4,6-trifluorobenzene-1,3,5triyl)tris(methylene))tris 
(phosphonate) (101) whose P–C bond lengths are 1.790 Å, 1.793 Å and 1.788 Å. The 
Cambridge Structural Database (CSD) does not contain any records of benzylic primary 
phosphines to our knowledge. 
 
Figure 3.7 ((2,4,6-trifluorobenzene-1,3,5triyl)tris(methylene))tris (phosphonate) (101), phosphonate 
reported by Vilela et al.229 
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Figure 3.8 X-ray crystal structure view of 100 (50% probability ellipsoids with interesting 
phosphorus, oxygen and carbon atoms labelled. Carbon atoms in grey). Hydrogen atoms have been 
omitted for clarity. Selected bond distances [Å] and angles [°]: P1–O1 1.4630(13), P1–C1 1.7937(18), 
P1–O3A 1.579(9), P1–O2B 1.563(11), O3A–C20A 1.460(10), C20A–C21A 1.471(7), O2B–C18B 
1.438(12), C18B–C19B 1.500(13); O1–P1–C1 117.47(8), O1–P1–O2A 114.0(9), O1–P1–O3A 
114.3(11), O1–P1–O2B 114.8(12), O3A–P1–C1 102.8(5), O2B–P1–C1 106.6(10), C20A–O3A–P1 
116.6(10), O3A–C20A–C21A 106.7(6), C18B–O2B–P1 122.9(18), O2B–C18B–C19B 106.3(14). 
 
Figure 3.9 X-ray crystal structure view of 94 (50% probability ellipsoids with interesting 
phosphorus, oxygen and carbon atoms labelled. Carbon atoms in grey). Hydrogen atoms have been 
omitted for clarity. Selected bond distances [Å] and angles [°]:P1–C1 1.847(3), C1–C2 1.499(4); C2–
C1–P1 109.66(19).   
 
For compound 95, the butyl group between the pyrene function and the phosphine group 
gave SOMO higher than −10 eV, which, as previously demonstrated by our group, 
suggests a threshold for air-stability. 
The starting material for the synthetic route was commercially available 1-pyrenebutanol, 
which undergoes a bromination reaction, resulting in the synthesis of bromide 102. An 
Arbuzov reaction230 with triethyl phosphite gave the ethyl phosphonate 103, which was 
reduced in order to obtain the final primary phosphine 95.  
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Figure 3.10 Synthesis of the primary phosphines 95. 
 
Following bromination, the NMR spectra showed that the typical singlet around 2 ppm 
for a proton in an α position, respect to an alcohol, was no longer visible and a further 
analysis by 13C{1H} NMR showed that there were no singlets around 60 ppm, the usual 
chemical shift for a carbon bound to a terminal alcohol.231 Electrospray mass 
spectrometry confirmed the presence of bromide 102 showing an ion, [M+H]+ at m/z 
337.0586. 
The bromine atom in compound 102 is an excellent leaving group, and was replaced by 
a phosphonate group using triethyl phosphite as the nucleophile. The 13C{1H} NMR data 
of phosphonate 103 showed a doublet at 25.7 ppm, for which the magnitude of J was 
140.9 Hz. Previous reports in the literature show that this is indicative of carbon atoms in 
an alpha position relative to the phosphorus atom,232 proving the formation of a C–P bond. 
Finally, 31P{1H} NMR spectra and showed a singlet with a shift of 32.8 ppm, which is 
also characteristic for phosphonates. 
The reduction of phosphonate 103 was carried out in the presence of lithium aluminium 
hydride and chlorotrimethylsilane, which yielded the primary phosphine 95. The work-
up of this reaction was performed in air and the compound proved to be air stable. The 
1H NMR spectrum shows a doublet of doublets of doublets, in the range of 2.96-2.43 ppm, 
with a 1JPH = 194.3 Hz. This suggests that there is a 
1JPH type coupling, as this 
1JPH value 
is very similar to those obtained for the binaphthalene phosphine 3 (1JPHa = 203.9 Hz and 
1JPHa’ = 203.9 Hz = 204.8 Hz) reported by our group.
233 The additional splitting is given 
by the magnetically inequivalent protons Ha and Ha’. The similar J values of primary 
phosphine 95 (1JHxHa = 7.3 Hz and 
1JHxHa’ = 7.4 Hz) causes the doublets to be close enough 
to overlap, resembling a triplet (Figure 3.11). The 31P{1H} NMR shows a singlet with a 
shift of −138.1 ppm proving the presence of a primary phosphine. 
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Figure 3.111H NMR spectrum of primary phosphine 95 showing the doublet of doublet of doublets 
produced by HX. The pascal triangle depicts how the similarity between 3JHxHa and the3JHxHa’ 
merges the two peaks. 
 
Samples of compounds 95, 102 and 103 suitable for X-ray crystallographic analysis were 
obtained from the slow evaporation of their dichloromethane solutions. The compounds 
allow for the  stacking, sandwich type, interactions of pyrene234 to be maintained 
thanks to their flat structures and electronic interactions. Compounds 95, 102 and 103 
seem to have a flat spatial disposition that could favour  stacking. However, their unit 
cell packing reveals that they have a head to tail “arrangement of which 95 has a herring 
bone”-type orientation. Compounds 102 and 103 are coplanar in a staggered 
configuration (Figure 3.12). The distances for the planes formed by the pyrene moieties 
are 3.505(1) Å for 95, 3.497(1) Å for 102 and 3.605(1) Å for 103. The highest value for 
103 makes sense since the phosphonate group is the bulkier than the phosphino and the 
bromide creating greater repulsion between the two planes. 
 
Figure 3.12 Left-up: Pack diagram of 95. Left-down: Pack diagram of 102. Right: Pack diagram of 
103. Colour legend: grey, carbon; purple, phosphorus; red, bromine. 
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Many alkyl bromide crystal structures235-239 show that the C–Br bond length tends to have 
a distance of 1.9 Å, which correlates to the value found in the structure of bromide 102, 
1.9545 Å. This trend is also seen in other long-chain alkyl bromides. For instance, the 
aliphatic C–Br bond length in the is indole 104 is 1.949 Å240, in the alcohol 105 is 1.995 
Å241 and the carboxylic acid 106 is1.995 Å.242 It is also interesting to highlight the C–C 
bond  to the carbon bearing the halide atom, because it is shorter than the rest of the 
aliphatic C–C bonds in the butyl chain (Figure 3.13). This must be induced by the bromine 
atom since it attracts the electron density from carbon adjacent to it; this creates polarity 
in the C–C bond, which makes it shorter than the rest. 
 
Figure 3.13 Examples of bromides reported in the Cambridge Structural Database. 
 
 
Figure 3.14 X-ray crystal structure view of 102 (50% probability ellipsoids with interesting 
bromine and carbon atoms labelled. Carbon atoms in grey). Hydrogen atoms have been omitted for 
clarity. Selected bond distances [Å] and angles [°]: Br1–C20 1.9545(14), C19–C20 1.5087(19), C18–
C19 1.5271(18), C17–C18 1.5258(19); Br1–C20–C19 110.32(10), C20–C19–C18 111.95(11), C19–
C18–C17 110.48(11). 
 
The analysis of the phosphonate 103 crystal structure shows that the C–P bond has a 
1.7803 Å bond length. This distance is typical for this type of pentavalent 
organophosphorus compound where the phosphonate is in the terminal position of an 
alkyl chain,243-248 for example, Bichlmaier reported ethyl phosphonate 107 whose C–P 
bond length is 1.790 Å249. The electronegativity of phosphorus, 2.2, and carbon, 2.5, is 
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not notably different. This means that the C–C bond adjacent to the C–P bond does not 
change in length relative to the C–C bond length in other alkyl bromides such as bromide 
102. This is also seen in other alkyl phosphonates that do not contain other functional 
groups on the aliphatic chain.245-248 For instance, the C–P bond length in the ethyl 
phosphonate 108 is 1.795 Å, whereas C7–C8 bond length is 1.525 Å, C8–C9 bond length 
is 1.554 Å and C8–C12 bond length is 1.531 Å250  
 
Figure 3.15 Examples of phosphonates reported in the Cambridge Structural Database.  
 
Figure 3.16 X-ray crystal structure view of 103 (50% probability ellipsoids with interesting 
phosphorus, oxygen and carbon atoms labelled. Carbon atoms in grey). Hydrogen atoms have been 
omitted for clarity. Selected bond distances [Å] and angles [°]: P1–O1 1.5843(12), P1–O2 
1.5758(13), P1– O3 1.4646(12), C20–P11.7803(15), O1–C21 1.4487(19), O2–C23 1.4381(19), C17–
C18 1.519(2), C18– C19 1.524(2), C19– C20 1.529(2), C21–C22 1.496(2), C23– C24 1.496(2); O1–
P1–C20 101.03(7), O2–P1–O1 105.58(7), O2–P1–C20 100.76(7), O3–P1–O1 113.93(7), O3–P1–O2 
114.30(7), O3–P1–C20 119.28(7), C21–O1–P1 120.01(10), C23–O2–P1 124.62(11), C17–C18–C19 
113.13(12), C18–C19–C20 110.27(12), C19–C20–P1 116.74(11), O1–C21–C22 107.24(13), O2–C23–
C24 107.87(14). 
 
The crystal structure of primary phosphine 95 is a rare example of a crystal structure of a 
primary phosphine containing an alkyl group bound to the phosphino –(PH2) function–. 
Very few examples of these exist as they are often oily compounds with a low molecular 
weight.7, 11, 13, 14, 251, 252 The C–P bond length in compound 95 is 1.850 Å, this value is 
similar to the few other reported crystal structures.11, 13, 14, 251, 252 For instance, in 
compound (2-phosphanylethyl)ferrocene 6 (Figure 1.3) the C–P bond length is 1.884 
Å.253 
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Figure 3.17 X-ray crystal structure view of 95 (50% probability ellipsoids with interesting 
phosphorus and carbon atoms labelled. Carbon atoms in grey). Hydrogen atoms have been omitted 
for clarity. Selected bond distances [Å] and angles [°]:C20–P1 1.8500(17), C17–C18 1.522(2), C18–
C19 1.526(2), C19–C20 1.523(2); C17–C18–C19 112.26(14), C20–C19–C18 112.02(14), C19–C20–P1 
117.65(12). 
 
The X-ray structures shown make it possible to compare the C–P bond length of the 
organophosphorus compounds 94, 95, 100 and 103, showing that this bond is longer in 
the phosphines 94 and 95 than in the phosphonates 100 and 103. They also show that for 
the compounds in which the linker is a methylene group, a dihedral angle is created 
between the pyrene plane and the C–P plane (Figure 3.18).  
 
Figure 3.18 Spatial representation of the measured dihedral angle  formed in 94 and 100. 
 
Compound Experimental 
C−P (Å) 
Calculated 
C−P (Å) 
Experimental 
 (°) 
Calculated 
 (°) 
PyrCH2Phos 100 1.7937(18) 1.832 92.7(2) 100.1 
PyrCH2PH2 94 1.847(3) 1.901 87.7(3) 99.7 
Pyr(CH2)4Phos 103 1.7803(15) 1.818 1.4(2) 0.62 
Pyr(CH2)4PH2 95 1.8500(17) 1.880 1.2(2) 0.0 
Table 3.1 Crystallographic and B3YLP calculated data of compounds 94, 95, 100 and 103. 
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The DFT calculations obtained through B3YLP (with the 6-31G* basis) of the C–P bond 
length and the dihedral angle show similar values. The difference might be because the 
P-atom does not allow a gauche configuration for the methylene analogues 94 and 100 
whereas the butyl analogues have an anti configuration. 
 
3.3.1 NMR experiments to determine the air stability of PyrCH2PH2 94 and 
Pyr(CH2)4PH2 95 
The air stability of novel primary phosphines PyrCH2PH2 94 and Pyr(CH2)4PH2 95 was 
examined by dissolving a sample (20 mg) of each phosphine in d-chloroform. The 
resulting solution was placed into an NMR tube without a cap, exposing the solution to 
atmospheric oxygen and was left in the dark for seven days. In order to allow integration 
of the different phosphorus signals within the spectrum, the 31P NMR spectrum was 
obtained in proton coupled mode, less NOE effects and with a relaxation time of three 
seconds between pulses.  
The oxidation of primary phosphines leads to different oxidised forms of phosphorus 
whose chemical shifts are more downfield than the phosphine parent. Therefore, it is 
possible to obtain the remaining percentage of phosphine in the solution by removing the 
integration value of the P-oxide formed signals around 0-40 ppm from the integration 
value of the primary phosphine signal. The primary phosphine PyrCH2PH2 94 was 
comparatively less stable towards oxidation as is shown in Figure 3.19. On day seven, 
there was 55.1% of the original sample of PyrCH2PH2 95. The results of the integration 
show that, for compound Pyr(CH2)4PH2 95, 98.2% of the original amount of phosphine 
was still present at the end of the seven days. 
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Figure 3.19 31P-1H NMR spectrum of PyrCH2PH2 94 and Pyr(CH2)4PH2 95 after seven days in a 
solution in d-chloroform. 
 
As was estimated, the butyl derivative 95 is more resistant to oxidation than the methyl 
analogue 94. Benzylic species are often unstable so perhaps this explains why PyrCH2PH2 
94 is more unstable than its butyl analogue. This benzylic position in PAH has shown to 
form highly stable radicals that are stabilised by low resonance stabilization energies as 
described by McMillen et al.254 Figure 3.20 shows the percentage of phosphines 94 and 
95 remaining in solution over the seven days the air oxidation stability test was conducted. 
 
Figure 3.20 Graph showing the percentage of phosphines PyrCH2PH2 94 and Pyr(CH2)4PH2 95 
remaining over seven days. 
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This experiment proved that PyrCH2PH2 94 is less stable towards air-oxidation than 
Pyr(CH2)4PH2 95 corroborating the calculations and the model presented in Section 3.2. 
These results indicated how stable these primary phosphines are. This opens a new 
starting material for the development of compounds with biological activity, not only to 
our group but also to other research groups interested in developing biological probes 
with pyrene. 
3.4 Synthesis of the pyrene-based ligand 109 
The novel phosphine 95 contains two P–H bonds which can undergo a 
hydrophosphination for the development of a tridentate phosphine derivative.255 Such 
double addition will yield target tridentate phosphine 109. This was to confirm that the 
resistance to air oxidation does not interfere with the behaviour of the normally reactive 
P–H bonds. A common reaction of a primary phosphine is the hydrophosphination 
reaction across a C=C double bond creating a tridentate ligand. This type of compound is 
important in coordination chemistry and homogeneous catalysis256 because they do not 
readily dissociate from the metal centre due to their chelating ability and hence confer 
kinetic stability on the resulting transition metal complexes. Therefore, it was decided to 
treat primary phosphine 95 with two equivalents of diphenylvinylphosphine, using [Pt(η2-
nb)3] as a catalyst, to generate the tridentate ligand 109 with a 55% yield (Figure 3.21). 
No starting material was recovered from this reaction which suggests that 45% of the 
starting material was turned into different unwanted side products. The reaction required 
a temperature of 110 °C and was left overnight, in contrast with previous reports from 
this group, for which the backbone of the phosphine was the BODIPY primary phosphine 
14b, in that case the required reaction time was five days.39  
 
Figure 3.21 The hydrophosphination of primary phosphine 95 and 2 equivalents of vinyldiphenyl 
phosphine. 
 
If the reaction is carried out without any catalyst, after three days of heating unwanted 
side products start to form but no presence of the tridentate phosphine can be detected 
using 31P{1H} NMR. This means that the double bond of the vinyldiphenyl phosphine 
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cannot interact with the phosphorus atom under these conditions. Hydrophosphination of 
primary phosphines can occur in the presence of a radical initiator, base or metal 
catalyst.257-261 This result correlates with Pringle’s work, showing the effectiveness of the 
[Pt(η2-nb)3] catalyst in hydrophosphination reactions.262, 263 Future work could investigate 
new metal based catalysts to improve the rate of conversion whilst maintaining high 
selectivity.  
 
Figure 3.22 The 31P{1H} NMR spectrum of tridentate phosphine 109 in d-chloroform, showing a 
characteristic doublet and triplet. 
 
The 31P{1H} NMR spectrum of 109 exhibited a typical AX2 system, producing a doublet 
at δ −12.1 ppm for the two equivalent terminal phosphines and a triplet at δ −20.6 ppm 
for the central phosphine. These signals are, in a 2:1 ratio, with a 3JPP coupling constant 
of 26.5 Hz (Figure 3.22). In the aromatic region of the 1H NMR spectrum, the 9 protons 
of the pyrene moiety plus 20 protons that belong to the four phenyl rings of the tridentate 
ligand are visible. The multiplicity of these protons is complex; therefore, their 
identification was made mainly by comparison of their integrals. The results of the HRMS 
analysis of tridentate ligand 109 also corroborates the molecular formula of the structure 
proposed for this compound. Ligand 109 was stored under atmospheric conditions 
showing no further oxidation proving that it is more stable than its parent, primary 
phosphine 95. 
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3.4.1 Group 10 coordination chemistry of tridentate phosphine 109 
Cis-platin (cis-Pt(NH3)2Cl2) is known to have DNA-modifying properties with strong 
anticancer potency.264 This compound is widely used despite its side effects, such as 
nephrotoxicity, ototoxicity and allergy.265 The limitations of cis-platin opens the 
possibility for the development of platinum complexes that overcome those limitations. 
Palladium complexes have been also investigated in order to compare their biological 
activity with that of their platinum analogues. This improves the understanding of the 
mechanism of action of these complexes.266 The success of cis-platin, led researchers to 
investigate and synthesise new metal-based drugs for experimental oncology. In recent 
years new metal-complexes have been identified as a very promising class of antitumor 
active compounds.267, 268 Nickel has been tested in complexes with ligands that have 
shown previous biological activity in order to modulate their interaction with cancer 
cells.269 
The aforementioned background knowledge about the transition metals of group 10, 
makes them important for research. Therefore, we decided to make group 10 metal 
complexes our novel ligand 109. 
 
 Platinum 
Platinum complexes have been widely used as versatile catalysts and anticancer drugs.270-
272 In 1965, it was discovered that electrolysis of platinum electrodes generated a soluble 
platinum complex which inhibited binary fission in Escherichia coli bacteria.273 The 
octahedral platinum(IV) complex cis-[PtCl4(NH3)2], but not the trans isomer, was found 
to be effective at producing this effect in the microorganism. Further tests showed that 
the square planar platinum(II) complex, cis-[PtCl2(NH3)2] 110 turned out to be even more 
effective.273 This finding led to the observation that 110 was indeed highly effective at 
reducing the mass of sarcomas in rats, which allow for the development of one of the 
most popular anticancer drugs used today.136 Cisplatin interferes with DNA replication 
since, in cellular conditions, a chloride ligand is slowly displaced by water giving the a 
complex cis-[PtCl(NH3)2(H2O)]
+.274, 275 The newly added H2O ligand in cis-
[PtCl(NH3)2(H2O)]
+ is itself easily displaced by the N-heterocyclic bases on DNA, which 
forms a crosslinked adduct when another N-heterocyclic base displaces the remaining 
chloride ligand.274, 275 This process interferes with cell division by mitosis, which finally 
leads to apoptosis, in some tissues, by a cascade of cell signalling.276 
  
107 
 
Different platinum(II) complexes have been tested, which shows that there is a strong 
relationship between the structural differences and the anticancer activity that the 
compounds can exert. This knowledge led to the synthesis of new interesting platinum(II) 
complexes that are available on the market, or that are still undergoing trials, as alternative 
anticancer drugs, such as carboplatin 111, oxaliplatin 112, nedaplatin 113, triplatin 
tetranitrate 114, among others.277-279 
 
Figure 3.23 Platinum based anticancer drugs, compounds 110-113 are currently in clinical use. 
Research on compounds 114 and 115 show promising biological properties. 
 
Although platinum(II) complexes are the basis of treatment for many cancers, initial 
positive results have been achieved in clinical use. However, it is possible for patients to 
develop resistance, reducing the effect of the drug.280 This has been explained by different 
mechanisms including changes in cellular uptake and efflux of the drug, increased 
detoxification of the drug, inhibition of apoptosis and increased DNA repair.281 The 
resistance mechanism opens a niche for the development of new complexes aimed at 
improving the efficacy of this kind of drug. Among the variety of platinum(II) complexes 
that have been investigated for antitumor activity, it was found that, in general, neutral 
complexes exhibit activity while charged species tend to be inactive and relatively 
nontoxic.282 This is not always the case, however, since there are examples of positively 
charged platinum(II) complexes that exhibit unusual potency as anticancer drugs. That is 
the case of triplatin tetranitrate 114279 and phenanthriplatin 115 (Figure 3.23).283 
The novel tridentate ligand 109, developed by this group, contains a pyrene moiety which 
is an example of PAH. PAHs are soluble in lipids, and are capable, when metabolically 
activated, of interacting with cellular molecules, such as proteins and nucleic acids. This 
leads them to be considered as indirect-acting carcinogens.284 PAHs can also act as DNA 
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intercalators, as was stated in Section 1.5.1.1 − they are characterized by the insertion of 
planar aromatic or heteroaromatic rings between DNA base pairs.285, 286 This kind of 
interaction leads to the inhibition of topoisomerases I and II, which would eventually 
inhibiting the activity of the DNA or RNA polymerases involved in the processes of DNA 
replication.287, 288 Therefore, PAHs offer a different approach to developing interesting 
chemotherapeutic DNA intercalators.85, 289, 290 
In an effort to make a platinum(II) complex similar to the cisplatin analogues presented 
above, 109 and [PtCl2(η2:η2-cod)] were reacted in dichloromethane at room temperature. 
After being washed with hexane to remove the remaining cyclooctadiene, [PtCl(109)][Cl] 
(116) was produced as a white solid with an excellent yield of 76% (Figure 3.24). 
 
Figure 3.24 Synthesis of the square planar platinum(II) complex [PtCl(109)][Cl] 116. 
 
The 31P{1H} NMR spectrum of complex [PtCl(109)][Cl] 116 displayed signals at δ 87.1 
ppm for the central phosphorus atom and at δ 44.0 ppm for the terminal phosphorus atoms, 
with 1JPPt values of 2883 and 2538 Hz. These values are common for a phosphorus atom 
trans to a chloride and a phosphorus atom trans to another phosphorus atom 
respectively.291-293 
No phosphorus-phosphorus coupling was observed, but this is not unexpected for 
complexes of this type. Meek et al. worked on a series of platinum-polyphosphine 
complexes, which showed coupling constants of <0.8 Hz.294 The 31P{1H} NMR signals 
for the coordinated phosphine are significantly shifted downfield in comparison to the 
free ligand, a phenomenon also found for related chelating ligand complexes.294-296 The 
magnitude of the change in chemical shift (Δδ) for chelated phosphines is dependent on 
the size and number of chelate rings containing the phosphorus atom.294-296 For example, 
the 31P{1H} NMR spectrum of the reported compound [PtCl(triphos-Ph)][SnPh2Cl3] 
showed a signal for the terminal P-atoms at δ 39.8 ppm, for the central P-atom at δ 83.7 
ppm, and the 1JPPt values found were 3015 and 2484 Hz respectively.
295 For the central 
phosphorus atom the observed Δδ from unchelated ligand to complex is 107.7 ppm, which 
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is extremely large compared to those of the terminal phosphorus atoms, where Δδ = 44.0 
ppm. The substantial difference in Δδ values for the central compared to the terminal 
phosphorus is due to the central phosphorus being part of two five-membered chelate 
rings.297 
 
Figure 3.25 31P{1H} NMR spectrum of [PtCl(109)][Cl] 116; the peak at δ 87.1 ppm is assigned to the 
central phosphorus atom and the peak at δ 44.0 ppm is assigned to the terminal phosphorus atoms. 
 
The satellites shouldering the main peaks in the 31P{1H} NMR spectrum of [PtCl(109)][Cl] 
116 occur due to the coupling of 31P with the platinum nucleus. The isotope 195Pt consists 
of about 33.8% of the atomic content of platinum, with the rest of the platinum isotopes 
being NMR inactive. This means that 66.2% of the 31P nuclei in the sample do not couple 
to any nuclei; whereas 33.8% do couple to 195Pt, creating the satellite signals which can 
be seen around the main peak. 
Crystals of [PtCl(109)][Cl] 116 suitable for X-ray crystallographic analysis were obtained 
from slow diffusion (hexane/dichloromethane). The Pt–P bond lengths (Figure 3.26) are 
in the expected range for platinum complexes and compare well to [PtCl(triphos-Ph)][Cl], 
where the Pt–Pterminal bond lengths were 2.312(2), 2.315(2) Å and the Pt–Pcentral bond 
length was 2.207(2) Å.297 The Pt–Pcentral bond length is found to be shorter than the Pt–
Pterminal due to the double chelate effect and to the lower trans influence of the chloride 
compared to the phosphorus atom. The complex has a distorted square planar geometry 
at the platinum, which is shown by the P–Pt–Cl bond angles of 93.71(5)° (P1–Pt–Cl1), 
175.78(6)° (P2–Pt–Cl1) and 95.80(5)° (P3–Pt–Cl1) and the P–Pt–P bond angles of 
84.93(5)° (P1–Pt–P2), 169.46(5)° (P1–Pt–P3) and 85.26(5) (4)° (P2–Pt–P3). However, 
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[PtCl(109)][Cl] 116 is less distorted relative to the ideal square planar geometry than 
similar nickel and palladium complexes.298 
 
Figure 3.26 X-ray crystal structure view of [PtCl(109)]Cl 116 (50% probability ellipsoids with 
interesting chloride, platinum, phosphorus and carbon atoms labelled. Carbon atoms in grey). 
Hydrogen atoms have been omitted for clarity: Pt1–P1 2.3090(12), Pt–P2 2.312(2), Pt–P3 
2.3057(11), Pt–Cl1 2.3613(10), P1–C13 1.850(5), P2–C35 1.820(5), P2–C14 1.811(5), P3–C36 
1.857(5); P1–Pt–P2 84.93(5), P1–Pt–P3 169.46(5), P2–Pt–P3 85.26(5), P1–Pt–Cl1 93.71(5), P2–Pt–
Cl1 175.78(6), P3–Pt–Cl1 95.80(5). 
 
 Palladium 
Palladium phosphine complexes are well known to be a useful resource for catalytic 
processes which utilise alkenes as substrates. For example, Pd(PPh3)4 117 has been used 
for creating a C–C bonds for synthesising caparratrien, a compound that shows 
considerable growth inhibition in CEM leukemia cells.299 These type of palladium 
complexes are widely used for coupling reactions. That is the case for the complexes 
(1,1'-bis(diphenylphosphino)ferrocene) palladium(II) dichloride 118,300 and the butyl-
containing complex [1,4-bis-(diphenylphosphine)butane] palladium(II) dichloride 119.301  
 
Figure 3.27 Examples of palladium phosphine complexes used in the catalysis of coupling reactions. 
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The similarity between the coordination chemistry of palladium(II) and platinum(II) 
compounds has encouraged studies of Pd(II) complexes as antitumor drugs, giving 
promising results due to the lanthanide contraction.302-305 It is worth noting that several 
Pd complexes have been reported to display favourable cytotoxicity at pH 6.8, a 
predominant condition in tumour cells (the pH of normal cells is 7.4).305 Furthermore, 
hydrolytic and DNA-binding studies on the Pd(II) and Pt(II) complexes with anticancer 
activities showed that the palladium complexes are kinetically labile, produce new 
charged species to interact with DNA and bind at a faster rate than the platinum 
complexes.303 However, Pt(II) complexes are more stable than those of Pd(II), since Pd(II) 
compounds exchange ligands 104–105 times faster than analogous Pt(II) compounds, 
which means that Pd(II) complexes do not reach the targeted tissue.266, 306 This might be 
modified using ligands that provide more stability to the complex. 
One equivalent of the novel tripodal ligand 109 was reacted with the palladium(II) 
precursor [PdCl2(PhCN)2] in dichloromethane for 2 hours,
307 which afforded the 
palladium(II) complex [PdCl(109)]Cl 120 (Figure 3.28). 
 
Figure 3.28 Synthesis of the palladium(II) complex, [PdCl(109)]Cl 120. 
 
As depicted in Figure 3.28; the three phosphino in ligand 109 coordinate to the palladium, 
replacing the labile benzonitrile ligands and a chloride atom. Coordination of the 
phosphine groups caused a downfield shift of their 31P{1H}NMR signals. The two 
terminal phosphines in the free tridentate ligand 109 produce a doublet at δ −12.2 ppm 
and the phosphine in the central position produces a triplet at δ −20.6 ppm, the 3JPP 
coupling value for these signals is 26.5 Hz. On the other hand, the 31P{1H}NMR spectrum 
of complex [PdCl(109)]Cl 120 shows a triplet at 115.1 ppm and a doublet at 47.9 ppm, 
whose 3JPP coupling value is 6.3 Hz.  
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Figure 3.29 31P{1H} NMR spectrum of the reaction of PdCl2(PhCN)2 and 109 in dichloromethane. 
 
Previous reports of phosphines with a palladium(II) centre indicate a difference in the 
bond length in P–Pd bond;308-310 the central tridentate phosphorus tends to form a shorter 
P–Pd bond than the ones located on the sides of the metallic centre. This trend is also 
observed on the novel complex [PdCl(109)]Cl 120. A sample suitable for X-ray 
crystallographic analysis was achieved from a saturated solution of [PdCl(109)]Cl 120 in 
dichloromethane and hexane. The complex shows a square planar palladium(II) 
coordination geometry with the following bond lengths: Pd1–Cl1 2.3593(7), Pd1–P1 
2.3188(7), Pd1–P2 2.2175(7) and Pd1–P3 2.3143(7). The angles of the palladium centre 
are: P1–Pd1–Cl1 94.77(2), P3–Pd1–Cl1 96.60(2), P2–Pd1–P1 84.06(2) and P2–Pd1–P3 
84.06(2). It is noticeable that the angles containing the Cl1 atom are slightly wider than 
the other two contained in the same plane. The chlorine atom is not significantly bigger 
than the phosphorus atom311; therefore, the increased angles are not due to steric 
interactions. The phenyl groups in P1 and P3 take a spatial arrangement that approach the 
vicinity of chlorine. Hence, they are more likely to be the factor that increases these angles 
(Figure 3.30). 
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Figure 3.30 X-ray crystal structure view of [PdCl(109)]Cl 120 (50% probability ellipsoids with 
interesting carbon, chlorine, palladium and phosphorus atoms labelled. Carbon atoms in grey). 
Hydrogen atoms have been omitted for clarity. Selected bond distances [Å] and angles [°]: Pd1–Cl1 
2.3593(7), Pd1–P1 2.3188(7), Pd1–P2 2.2175(7), Pd1–P3 2.3143(7); P1–Pd1–Cl1 94.77(2), P2–Pd1–
Cl1 175.80(3), P2–Pd1–P1 84.06(2), P3–Pd1–Cl1 96.60(2), P3–Pd1–P1 167.74(2), P2–Pd1–P3 
84.06(2). 
 
 Nickel 
Nickel complexes have mainly been studied for their application in catalysis.312-316 The 
most common example of the use of nickel in catalysis is the Raney nickel alloy, which 
is used as a catalyst in organic chemistry for the hydrogenation double bonds.317 Previous 
studies in prokaryotic and eukaryotic cells have shown that nickel is required to produce 
certain vital enzymatic activities. For example, the enzyme urease, used for converting 
urea in ammonia, requires the presence of nickel in order for the cell to function 
correctly.318 On the other hand, nickel is known to be a toxic metal when found in the 
human body in high concentrations.319, 320 Various studies show that nickel complexes 
have interesting biological properties.269, 321 Ferrari et al. developed a nickel complex 
using a p-fluorobenzaldehyde thiosemicarbazone as a ligand, which produced a cell 
inhibiting effect in very resistant human cell lines. No cytotoxic effects were observed 
during this procedure.322 Notably, most biological studies on this element have been 
performed in its complexed form using different thiocarbazones as ligands.269, 321-324 
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To our knowledge, there are no examples of nickel(II) phosphine complexes with a 
fluorescent polyaromatic hydrocarbon moiety. Therefore, one equivalent of 109 was 
reacted with the nickel(II) precursor [NiCl2(py)4] in dichloromethane for 2 hours, which 
afforded the nickel(II) complex [NiCl2(py)(109)] 121. 
 
Figure 3.31 Synthesis of the nickel(II) complex, [NiCl2(109)] 121.  
 
The 31P{1H} NMR spectrum of the compound showed a triplet at δ 115.9 ppm, and a 
doublet at δ 50.0 ppm with 3JPP = 42.5 Hz. Both signals are significantly shifted downfield 
in comparison with the uncoordinated ligand 109, whose doublet comes at −12.2 and 
triplet at −20.6 ppm, proving that there was a change in the chemical environment of the 
phosphorus atoms. In addition, the presence of no more than two signals indicates that 
there was no formation of different structural isomers. 
 
Figure 3.32 31P{1H} NMR spectrum of the reaction of [NiCl2(py)4] and 109 in dichloromethane to 
give the proposed complex 121. 
 
The X-ray analysis confirmed that the tridentate ligand displaced three pyridine 
molecules as expected. However, a fourth pyridine molecule was also eliminated, which 
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resulted in the coordination geometry around the nickel atom to be intermediate between 
trigonal bipyramidal (with Cl1 and P2 atoms at the axial sites) and square pyramidal (with 
a Cl2 atom at the axial site). The Ni−Cl2 bond, 2.7749 Å, is 0.2238 Å longer than the 
Ni−Cl1 bond. A previous report about a similar phosphine with an unusually long Ni–Cl 
bond, 2.669 Å, indicates that this can be attributed to electronic effects.325, 326 Another 
interesting feature of this analysis is that Ni−P2 and Ni−P3 bonds are longer than Ni−P(1) 
due to the higher trans influence of the phosphine ligands compared to chloride. 
 
Figure 3.33 X-ray crystal structure view of [NiCl2(109)] 121 (50% probability ellipsoids with 
interesting carbon, chlorine, phosphorus and nickel atoms labelled. Carbon atoms in grey). 
Hydrogen atoms have been omitted for clarity. Selected bond distances [Å] and angles [°]: Ni1−Cl1 
2.2510(7) Ni1−Cl2 2.4749(7), Ni1−P1 2.2176(8), Ni1−P2 2.1577(7), Ni1−P3 2.1856(9), P1−C13 
1.843(2), P2−C14 1.829(3), P2−C35 1.825(3), P3−C36 1.843(2); Cl1−Ni1−Cl2 93.71(2), P1−Ni1−Cl1 
92.51(2), P1−Ni1−Cl2 97.70(2), P2−Ni1−Cl1 170.24(3), P3−Ni1−Cl2 116.04(2), P2−Ni1−Cl2 96.03(2), 
P2−Ni1−P1 85.61(2), P2−Ni1−P3 86.51(2), P3−Ni1−Cl1 89.76(2), P3−Ni1−P1 145.97(3). 
 
The CSD contains three examples of pentacoordinated nickel (II) complexes containing 
three phosphines and two chlorines as ligands, complexes 122-124 (Figure 3.34).327, 328 
These complexes also displayed intermediate geometry between trigonal bipyramidal 
with a Cl atom in the axial position and square pyramidal. 
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Figure 3.34 Ni(II) complexes containing phosphines as ligands, the three complexes display an 
intermediate geometry between trigonal bipyramidal and square pyramidal. 
 
3.4.2 Group 9 coordination chemistry of tridentate phosphine 109 
 Rhodium 
Four-coordinate polydentate phosphine complexes of rhodium have been investigated for 
use in catalysis329 and medicine. This is because the d8 electronic configuration mimics 
that of the cytotoxic complex cisplatin.27 Therefore we were interested in the coordination 
chemistry of ligand 109 with the group 9 metal. 
This reaction was tried using [Rh(nbd)2]BF4 and [Rh(η2:η2-cod)2]BF4 as the source of Rh 
and reacting them, separately, with the tridentate ligand 109. However, the 31P{1H} NMR 
analysis of both samples showed a mixture of different products, probably due to the 
formation of different isomers. Finally, [Rh(η2:η2-cod)Cl]2 was used. The reaction of two 
equivalents of 109 with one equivalent of [Rh(η2:η2-cod)Cl]2 in dichloromethane at 
ambient temperature produced the rhodium(I) species [Rh(Cl)(109)] 125, as depicted 
below.  
 
Figure 3.35 Preparation of rhodium(I) complex [Rh(cod)](109) 125. 
 
The 31P{1H} NMR spectrum of the Rh-Triphos complex [RhCl(PhP(CH2CH2PPh2)2)] in 
CD2Cl2 consists of a simple first-order AM2X splitting pattern producing a doublet of 
triplets for the central phosphorus atom and a doublet of doublets for the two magnetically 
equivalent terminal P atoms of the PhP(CH2CH2PPh2)2 ligand.
330 This is the same pattern 
displayed by the 31P{1H} NMR spectrum of 125 where the central phosphorus atom 
shows a triplet and the two terminal phosphorus atoms display a doublet that resembles 
  
117 
 
an AM2X system. The 
31P{1H} NMR spectrum of 125 shows a doublet of triplets at δ 
93.4 ppm with a 1JPRh = 120.2 Hz, proving the formation of a P−Rh bond with the central 
P atom, and a 2JPP = 23.0 Hz. This value of 
1JPRh correlates to the one reported for the 
central P atom in the [RhCl(PhP(CH2CH2PPh2)2)] complex, 
1JPRh = 163 Hz. 
330 The 
spectrum also shows a doublet of doublets at δ 55.9 ppm with a 1JPRh = 124.5 Hz. This 
value proves the formation of a P−Rh bond with the terminal P atoms of the ligand. 
Unfortunately it was not possible to obtain crystalline material suitable for X-ray 
crystallography in order to get more information about the structural arrangement of this 
compound. 
 
Figure 3.36 The 31P{1H} NMR spectrum of [RhCl(109)] 125 showing a AM2X multiplicity pattern. 
 
The 1H NMR spectrum of [RhCl(109)] 125 does not show the peaks reported for η2:η2-
cod protons in [Rh(η2:η2-cod)Cl]2,331 which suggests that the final product does not 
contain that moiety. This spectrum was measured in a Bruker machine model Ascend 
with a 700 MHz magnet in order to improve the definition of the sample since the 
spectrometer JEOL ECS with a 400 MHz magnet provided poor definition. 
The NMR analysis suggests that the structure of the resulting product is the one depicted 
in Figure 3.35 for the complex [Rh(Cl)(109)] 125 where the tridentate ligand 109 is 
tricoordinated to the Rh atom which holds a chlorine ligand.  
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 Iridium 
Iridium organometallic complexes have recently shown promising potential in medicinal 
imaging with particular emphasis in fluorescence confocal microscopy using 2-
phenylpyridine based ligands.332-334 Complex 126 was developed by Murphy et al.332 as 
an agent which emission can be reversibly red-shifted when protonated. Complex 127 has 
been developed as a luminescent compound that shows interesting cytotoxic properties 
toward HeLa cell lines.333 Research carried out by Meggers et al. afforded the iridium 
complex 128, which shows dual anticancer activity, (I) it contains a structural scaffold 
for molecular recognition of protein kinases, which results in antiangiogenic properties, 
and (II) it shows visible-light induced anticancer activity through the initiation of cellular 
apoptosis (Figure 3.37).335 
 
Figure 3.37 Iridium complexes 126-128 that have shown interesting biological properties.335 
 
Following the interesting results with rhodium, and the aforementioned background 
knowledge about the biological applications of iridium(I) complexes, we attempted the 
preparation of a fluorescent iridium(I) complex, which may have therapeutic and cell 
imaging applications parallel to the complexes introduced previously. Kubiak and co-
workers showed that the complex [Ir(cod)(triphos-Ph)][Cl] is formed from reacting 
triphos-Ph and [Ir(cod)Cl]2.  Therefore, two equivalents of 109 were therefore reacted 
with a DCM solution of [Ir(cod)Cl]2, which led to the formation of [IrCl(109)] 129 
(Figure 3.38), whose structure was corroborated through the molecular formula found by 
HRMS.  
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Figure 3.38 Synthesis of the iridium(I) complex [IrCl(109)][Cl] 129. 
 
The 31P{1H} NMR spectrum gave an AX2 spin system: δ 62.7 (t), 27.5 (d) ppm (1:2) with 
a small 3JPP coupling constant of 10.6 Hz, these values match those of the iridium(I) 
complex [Ir(cod)(triphos-Ph)][Cl]336 well. Unlike the iridium(I)-triphos complex reported, 
the complex we obtained retained the chloride ligand at the expense of the cyclooctadiene 
ligand. Unfortunately, it was not possible to obtain a crystal structure suitable for X-ray 
analysis. However, characterisation using HRMS allowed us to determine the mass of the 
sample. The observed mass for this compound matches the mass of the theoretical isotope 
pattern of proposed structure 129. The mass m/z value found in the sample was 943.2125 
which is the same mass of the protonated form of complex 129. The 1H NMR analysis of 
complex 129 was too broad for accurate interpretation. 
As mentioned previously, iridium complexes have shown interesting features as confocal 
microscopy agents. Therefore, complex 129 could be tested in this area. 
 
Figure 3.39 31P{1H} NMR spectrum of [Ir(Cl)(109)] 129 in d-chloroform, showing the expected 
doublet and triplet splitting. 
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3.5 Photophysical data 
After the effective synthesis of the tridentate phosphine 109 and several transition metal 
complexes, it was imperative to determine their photophysical properties in order to 
understand how the different metals change the properties of the pyrene moiety in the 
different analogues. Our initial concern was whether the heavy metals or would quench 
the fluorescence of the PAH fluorophore, a phenomenon which is well documented, 
including in systems where pyrene is the fluorophore.337-340 The three phosphorus atoms 
of the tridentate ligand 109 could provoke a similar effect. Table 3.2 shows the absorption 
maxima (λabs) and emission maxima (λem) of the series of interest showing similar values 
to the ones recorded for other propargyl pyrene derivatives.341 It is possible to observe 
that the Stokes shift (Δνst) in the different compounds did not experience a considerable 
change. The most common cause of Δνst is the rapid photon decay from S1 to S0. In 
addition, fluorophores can decay through vibrational levels, resulting in an additional loss 
of excitation energy in the form of heat.40 Therefore, the lack of variation in the reported 
Δνst values indicates that the different functional groups and metals do not increase 
vibrational effects.  
Compound λabs (nm) λem (nm) ε (cm−1/M) Δνst (nm) 
Pyr(CH2)4Br 102 342 376 49,000 34 
P(O)(OEt)2 103 343 376 51,000 33 
Pyr(CH2)4PH2 95 344 377 64,000 33 
Pyr(CH2)4P3 109 344 377 30,000 33 
[RhCl(109)] 125 342 376 64,000 34 
[NiCl2(109)] 121 342 376 10,000 34 
[PdCl(109)]Cl 120 342 376 10,000 34 
[PtCl(109)]Cl 116 344 377 43,000 33 
Table 3.2 Photophysical data for the tridentate phosphine 109, its parent compounds and the 
complexes formed with it. Measured in degassed tetrahydrofuran at room temperature; dyes were 
excited at 350 nm. 
 
Pyrene is a compound that, in solution, forms species known as excimers.48 An excimer 
is a short-lived dimeric or heterodimeric molecule formed from two molecules, at least 
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one of which has electrons that can be promoted to the excited state. This is key, because 
the formation of dimeric molecules takes place when the electrons are in the excited 
state.47 This kind of phenomenon is quite common for pyrene, and results in fluorescence 
quenching of the sample.342 Therefore, using pyrene as a reference to determine the ΦF of 
the synthesised compounds could lead to inconsistent results, due to the fluorescence 
quenching caused by excimer formation. There are studies in which the anthracene 
derivative 9,10-diphenylanthracene was used as a standard to measure ΦF of pyrene 
containing compounds.343 Therefore, it was decided to use both pyrene and anthracene as 
fluorescence standards in order to compare the results. In order to avoid excimer 
formation, it was decided that all the samples should be prepared with an absorption of 
0.04 at 317 nm when using pyrene as the fluorescence standard, since it is known that the 
formation of pyrene excimers takes place in solutions with higher concentrations than 
this.48 
 
Figure 3.40 Compounds used as fluorescence standards to measure the ΦF of the synthesised 
compounds.83 
 
The resulting ΦF values are presented in the Table 3.3. They show that using pyrene as 
the fluorescence standard resulted in higher ΦF values than those obtained when using 
anthracene. The formation of pyrene excimers could explain this trend, since they produce 
a self-quenching effect, reducing the emission of the sample. Since the values obtained 
for the ΦF were higher when using pyrene as the standard, we can infer that the formation 
of excimers in the synthesised compounds is less prevalent than in pyrene. The results 
show that the phosphonate P(O)(OEt)2 103 has the highest ΦF of all the compounds 
synthesised in the series. When using THF as the solvent it is possible to find a general 
trend of the ΦF regardless the fluorescent standard used: ΦF PyrP(O)(OEt)2 103 > ΦF 
Pyr(CH2)4P3 109 > ΦF Pyr(CH2)4Br 102 > ΦF Pyr(CH2)4PH2 95 > ΦF[NiCl2(109)] 121 > 
ΦF[RhCl(109)] 125 > ΦF[PtCl(109)]Cl 116 > ΦF[PdCl(109)]Cl 120. On the other hand, 
there is no obvious trend when using chloroform as a solvent since it shows an 
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inconsistency for compounds Pyr(CH2)4Br 102 and Pyr(CH2)4P3 109. Another interesting 
feature is the fact that tetrahydrofuran appears to show the highest ΦF. 
Compound ΦFa,b  ΦFa,c ΦFd,b ΦFd,c 
Pyr(CH2)4Br 102 0.39 0.23 0.65 0.45 
P(O)(OEt)2 103 0.43 0.27 0.73 0.61 
Pyr(CH2)4PH2 95 0.39 0.26 0.49 0.27 
Pyr(CH2)4P3 109 0.42 0.21 0.72 0.49 
[RhCl(109)] 125 0.11 0.06 0.19 0.11 
[NiCl2(109)] 121 0.12 0.09 0.33 0.27 
[PdCl(109)]Cl 120 0.01 0.01 0.13 0.09 
[PtCl(109)]Cl 116 0.02 0.02 0.17 0.12 
a Measured in degassed chloroform at room temperature. b Measured with respect to pyrene; dyes were 
excited at 317 nm. c Measured with respect to anthracene; dyes were excited at 350 nm d Measured in 
degassed tetrahydrofuran at room temperature. 
Table 3.3 ΦF values using different fluorescence standards (pyrene and anthracene) to investigate 
the excimer formation effect of pyrene when using it as fluorescence standard. 
 
Typically, the fluorophore has a larger dipole moment in the excited state (E) than in the 
ground state (G). Following excitation the solvent dipoles reorient or relax around E 
reducing the energy of the excited state. The effects of solvent polarity are shown in the 
diagram below. Less polar solvents contribute to the vibrational relaxation to a lesser 
extent in comparison with more polar solvents. This causes the emission in less polar 
solvent to be higher.40 
Tetrahydrofuran and chloroform have similar polarities, 4.0 and 4.1. Therefore, the results 
shown in Table 3.3 cannot be fully explained by this solvent relaxation effect. Another 
possible explanation would be the heavy atom effect. Since the magnitude of the nuclear 
magnetic field is directly proportional to the nuclear charge and to the atomic number, 
spin-orbit coupling increases with a higher atomic number. This results in an increase in 
the rate of radiationless transitions for molecules in the presence of atoms with high 
atomic numbers. 
  
123 
 
 
Figure 3.41 Jablonski diagram for fluorescence with solvent relaxation effects included. 
 
When heavy atoms get in close contact to the fluorophore, the rate of intersystem crossing 
increases by a spin–orbit coupling.344 Thus, the decrease of fluorescence (S1-S0) can be 
explained by an increase in the population of the competing triplet state (S1-Tn), which is 
a radiationless transition of the fluorophore.345 In addition, Kasha found that fluorescence 
quenching of aromatic compounds in solution in the presence of alkyl halides was due to 
an increase in spin-orbit coupling resulting from collisional or external perturbation due 
to interactions with molecules whose atoms have high atomic numbers.346 The nature of 
the solvent can explain the ΦF obtained, since chloroform might exert the same quenching 
effect as that observed by Kasha. Therefore, the lower ΦF in the solutions prepared in 
chloroform could be due to the presence of chlorine atoms, with an atomic number, of 17, 
higher than any atom in tetrahydrofuran. A similar explanation can be used to rationalise 
the ΦF in the transition metal complexes. Previous comparisons have been made of the 
luminescent properties of first-row transition-metals in macrocycles, which showed that 
the nature of the central metal ion influences the ground-state absorption spectra of the 
macrocycle’s excited singlet and triplet states.347, 348  
The heavy atom effect suggests that high atomic numbers of metals in complexes would 
reduce their ΦF values. Therefore, the atomic numbers of the metals used for synthesising 
the complexes presented in this work (Ni = 28, Rh = 45, Pd = 46, Pt = 78) would suggest 
the following ΦF trend: ΦF[NiCl2(109)] 21 > ΦF[RhCl(109)] 125 > ΦF[PdCl(109)]Cl 120 
> ΦF[PtCl(109)]Cl 116. This trend is correct for Ni and Rh based metals. However, for 
Pd and Pt the trend is reversed. The same trend is observed regardless the solvent or the 
fluorescent standard used for measuring the different ΦF of the synthesised complexes. 
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This experimentally found trend can be observed in the emission spectra in Figure 3.42. 
It is possible to observe the reduction in fluorescence from the tridentate ligand 109 to 
[NiCl2(109)] 121. Then [RhCl(109)] 125 and [PtCl(109)]Cl 116 show quite similar 
fluorescence intensities, albeit the fluorescence of the Rh complex is slightly higher than 
that of Pt complex. Finally, the fluorescence intensity of [PdCl(109)]Cl 120 is the lowest 
one of the whole set of complexes. 
Another explanation for this lower fluorescence in the metal complexes in comparison 
with the free ligand 109 might be the solubility. The free ligand 109 is extremely soluble 
in THF and chloroform. However, in order to solubilise the different complexes, it was 
necessary to use a sonicator bath to dissolve them thoroughly. The sonication process 
might have dispersed small particles that might have reduced the fluorescence due a self-
quenching effect.349 This could explain the fact that the Pd complex had a lower 
fluorescence than the Pt complex despite their atomic numbers. 
 
Figure 3.42 Emission spectra of the tridentate phosphine 109 and complexes [RhCl(109)] 125, 
[NiCl2(109)] 121, [PdCl(109)][Cl] 120 and [PtCl(109)][Cl] 116 in tetrahydrofuran (excitation at 350 
nm) at 25 °C. 
 
The π*-π emission spectrum of monomer pyrene350 and propargyl pyrene derivatives341 
show two well-defined major bands between 370 and 400 nm and two shoulders with 
lower intensity between 410 nm and 450 nm. These bands and shoulders can be seen in 
the emission spectra of the free ligand 109 and its related metal complexes. There is no 
sign of hypsochromic or bathochromic shifts; which means that the bands are visible at 
the same wavelengths as in the pyrene emission spectrum. 350 The monomeric version of 
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pyrene in ethanol shows λem at 393 nm.351 Birks has reported that excimers of pyrene 
usually show a signal around 500 nm,342 which is not visible in Figure 3.42. This suggests 
that there was no formation of excimers during the excitation of the complexes. 
If these novel complexes are to be used as fluorescent probes, it is important for them to 
display fluorescence. These studies have shown that the complexes are fluorescent, so 
next their biological properties can be tested. 
3.6 Cell studies with [PtCl(109)][Cl] 116 
This section was done in collaboration with the research group of Dr Kogularamanan 
(Rama) Suntharalingam at King’s College London. 
Given the similarity in structure of [PtCl(109)][Cl] (116) and platinum-acridine agents352-
358 capable of intercalating between DNA base pairs and forming monofunctional-DNA 
adducts, the interaction of [PtCl(109)][Cl] (116) with double-stranded DNA was 
investigated.  
 
Figure 3.43 Examples of different platinum-acridine agents developed as anticancer agents. 
 
In order to determine the DNA affinity constant of [PtCl(109)][Cl] (116), UV-Vis 
spectroscopic studies were carried out with calf thymus DNA (ct-DNA).359 Upon addition 
of aliquots of DNA (in the mM range) to an aqueous solution of [PtCl(109)][Cl] (116) 
(50 μM), significant spectral changes (hyperchromicity) were observed indicative of 
strong DNA interactions (Figure 3.44).  
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Figure 3.44 UV-Vis spectra of [PtCl(109)][Cl] (116) (50μM) upon addition of aliquots of ct-DNA. 
The arrows show the hyperchromicity, indicator of strong DNA interactions. 
 
From the change in absorption intensity, the concentrations of the bound and unbound 
metal complex were calculated and extrapolated to determine the apparent binding 
constant. The binding affinity of [PtCl(109)][Cl] (116) for ct-DNA was 6.1 x 105 M−1. 
The planarity of the pyrene moiety suggests that the mode of interaction ought to be 
intercalative − such interactions result in hypochromicity upon DNA binding. However, 
in this case a large hyperchromic effect was observed upon addition of DNA to 
[PtCl(109)][Cl] (116). In contrast, comparison of the UV-Vis spectrum of [PtCl(109)][Cl] 
(116) (50 μM) in DMSO and [PtCl(109)][Cl] (116) (50 μM) with ct-DNA (10 equivalents) 
in aqueous buffer, revealed a hypochromic effect accompanied by a red shift, indicative 
of intercalation (Figure 3.45).  
 
Figure 3.45 UV-Vis spectra of [PtCl(109)][Cl] (116) or ASC1 (50 μM) in DMSO (red) and 
[PtCl(109)][Cl] (116) or ASC1 (50 μM) with ct-DNA (10 equivalents) in aqueous buffer (black). 
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Collectively, the data implies that the complex self-aggregates in aqueous solutions, 
yielding a lower absorbance of the complex in the absence of DNA − this explains the 
hyperchromicity observed in Figure 3.44. Upon DNA binding, the [PtCl(109)][Cl] (116) 
aggregates are thought to disperse (increases absorption) before binding to DNA 
intercalatively. To confirm intercalation, the ethidium bromide displacement assay130 was 
performed. Upon addition of [PtCl(109)][Cl] (116) to a solution of ct-DNA and ethidium 
bromide (1:20 ratio), the emission associated to the ethidium bromide-DNA complex 
(originating from the intercalation of ethidium bromide between DNA base pairs) 
decreased (Figure 3.46), showing that [PtCl(109)][Cl] (116) is able to displace ethidium 
bromide from DNA.  
 
Figure 3.46 Emission spectra for ethidium bromide (20 μM) bound to ct-DNA (1:20 ratio) upon 
addition of aliquots of ct-DNA. 
 
This result confirms that [PtCl(109)][Cl] (116) is able to interact with DNA in an 
intercalative manner (most likely via the pyrene moiety). To assess the ability of 
[PtCl(109)][Cl] (116) to form irreversible covalent interactions with DNA (via the 
platinum-phosphine moiety), the ct-DNA precipitation assay was carried out. ct-DNA 
and [PtCl(109)][Cl] (116) were incubated (5:1 ratio) at 37 oC in aqueous buffer and, at 
certain time-points, ct-DNA was selectively precipitated. The amount of unbound 
complex was determined by measuring the UV-Vis absorption of the supernatant (Figure 
3.47).  
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Figure 3.47 Percentage unbound [PtCl(109)][Cl] (116) or ASC1 (25 μM) at various time points after 
exposure of ct-DNA (250 μM). 
 
The absorption intensity of the supernatant decreased exponentially with time, suggestive 
of covalent binding to DNA. Around half of the available [PtCl(109)][Cl] (116) bound to 
DNA within 90 min. Overall, the biophysical data suggests that [PtCl(109)][Cl] (116) 
binds to DNA in dual-mode manner, intercalatively (via the pyrene moiety) and 
covalently (via the platinum-phosphine unit). 
Metal complexes that show high affinity for DNA, often display promising 
antiproliferative properties. Thus, the cytotoxicity of [PtCl(109)][Cl] (116) toward bone 
osteosarcoma (U2OS) and transformed mammary cancer (HMLER) cells was determined 
using the colourimetric MTT assay. Cisplatin, a clinically administered platinum-
containing anticancer drug, was used as a positive control. The IC50 values (the 
concentration required to reduce cell viability by 50%) were derived from dose-response 
curves (Figure 3.48 and Figure 3.49) and are summarised in Table 3.4. 
 
Figure 3.48 Average dose-response curves for the treatment of bone osteosarcoma (U2OS) cells 
with [PtCl(109)][Cl] (116) or ASC1 (n = 18 for each point). 
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Figure 3.49 Average dose-response curves for the treatment of transformed mammary cancer 
(HMLER) cells with [PtCl(109)][Cl] (116) or ASC1 (n = 18 for each point). 
 
The novel platinum(II) complex 116, displayed micromolar potency towards both cell 
lines, to a similar or better degree than cisplatin. Given the promising antiproliferative 
data, further in vitro studies are now planned to decipher the mechanism of action of 
[PtCl(109)][Cl] (116). The intercalating ability of the fluorescent pyrene function of 
complex 116, should call into question its cell cytotoxic mechanism. The mechanism for 
[PtCl(109)][Cl] (116) could be different from the mechanism of cisplatin since the 
popular anticancer drug cannot undergo DNA intercalation. Furthermore, via 
modifications to the pyrene and/or platinum-phosphine backbones, we hope to develop 
more potent agents. 
 
Compound U20S IC50 [μM][a] HMLER IC50 [μM][a] 
116 29.97 ± 3.09 1.62 ± 0.18 
Cisplatin 20.35 ± 0.11 2.79 ± 0.18 
Table 3.4 IC50 values of the complex 116 and cisplatin against bone osteosarcoma (U20S) and 
transformed mammary cancer (HMLER) cells. [a] Determined after 72 h incubation (mean of three 
independent experiments ± SD). 
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3.7 Summary 
By employing pyrene as a remote stability function, the novel air-sable primary 
phosphines PyrCH2PH2 94 and Pyr(CH2)4PH2 95 was prepared. This air-stability is 
consistent with that predicted theoretically by a DFT-based model. According to the 
calculations obtained, the addition of an alkyl linker group between the pyrene group and 
the phosphine group would provide a SOMO energy above −10 eV, which is the apparent 
threshold for air-stable phosphines, in line with our previous reports.37 Once attained, the 
stability of the primary phosphines 95 was compared to that of the primary pyrene 
methylene phosphine, 94. The stability of the phosphine containing a butyl group as the 
alkyl linker, 95, was higher than its pyrene methylene analogue 94, when left in a solution 
in chloroform under atmospheric conditions. The result showed that after 7 days in 
solution, 1.8% of a sample of Pyr(CH2)4PH2 95 was oxidized, compared to 44.9% for 
PyrCH2PH2 93. DFT calculations based on the B3LYP function with a 6-31G* basis set 
showed that the SOMO value of the pyrene methylene phosphine 94 is −9.4 eV, closer to 
the threshold value of −10 eV, than the SOMO value calculated for pyrene butyl 
phosphine 95 (−8.6 eV). As explained earlier in Section 1.3.1, a radical cation generated 
from a more stable orbital will be more reactive than an analogue with a higher 
HOMO/LUMO, and is therefore more likely to oxidize. However, with a value of –9.4 
eV we would − according to the model − expect air-stability for 94 which is not observed 
under the used conditions. This requires further investigation. The air stability of primary 
phosphine Pyr(CH2)4PH2 95 does not interfere with its reactivity; the tridentate ligand 
109 was thus fruitfully synthesised via a double hydrophosphination reaction of the 
primary phosphine 95 with vinyl diphenylphosphine in the presence of [Pt(η2-nb)3] as a 
catalyst. This suggests that the novel primary phosphine 95 can be used as the starting 
material for a range of different compounds, as the P–H bonds are highly reactive and can 
be easily functionalised.34 Subsequent complexation reactions of 109 with group 9 and 
10 metals produced interesting complexes, whose photophysical properties were tested 
proving that the fluorescence of these complexes is not quenched. The ΦF values of the 
complexes obtained were lower in comparison with the free ligand 109, mostly likely due 
to the heavy atom effect. It is also possible to see that the atomic number did not determine 
the ΦF trend of the complexes since the Pd complex has a lower ΦF than the Pt complex. 
Ni and Rh complexes followed the expected trend. One of the complexes obtained from 
the group 10 metals study has particularly interesting properties. Complex [PtCl(109)]Cl 
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116 is an interesting alternative to the well-known cis-[PtCl2(NH3)2] 110, a compound 
commonly used for treating various types of cancer.360 The DNA affinity of the novel 
platinum(II) complex 116 has been tested due to its similarity to different platinum-
acridine compounds, these agents have shown interesting biological activity.352-357 The 
UV-Vis spectrum of a solution of the novel platinum(II) complex 116 with DNA showed 
that the complex interacted with DNA. The reduction of the π*-π absorption bands of its 
spectrum provided the main proof of an interaction. Further tests in cells made it possible 
to compare the potency of our complex against the drug cis-[PtCl2(NH3)2] 110. The novel 
platinum(II) complex proved potent against bone osteosarcoma (U20S) and transformed 
mammary cancer (HMLER) cells to a similar or higher degree than cisplatin. Further 
research on the mechanism of action of compound 116 on these cancer cells may allow 
us to improve upon its biological activity. 
3.8 Experimental 
3.8.1 General Procedure 
All air- and/or water-sensitive reactions were performed under a dinitrogen atmosphere 
using standard Schlenk line techniques. Tetrahydrofuran and toluene were dried over 
sodium/benzophenone and sodium respectively, dichloromethane was dried over calcium 
hydride; all solvents were distilled prior to use. All starting materials were purchased 
from Aldrich, Acros Organics, Alfa Aesar or Strem and used as received. Compounds 
PyrCH2Phos 100,
361 Pyr(CH2)4Br 102,
362 and Pyr(CH2)4Phos 103
363 were prepared 
according to literature procedures. Flash chromatography was performed on silica gel 
from Fluorochem (silica gel, 40-63u, 60A). Thin-layer chromatography was carried out 
on Fisher aluminium-based plates with silica gel and fluorescent indicator (254 nm). 
Melting points were determined in open glass capillary tubes on a Stuart SMP3 melting 
point apparatus. 1H, 13C{1H} and 31P{1H} NMR spectra were recorded on a JEOL 
Lambda 500 (1H 500.16 MHz) or JEOL ECS-400 (1H 399.78 MHz) spectrometer at room 
temperature (21°C); 1H and 13C shifts were relative to tetramethylsilane, 31P relative to 
80% H3PO4. Infrared spectra were recorded on a Varian 800 FT-IR spectrometer. UV-
Vis absorption and emission spectra were recorded on a UV-1800 Shimadzu 
spectrophotometer and RF-6000 Shimadzu spectrofluorometer respectively. Mass 
spectrometry was carried out by the EPSRC National Mass Spectrometry Service Centre, 
Swansea. 
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3.8.2 Diethyl 1-pyrenylmethylene phosphonate 100 
 
1-(Bromomethyl)pyrene (0.33 g, 1.12 mmol) was placed in a Schlenk flask, then 
dissolved in P(OEt)3 (3 mL) under dinitrogen. The mixture was heated to 145 °C and was 
left to react for 1.5 hours. The reaction was monitored by TLC and, once complete, the 
reaction was left to cool room temperature and the solvent was then evaporated. The 
resulting crude material was purified using column chromatography (ethyl 
acetate/petroleum ether 1:1, Rf = 0.3). The product was a light brown solid (0.25 g, 63%). 
A sample suitable for X-ray crystallographic analysis was obtained from chloroform. MP: 
76.1 °C. 1H NMR (300 MHz, CDCl3) δ 8.12 (d, 3JHH = 9.3 Hz, 1H), 7.99 (d, 3JHH = 2.3 
Hz, 1H), 7.97 (d, 3JHH = 2.3 Hz, 1H), 7.95-7.90 (m, 2H), 7.87-7.77 (m, 4H), 3.86-3.64 (m, 
6H), 1.00 (t, 3JHH = 7.0 Hz, 6H) ppm, 13C{1H} NMR (75 MHz, CDCl3) δ 131.3, 130.8, 
130.5, 129.3 (d, JCP = 6.5 Hz), 128.8 (d, JCP = 6.5 Hz), 127.6, 127.4, 127.2, 126.0, 125.8, 
125.7 (d, JCP = 6.5 Hz), 125.2, 125.0, 124.8, 124.7, 123.8, 62.3 (d, 
2JCP = 7.1 Hz), 31.5 
(d, 1JCP = 138.5 Hz), 16.4 (d, 
3JCP = 5.8 Hz) ppm, 31P{1H} NMR (121 MHz, CDCl3) δ 
25.9 ppm. 
3.8.3 1-Pyrenylmethylene phosphine 94 
 
Chlorotrimethylsilane (0.23 g, 2.13 mmol) was placed in a flask and dissolved in 
anhydrous THF (6 mL). The solution was cooled in a dry ice bath. A suspension of 
LiAlH4 (0.08 g, 2.13 mmol) in anhydrous THF (2 ml) was then added dropwise. The 
solution was taken out of the dry ice bath. In another flask, diethyl 1-pyrenylmethylene 
phosphonate (100) (0.25 g, 0.71 mmol) was dissolved in anhydrous THF (5 mL), giving 
a transparent solution. The phosphonate 100 solution, in the second flask, was added 
dropwise into the flask containing the reducing solution, using a dry ice bath to reduce 
the temperature to −78 °C. The reaction was then left stirring at room temperature for 3 
hours and was quenched by adding water dropwise (1 mL). The mixture was then 
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extracted with DCM (20 mL x 3). Purification using column chromatography on silica 
gel (petrol, Rf = 0.8) yielded a white-yellowish solid (0.11 g, 62%). A sample suitable for 
X-ray crystallographic analysis was obtained from the saturated solution of the compound 
dissolved in dichloromethane cooled in an ice bath. MP: 95.6 °C. 1H NMR (300 MHz, 
CDCl3) δ 8.14 (d, 3JHH = 9.4 Hz, 1H), 8.10 (d, 3JHH = 2.7 Hz, 1H), 8.08 (d, 3JHH = 2.7 Hz, 
1H), 8.05 (d, 3JHH = 7.2 Hz, 1H), 8.02 (d,
 3JHH = 5.7 Hz, 1H), 7.96-7.88 (m,
 3H), 7.79 (d, 
3JHH = 8.3 Hz, 1H), 3.54 (m, 2H), 3.12 (m,
 2H) ppm, 13C{1H} NMR (100 MHz, CDCl3) 
δ 137.1, 131.5, 131.0, 129.9, 127.6, 127.4, 126.8, 126.6, 126.5, 126.0, 125.4, 125.3, 125.1, 
125.0, 124.8, 123.2, 19.0 (d, 1JCP = 12.3 Hz) 31P{1H} NMR (121 MHz, CDCl3) δ −121.3 
ppm. 
3.8.4 1-(4-Bromobutyl)-pyrene 102 
 
1-(Butan-4-ol)-pyrene (0.20 g, 0.73 mmol, 1 eq.) was dissolved in DCM (15 mL) forming 
a yellow suspension which was placed in an ice bath; tetrabromomethane (0.32 g, 0.91 
mmol, 1.25 eq.) and K2CO3 (0.15 g, 1.5 eq.) were then added to the solution forming a 
white suspension. PPh3 (0.24 g, 0.91 mmol, 1.25 eq.) was dissolved in DCM (5 mL). The 
resulting transparent solution was then added dropwise to the suspension containing the 
mixture with 1-(butan-4-ol)-pyrene while this was still in the ice bath. The mixture was 
then left to warm to room temperature and reacted over 12 hours. After that period the 
solvent was evaporated under reduced pressure. The compound was purified using 
column chromatography on silica gel (hexane/ethyl acetate 8:1, Rf = 0.5) resulting in a 
pale yellow solid (0.18 g, 75%). A sample suitable for X-ray crystallographic analysis 
was obtained from dichloromethane. MP : 77-80 °C. 1H NMR (400 MHz, CDCl3) δ 8.26 
(d, 3JHH = 9.0 Hz, 1H), 8.17 (d,
 3JHH = 2.7 Hz, 1H), 8.15 (d,
 3JHH = 2.7 Hz, 1H), 8.11 (d,
 
3JHH = 9.0 Hz, 2H), 8.05-7.96 (m, 3H), 7.85 (d, 
3JHH = 7.9 Hz, 1H,), 3.46 (t,
 3JHH = 6.3 Hz, 
2H), 3.37 (t, 3JHH = 7.1 Hz, 2H), 2.02 (m,
 4H) ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 
136.1, 131.5, 131.0, 130.0, 128.7, 127.6, 127.5, 127.3, 126.8, 125.9, 125.2, 125.1, 125.0, 
124.9, 124.8 123.3, 33.7, 32.8, 32.7, 30.3 ppm. IR (neat): 𝜈 = 3044 (w), 2941 (w), 2868 
(w), 1464 (s), 1193 (s), 838 (s), 709 (s), 652 (s) cm−1. HRMS (ESI+) exact mass calcd. 
for C20H18Br1 [M+H]
+ requires m/z 337.0586, found m/z 337.0582 (1.2 ppm). 
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3.8.5 Diethyl (4-(pyren-1-yl)butyl)phosphonate 103  
 
1-(4-Bromobutyl)-pyrene 102 (0.34 g, 1.01 mmol) was placed in a Schlenk flask, was 
then dissolved in P(OEt)3 (4 mL) under dinitrogen. The mixture was heated to 145 °C and 
was left to react for 1.5 hours. The reaction was monitored by TLC and, once complete, 
the reaction was left to cool to room temperature; the solvent was then evaporated. The 
resulting crude material was purified using column chromatography (ethyl acetate, Rf = 
0.4). The product was a pale yellow solid (0.25 g, 63%). A sample suitable for X-ray 
crystallographic analysis was obtained from dichloromethane. MP: 79-82 °C. 1H NMR 
(400 MHz, CDCl3) δ 8.08 (d, 3JHH = 9.0 Hz, 1H), 8.04 (d, 3JHH = 2.5 Hz, 1H), 8.02 (d, 3JHH 
= 2.5 Hz, 1H), 7.96 (d, 3JHH = 4.5 Hz, 1H), 7.94 (d,
 3JHH = 5.6 Hz, 1H), 7.91-7.85 (m, 3H), 
7.68 (d, 3JHH = 8.0 Hz, 1H), 4.08-3.97 (m, 4H), 3.19 (t,
 3JHH = 7.5 Hz, 2H), 1.85-1.66 (m, 
6H), 1.25 (t, 3JHH = 6.5 Hz, 6H) ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 136.3, 131.5, 
131.0, 129.9, 128.6, 127.6, 127.3, 127.3, 126.7, 125.9, 125.2, 125.1, 125.0, 124.9, 124.8, 
123.3, 61.5 (d, 2JCP = 6.2 Hz), 33.2, 32.8 (d, 
2JCP = 16.3 Hz), 25.7 (d, 
1JCP = 140.9 Hz), 
22.7 (d, 2JCP = 5.1 Hz), 16.6 (d, 
3JCP = 6.3 Hz) ppm. 31P{1H} NMR (162 MHz, CDCl3) δ 
32.8 ppm. IR (neat): 𝜈 = 3045 (w), 2981 (w), 2883 (w), 2360 (w), 1602 (s), 1253 (s), 
1229 (s), 1058 (s), 1018 (s), 955 (s), 842 (s), 708 (s) cm−1. HRMS (ESI+) exact mass 
calcd. for C24H28O3P1 [M+H]
+ requires m/z 395.1771, found m/z 395.1768 (1.5 ppm). 
3.8.6 4-(Pyren-1-yl)butylphosphine 95 
 
Chlorotrimethylsilane (0.17 g, 1.59 mmol) was placed in a Schlenk flask and dissolved 
in anhydrous THF (6 mL). The Schlenk flask was cooled in a dry ice bath to −78 °C. A 
suspension of LiAlH4 (0.06 g, 1.59 mmol) in anhydrous THF (2 ml) was then added 
dropwise. The solution was taken out of the dry ice bath and allowed to warm to room 
temperature. In another flask, diethyl (4-(pyren-1-yl)butyl)phosphonate (103) (0.21 g, 
0.53 mmol) was dissolved in anhydrous THF (5 mL), giving a transparent solution. The 
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phosphonate 103 solution, in the second flask, was added dropwise into the flask 
containing the chlorotrimethylsilane solution using a dry ice bath to reduce the 
temperature to −78 °C. The reaction then left stirring at room temperature for 3 hours and 
was quenched by adding water dropwise (1 mL). The mixture was then extracted with 
DCM (20 mL x 3). Purification using column chromatography on silica gel (ethyl 
acetate/petroleum ether 1:7, Rf = 0.6) yielded a white solid (0.13 g, 70%). A sample 
suitable for X-ray crystallographic analysis was obtained from dichloromethane. MP: 
89.9 °C. 1H NMR (400 MHz, CDCl3) δ 8.26 (d, 3JHH = 9.3 Hz, 1H), 8.16 (d, 3JHH = 2.5 
Hz, 1H), 8.14 (d, 3JHH = 2.5 Hz, 1H), 8.11 (d,
 3JHH = 1.8 Hz, 1H), 8.09 (d,
 3JHH = 3.5 Hz, 
1H), 8.04-7.96 (m, 3H), 7.85 (d, 3JHH = 8.0 Hz, 1H), 3.33 (d,
 3JHH = 7.9 Hz, 2H), 2.69 (ddd, 
3JHaHx = 7.4 Hz,
 3JHa’Hx = 7.3 Hz,
 1JHP = 194.3 Hz, 2H), 1.96-1.88 (m, 2H), 1.75-1.65 (m, 
2H), 1.63-1.52 (m, 2H) ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 136.8, 131.5, 131.0, 
129.9, 128.7, 127.6, 127.3, 126.9, 126.7, 125.9, 125.2, 125.1, 125.0, 124.9, 124.8, 123.5, 
33.3, 33.1, 33.8 (d, JCP = 5.8 Hz), 13.8 (d, JCP = 7.5 Hz) ppm. 31P{1H} NMR (162 MHz, 
CDCl3) δ −138.1 ppm. IR (neat): 𝜈 = 3044 (w), 2923 (w), 2855 (w), 2298 (s), 840 (s), 
710 (s) cm−1. HRMS (ESI+) exact mass calcd. for C20H20P1 [M+H]
+ requires m/z 
291.1297, found m/z 291.1298 (0.3 ppm). 
3.8.7 4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine 109 
 
4-(Pyren-1-yl)butylphosphine 95 (0.42 g, 1.45 mmol) was dissolved in anhydrous toluene 
(20 mL). To this vinyldiphenylphosphine (0.58 mL, 2.90 mmol) and [Pt(η2-nb)3] (0.07 g, 
0.15 mmol) were added, in that order. The reaction was stirred at reflux for 24 hours under 
dinitrogen. On completion of the reaction, the volatiles were removed in vacuo leaving a 
brown solid. Purification was performed by column chromatography on silica gel 
(hexane/dichloromethane 1:1, Rf = 0.6) to produce a white powder (0.56 g, 55%). MP: 
94.9 °C. 1H NMR (400 MHz, CDCl3) δ 8.15 (d, 3JHH = 9.3 Hz, 1H), 8.09 (d, 3JHH = 7.6 
Hz, 2H), 8.01 (d, 3JHH = 4.4 Hz, 1H), 7.99 (d,
 3JHH = 3.0 Hz, 1H), 7.96-7.88 (m, 3H), 7.74 
(d, 3JHH = 7.6 Hz, 1H), 7.32-7.19 (m,
 20H), 3.21 (t, 3JHH = 7.5 Hz, 2H), 2.02-1.90 (m,
 4H), 
1.85-1.73 (m, 2H), 1.48-1.34 (m, 8H) ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 138.4 (d, 
JCP = 3.0 Hz), 138.2 (d,
 JCP = 3.0 Hz), 136.7, 132.9 (d,
 JCP = 5.0 Hz), 132.6 (d,
 JCP = 5.0 
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Hz), 131.5, 130.9, 128.7, 128.6-128.3 (overlapping signals), 127.6, 127.2, 126.6, 125.8, 
125.1, 125.0, (d, JCP = 3.6 Hz), 124.9, 124.8, 124.7, 123.4, 33.5 (d,
 JCP = 10.6 Hz), 33.3, 
26.3, 26.1, 25.9 (d, JCP = 13.0 Hz), 22.8 (d,
 JCP = 134.0 Hz) ppm. 31P{1H} NMR (162 
MHz, CDCl3) δ −12.2 (d, 3JPP = 26.5 Hz), −20.6 (t, 3JPP = 26.5 Hz) ppm. IR (neat): 𝜈 = 
3044 (w), 2933 (w), 2360 (w), 1434 (s), 836 (s), 736 (s), 693 (s) cm−1. HRMS (ESI+) 
exact mass calcd. for C48H46P1 [M+H]
+ requires m/z 715.2807, found m/z 715.2806 (1.5 
ppm). 
3.8.8 [PtCl(109)][Cl] 116 
4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine (109) (0.13 g, 0.18 
mmol) was dissolved in anhydrous dichloromethane (1.5 mL) and added to a stirred 
solution of [PtCl2(η2:η2-cod)] (0.07 g, 0.18 mmol) in anhydrous dichloromethane (1.5 
mL). The mixture was stirred at room temperature for 2 hours and the solvent removed. 
The solid was washed with hexane (3 x 5 mL) and dried in vacuo (0.13 g, 72%). A sample 
suitable for X-ray crystallographic analysis was obtained from hexane/dichloromethane. 
1H NMR (400 MHz, CDCl3) δ 8.10 (d, 3JHH = 2.3 Hz, 1H), 8.07 (d, 3JHH = 2.3 Hz, 1H), 
8.05-7.88 (m, 7H), 7.73-7.63 (m, 4H), 7.61-7.51 (m, 4H), 7.45-7.18 (m,12H), 3.62-3.37 
(m, 2H), 3.05 (t, 3JHH = 7.3 Hz, 2H), 2.62-2.24 (m, 6H), 2.05-1.72 (m, 4H), 1.60-1.47 (m, 
2H) ppm. 13C{1H} NMR (126 MHz, CDCl3) δ 135.4, 133.2, 132.8, 132.3, 132.0, 131.4, 
130.9, 129.9, 129.5, 129.4, 129.3, 129.2, 128.5, 127.5, 127.2, 126.8, 125.9, 125.0, 124.9, 
123.2, 32.6, 32.5, 29.7, 27.0, 26.9, 25.9 ppm. 31P{1H} NMR (121 MHz, CDCl3) δ 87.1 
(1JPPt = 2883.8 Hz, 1P), 44.0 (
1JPPt = 2538.1 Hz, 2P) ppm. IR (neat): 𝜈  = 3049 (w), 2914 
(w), 2360 (w), 1596 (m), 1433 (s), 1103 (m), 838 (m), 756 (s) cm−1. HRMS (ESI+) calcd. 
for C48H45Cl1P3Pt1 [M]
+ requires m/z 939.2016, found m/z 939.2002 (0.1 ppm). 
3.8.9 [PdCl(109)][Cl] 120 
4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine (109) (0.05 g, 0.07 
mmol) was dissolved in anhydrous dichloromethane (1.5 mL) and added to a stirred 
solution of [PdCl2(PhCN)2] (0.03 g, 0.07 mmol) in anhydrous dichloromethane (1.5 mL). 
The mixture was stirred at room temperature for 2 hours and the solvent removed. The 
solid was washed with hexane (3 x 5 mL) and dried in vacuo (0.04 g, 64%). A sample 
suitable for X-ray crystallographic analysis was obtained from hexane/dichloromethane. 
1H NMR (400 MHz, CDCl3) δ 8.09 (d, 3JHH = 3.4 Hz, 1H), 8.07 (d, 3JHH = 3.4 Hz, 1H), 
8.03 (d, 3JHH = 9.5 Hz, 1H), 7.98 (d, 
3JHH = 9.5 Hz, 1H), 7.95-7.89 (m, 5H), 7.71-7.64 (m, 
4H), 7.63-7.57 (m, 4H), 7.42-7.37 (m, 2H), 7.34-7.27 (m, 6H), 7.26-7.20 (m, 4H), 3.68-
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3.46 (m, 2H), 3.07 (t, 3JHH = 7.2 Hz, 2H), 2.65-2.54 (m, 2H), 2.50-2.37 (m, 4H), 1.88-
1.77 (m, 2H), 1.64-1.51 (m, 2H) 0.84-0.75 (m, 2H) ppm. 13C{1H} NMR (126 MHz, 
CDCl3) δ 134.3, 132.0-131.8 (overlapping signals), 131.1, 130.4, 129.9, 128.9, 128.4-
128.3 (overlapping signals), 127.7, 127.5, 127.2, 127.0, 126.5, 126.2, 125.7, 124.9, 124.0-
123.9 (overlapping signals), 122.2, 31.6, 30.9, 28.3, 25.2, 24.9, 21.7 ppm. 31P{1H} NMR 
(121 MHz, CDCl3) δ 115.1 (t, 3JPP = 6.3 Hz), 47.9 (d, 3JPP = 6.3 Hz) ppm. IR (neat): 𝜈  = 
2961 (w), 2917 (w), 2849 (m), 2363 (w), 1435 (w), 1260 (m), 1095 (s), 1016 (s), 795 (m), 
689 (m) cm−1. 
3.8.10 [NiCl2(109)] 121 
4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine (109) (0.05 g, 0.07 
mmol) was dissolved in anhydrous dichloromethane (2 mL) and added to a stirred 
solution of [NiCl2(py)4] (0.05 g, 0.07 mmol) in degassed ethanol (1 mL). The mixture 
was stirred at room temperature for 2 hours and the solvent removed. The solid was 
washed with hexane (3 x 5 mL) and dried in vacuo (0.03 g, 51%). A sample suitable for 
X-ray crystallographic analysis was obtained from dichloromethane. 31P{1H} NMR (121 
MHz, CDCl3) δ 115.9 (t, 3JPP = 42.5 Hz), 50.0 (d, JPP = 42.5 Hz) ppm, IR (neat): 𝜈  = 2915 
(w), 2358 (w), 2343 (w), 1436 (m), 1260 (m), 1096 (m), 1026 (m), 801 (m), 739 (s), 692 
(s) cm−1. 
3.8.11 [RhCl(109)] 125 
4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine (109) (0.05 g, 0.07 
mmol) was dissolved in anhydrous dichloromethane (2 mL) and added to a stirred 
solution of [Rh(η2:η2-cod)Cl]2 (0.02 g, 0.04 mmol) in anhydrous dichloromethane (2 mL). 
The mixture was stirred at room temperature for 2 hours and the solvent removed. The 
solid was washed with hexane (3 x 5 mL) and dried in vacuo (0.03 g, 58%). 1H NMR 
(700 MHz, CDCl3) δ 8.21 (d, 3JHH = 9.1 Hz, 1H), 8.18 (d, 3JHH = 8.0 Hz, 1H), 8.11 (d, 
3JHH = 9.1 Hz, 1H), 8.07, (d, 
3JHH = 7.5 Hz, 1H), 8.04-7.99 (m, 4H), 7.81 (d, 
3JHH = 7.5 
Hz, 1H), 7.75-7.70 (m, 6H), 7.56-7.53 (m, 3H), 7.51-7.46 (m, 5H), 7.45-7.41 (m, 4H), 
7.27 (d, 3JHH = 8.0 Hz, 1H), 7.20 (d, 
3JHH = 7.8 Hz, 1H), 3.31 (t, 
3JHH = 7.7 Hz, 2H), 2.51-
2.40 (m, 4H), 1.98-1.87 (m, 6H), 1.81-1.74 (m, 2H), 1.68-1.62 (m, 2H) ppm, 13C{1H} 
NMR (176 MHz, CDCl3) δ 132.5, 132.2, 131.9, 131.4, 131.3, 131.0, 130.9-130.8 
(overlapping signals), 129.9, 129.0, 128.9-128.8 (overlapping signals), 128.5, 128.3, 
127.5, 126.3, 125.3, 125.1, 124.9-124.8 (overlapping signals), 33.0, 30.4, 28.9, 23.8, 23.0, 
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21.5 ppm; 31P{1H} NMR (121 MHz, CDCl3) δ 93.4 (dt, 3JRhP = 120.2 Hz, 3JPP = 23.0 Hz), 
55.9 (dd, 3JPP = 124.5Hz,
 3JPP = 23.0 Hz) ppm. 
3.8.12 [IrCl(109)] 129 
4-(Pyren-1-yl)butyl-P-bis-(2-ethyldiphenylphosphino)phosphine (109) (0.08 g, 0.18 
mmol) was dissolved in anhydrous dichloromethane (3 mL) and added to a stirred 
solution of [Ir(η2:η2-cod)Cl]2 (0.04 g, 0.09 mmol) in anhydrous dichloromethane (3 mL). 
The mixture was stirred at 40 °C for 2 hours and the solvent removed. The solid was 
washed with hexane (3 x 5 mL) and dried in vacuo (0.06 g, 57%). 31P{1H} NMR (121 
MHz, CDCl3) δ 62.7 (t, JPP = 10.6 Hz), 27.5 (d, 3JPP = 10.6 Hz) ppm. IR (neat): 𝜈 = 3051 
(w), 2911 (w), 2342 (w), 1557 (s), 1434 (m), 1183 (m), 1070 (w), 845 (m), 752 (s), 694 
(s) cm−1. HRMS (ESI+) calcd. for C48H46Cl1Ir1P3 [M]
+ requires m/z 943.2125, found m/z 
943.2125(0.1 ppm). 
3.8.13 Absorption and Emission Spectroscopy 
Absorption spectra were recorded with a Shimadzu Model UV-1800 spectrophotometer 
while fluorescence studies were recorded with a Shimadzu RF-6000 fluorophotometer. 
Solvents used for spectroscopic experiments were spectrophotometric grade. Absorption 
and emission spectra were recorded in dry degassed tetrahydrofuran and chloroform 
solutions at room temperature. Fluorescence quantum yields were measured with respect 
to pyrene (ΦF = 0.32, λabs = 335 nm, λem = 381 nm, ε = 54,000cm M−1cm−1, cyclohexane) 
and anthracene (ΦF = 0.36, λabs = 356 nm, λem = 396 nm, ε = 9,700cm M−1cm−1, 
cyclohexane).83 Dyes were excited at 317 nm, when compared with pyrene, and at 350 
nm, when compared with anthracene; excitation and emission slits were both set to 5 nm. 
3.8.14 Quantum Yield Method 
The fluorescence quantum yield (ΦF) can be defined as the ratio of emitted photons 
relative to the number of absorbed photons.41 All quantum yields were measured in 
solution at room temperature. In order to define the fluorescence quantum yield 
appropriate fluorescence standard reference compounds were selected, which absorb and 
emit over ranges comparable to those of the studied samples. The excitation wavelength, 
slit widths and the emission range were kept constant for both the reference and the 
sample. Dilute solutions were prepared, possessing the same absorbance at the excitation 
wavelength (A < 0.09 at the excitation wavelength, with an error limit of ±0.005 between 
the reference and sample). The following formulae were used to correct the relative 
emission areas for minor differences in absorbance: 
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A is the absorbance, I0 is the intensity of incident light, IT is the intensity of the transmitted light, Ia is the 
intensity of absorbed light and 
RELQY is the relative quantum yield.
17  
 
Where necessary the quantum yields were corrected for the differences in the refractive 
index of the solvent: 
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The subscripts A and B denote two difference solvents and η is the refractive index.17 
 
The quantum yield of the sample can now be determined using the following equation: 
f
f
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Superscript Sl and Ref denote sample and reference respectively.40 
3.8.15 UV/Vis titration 
The UV/Vis spectra were recorded on a Cary 100 spectrometer. To determine the binding 
constants of the complexes with ct-DNA, [PtCl(109)][Cl]116 (50 μM) was titrated with 
concentrated solutions of ct-DNA (2.9 mM, nucleotide) in Tris-HCl (50 mm, pH 7.4) 
buffer. A quartz cuvette (1 cm path length) was used to carry out the measurements. The 
binding constants were obtained by fitting the data to a reciprocal plot of D/Δεap versus 
D by using the following equation: D/Δεap = D/Δε + 1 / (Δε x K), in which the 
concentration of DNA is expressed in terms of base pairs (determined by measuring the 
absorption at λ = 260 nm and the appropriate extinction coefficients), the apparent molar 
extinction coefficient εa = Aobserved/[complex], Δεap = [εa – εf], Δε = [εb – εf], in which εb is 
the extinction coefficient of the DNA-bound complex, εf is the extinction coefficient of 
the free complex and Δεap = |εa −εf|. 
3.8.16 Ethidium bromide displacement assay 
To a solution of ct-DNA (20 µM) in Tris-HCl (50 mm, pH 7.4) buffer, ethidium bromide 
(1 µM) was added and the resulting solution was incubated at room temperature for 10 
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min. After this period, the emission spectrum was recorded between 530 and 750 nm with 
an excitation wavelength of 520 nm. Aliquots of 116 were added to the resultant solution 
and the emission spectrum was recorded after 10 min incubation. This was repeated until 
the emission spectrum remained constant. 
3.8.17 ct-DNA precipitation assay 
The amount of 116 covalently bound to ct-DNA was determined by modification of a 
previously reported protocol. A solution of ct-DNA (0.25 mM, nucleotide) was incubated 
with 116 at a base pair:metal complex ratio of 5:1 at 37 ºC in Tris-HCl (50 mm, pH 7.4) 
buffer. At certain time points, a 250 μL aliquot was removed and the DNA was 
precipitated by adding 10 μL of KCl (5 M) and 1.0 mL of EtOH (stored at 4 °C). The 
solution was centrifuged to remove DNA, and the concentration of covalently unbound 
116 was determined by measuring the UV-Vis absorption of the supernatant. 
3.8.18 Cell lines and cell culture conditions 
U20S bone osteosarcoma cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM-low glucose) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. HMLER transformed mammary cancer cells were maintained in 
Mammary Epithelial Cell Growth Medium (MEGM) with supplements and growth 
factors (BPE, hydrocortisone, hEGF, insulin, and gentamicin/amphotericin-B). All cells 
were grown at 310 K in a humidified atmosphere containing 5% CO2. 
3.8.19 Cytotoxicity MTT assay 
The colorimetric MTT assay was used to determine the toxicity of 116 and cisplatin. Cells 
(3 × 103) were seeded in each well of a 96-well plate. After incubating the cells overnight, 
various concentrations of test compound (0.3-100 µM) were added and incubated for 72 
h (total volume 200 µL). 116 was prepared as 10 mM solutions in DMSO and diluted 
using media. The final concentration of DMSO in each well was 0.5% and this amount 
was present in the untreated control as well. Cisplatin was prepared as a 5 mM solution 
in PBS and diluted further using media. After 72 h, the medium was removed, 200 μL of 
a 0.4 mg/mL solution of MTT in DMEM or MEGM was added, and the plate was 
incubated for an additional 1-2 h. The DMEM/MTT or MEGM/MTT mixture was 
aspirated and 200 μL of DMSO was added to dissolve the resulting purple formazan 
crystals. The absorbance of the solution wells was read at 550 nm. Absorbance values 
were normalized to DMSO-containing control wells and plotted as concentration of test 
compound versus % cell viability. IC50 values were interpolated from the resulting dose 
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dependent curves. The reported IC50 values were averaged from three independent 
experiments, each of which consisted of six replicates per concentration level. 
  
  
142 
 
4 Synthesis of a fluorescent chelator ligand derived from 8-
((4-dicyclohexylphosphino)phenyl)-4,4-diphenyl-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 
This part of the thesis describes the development of a compound with the aim of creating 
a novel probe specific for targeting the mitochondrion of cells. The chemical features of 
this novel probe make it a fluorescent PET carrier, turning the compound into a useful 
agent for in vivo and in vitro imaging techniques. The introduction will include key 
information about the biological importance to these types of compounds. 
4.1 Mitochondria  
Mitochondria generate most of the adenosine triphosphate (ATP) supply in cells; this 
compound is used as a source of chemical energy for the different processes required in 
living systems.364 Energy production is not the only task that this organelle carries out, it 
is also a keystone in cellular signalling and differentiation, as well as cell death and cell 
growth.365 The procedures this organelle is involved with make it an important target for 
drugs.366 Mitochondria can be found in all eukaryotic organisms and vary widely 
depending on the living system, tissue and cell type. For example, red blood cells do not 
contain any mitochondria, whereas liver cells contain one of the highest densities of 
mitochondria in the human body.366 The outer membrane of mitochondria has a high 
density of a specific trans-membrane protein called porin.367 These proteins are mainly 
shaped by β strands, arrangements of amino acids that keep a specific 2-dimensional 
rectangular motif, linked together by peptide chains that are located in the cytosol. The 
spatial disposition of the protein makes it look like a cylindrical tube, hence its name, β 
barrel.368 The nonpolar residues of the protein are folded outwards, allowing them to 
interact with the lipids that are situated in the outer membrane. On the other hand, the 
polar residues face inwards towards the centre of the barrel, producing a chemical 
environment attractive to molecules of water that form an aqueous channel.368 The 
channel found in the porin is partially blocked by a loop, called an eyelet. This loop is 
placed in the cavity formed by the barrel; its morphology can be variable, which controls 
the affinity of the channel for certain solutes according to their size. The surface of the 
inner walls of the channel mainly contains charged amino acids, creating a transversal 
electric field along the inner pore. However, the eyelet has an excess of negative charges 
given by the side chains of the amino acids that form it.369 
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Figure 4.1 Representation of mitochondria and its outer membrane containing the transport 
protein porin. 
 
It is thought that a combination of the features mentioned above provide selectivity 
allowing certain compounds to diffuse through the channel. As mentioned above, a key 
characteristic of mitochondria is the utilization of a proton electrochemical gradient 
potential, or electrochemical proton motive force, to generate ATP. This procedure 
requires different specialized proteins, whose main function is to transport protons against 
their concentration gradient across the inner mitochondrial membrane.370 This 
transmembrane potential (Δψm) is altered in processes involving cancer caused directly 
by mitochondrial dysfunction produced by DNA mutation or oxidative stress.371 As such, 
probes that can give information on the state of mitochondrial function are sought after. 
4.1.1 Mitochondria as a drug target 
Mitochondria has been studied for many years principally because of their functional 
importance. Janus green B 137 (Figure 4.2) was the first dye to be used to stain 
mitochondria in cells that are not alive.372 This dye specifically stains mitochondria as it 
gets oxidised in the non-mitochondrial parts of the cell. This reduction does not affect the 
compound absorbed in the mitochondria, which maintains the stain.372 The nature of the 
mitochondrial membrane means that it possesses an electric potential, Δψm − it has been 
shown that this potential is higher in carcinoma cells than in healthy epithelial cells.103, 
373, 374 An example of this is found in the Δψm difference between the colon carcinoma 
cell line CX-1 and the control green monkey kidney epithelial cell line CV-1. This has 
been reported at nearly 60 mV (163 ± 7 mV for cell line CX-1 vs. 104 ± 9 mV for cell 
line CV-1).103 Positively charged cations with lipophilic structures or delocalised 
lipophilic cations (DLCs) can diffuse into the barriers of the plasma and mitochondrial 
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membranes, and accumulate in the organelle, due to the negative inner transmembrane 
potentials − this does not require the use of any transporter protein that needs energy to 
function. They use proteins, such as porins, where diffusion is allowed for positively 
charged compounds.375-377 According to the Nernst equation, a difference of 60 mV 
between the membrane potential of the carcinoma cell and the control epithelial cell; is 
enough to obtain a 10-fold greater concentration in the carcinoma mitochondria in 
comparison with the control cell. Therefore, the concentration of DLC found in carcinoma 
mitochondria is directly proportional to the Δψm: the higher this magnitude, the higher 
the concentration of DLC in the mitochondria.293 Most DLCs tend to exert toxic activity 
on mitochondria at high concentrations. The mechanisms used by this type of compound 
to provoke toxic effects in the mitochondria are quite diverse. Rhodamine 123 138, a 
probe for membrane polarization in live cell assays within mitochondria and bacteria,375 
and thiopyrylium AA-1 139, an antitumor agent,378 both inhibit the regular synthesis of 
ATP, which leads to the depletion of an energy source for the affected cell.103, 377, 379 The 
quaternary ammonium compound, dequalinium chloride 140, a salt with mild antibiotic 
activity,380 inhibits mitochondrial respiration by inhibiting NADH-ubiquinone, a vital 
enzyme for respiration in the system that transports electrons in the mitochondria.381 
Rhodacyanine MKT-077, 141, is a compound that degrades mitochondrial membranes − 
a non-specific inhibition of the enzymes in charge of mitochondrial respiration is 
produced as a result. Additionally, this cyanine exerts a slightly disruptive effect on the 
mitochondrial DNA.382 
 
Figure 4.2 Delocalised lipophilic cations (DLCs) that have shown to possess a high distribution in 
the mitochondria. 
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Despite the various mechanisms used by DLCs to exert cytotoxicity, they nonetheless 
have something in common: they provoke a significant decrease in ATP production when 
their accumulation in mitochondria is sufficiently high. A recent study compared the 
effect of dequalinium chloride 140 in control epithelial CV-1 cells against its effect on 
DU-145 prostate carcinoma cells.381 The data revealed that, after 3 hours of exposure to 
5 M of dequalinium chloride 140, the number of viable DU-145 prostate carcinoma cells 
was reduced by 50% and the ATP content in the viable cells was reduced by 62%. In 
addition, it was found that the longer the exposure, the higher the effect exerted by the 
chosen DLC. Control epithelial CV-1 cells did not show any change on their viability or 
ATP concentrations. This supports the idea that the diffusion of the DLCs is caused by 
Δψm, resulting in a selective cytotoxic effect and the inhibition of metabolic activity by 
DLCs in carcinoma.381 
The information above suggests that mitochondrion is an excellent target for the 
development of highly selective cytotoxic compounds or probes for diagnoses. 
4.2 Phosphonium cations capable of binding Cu(II)  
As introduced above, mitochondria can be used as a target for the development of 
compounds with biological activity, because they undergo certain changes during 
cancerous processes, such as the change in the transmembrane potential Δψm.103, 373, 374 
The increase in this potential in cancerous cells103, 373, 374 creates a negative charge 
increment in the mitochondria that selectively increases the diffusion of cations inside the 
organelle in cancerous cells. This feature has been exploited during the development of 
radiotracers, and led to the study of radiolabelled quaternary ammonium, phosphonium 
and arsonium cations, whose phosphine charge will cause them to accumulate in the 
mitochondria. The compound 4-(18F-benzyl) triphenylphosphonium 142 was developed 
by taking advantage of the mitochondrial distribution of phosphonium cations. This 
compound is a targeted PET radiotracer for determining myocardial perfusion and for 
tumour imaging. However, it showed a high uptake in the heart and liver, which 
represents a considerable shortcoming for its potential use as a diagnostic agent of cancer 
in chest and abdominal regions.383-388 
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Figure 4.3 The cationic PET radiotracer 4-(18F-benzyl)triphenylphosphonium 142. 
 
Other triphenylphosphonium cations had proved to fulfil both the required biodistribution 
profile for a selective radiotracer and their imaging properties in small animals388 and 
dogs.383, 386 Despite these findings, the radionuclides used to radiolabel the phosphonium 
cations, 11C and 18F, limit their utility due to their short half-lives. The high cost of the 
infrastructure required to produce these radionuclides is itself another notable 
shortcoming. In addition, the chemistry of 62Cu and 64Cu allows them to form complexes 
with a broad variety of ligand carriers in the very last step of the synthesis. Therefore, the 
development of new PET radiotracers based on phosphonium cations with radionuclides 
that fulfil time, cost and chemistry flexibility requirements is important. The development 
of more versatile radiolabelled phosphonium ions will provide new tools in non-invasive 
cancer diagnosis. 
Important research in the field of PET radiotracers incorporating on phosphonium cations 
was carried out by Zhou et al.389 This team used Cu(II) as a source of the 64Cu 
radionuclide in order to radiolabel the final phosphonium cation. The d9 configuration of 
Cu(II) makes its complexes kinetically labile; they thus used different bifunctional 
chelators to create complexes with high thermodynamic stability and kinetic inertness to 
counter this property. This approach has been taken before to create stable 62/64Cu labelled 
complexes.390-393 Their findings showed that more than one positive charge in the 
radiotracer can provoke a high absorption in hepatocytes which diminishes absorption in 
any other part of the body. The general structure of their radiotracers contained the 
chelating ligand attached to the phosphonium moiety via a linker group. In general, the 
radiotracers made by this group were useful for imaging multidrug resistant (MDR) 
negative tumours by PET, because the compounds had a high tumour selectivity. 
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Figure 4.4 Depiction of the general concept of the development of the compounds developed by 
Zhou.389 
 
Figure 4.4 includes a representation of the importance of the phosphonium cation in the 
development of these radiotracers – it renders the compounds specific for 
mitochondria/cancer tissue. It also contains some examples of the phosphonium salt 
macrocyclic ligands created by that group. 
Comparisons between phosphonium and ammonium cations have been reported.394 In this 
particular study the phosphonium cation was sacrificed in order to couple the bifunctional 
chelator to an acridine moiety, a well-known dye that interacts with DNA by 
intercalation.132 The phosphonium cation 147 was synthesised and its tumour intake was 
better that one reported for the pharmaceutical agent 99mTc-Sestamibi, used for 
myocardial imaging studies.393 The biodistribution of phosphonium cation 147 was 
compared to the acridinium cation 148. The evaluation showed that acridinium 148 made 
tumours clearly visible in the athymic nude mice bearing U87MG human glioma 
xenografts. It was possible to assure acridinium 148 absorption by mitochondrion 
U87MG glioma cells using fluorescent microscopic technique.394 This makes it possible 
to visualise the compound of interest directly in the cell, whereas PET allows the 
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radiotracer in tissue to be visualised. Additionally, it makes it possible to visualise the 
‘cold’ compound without the need of a cyclotron. This shows that combining PET and 
fluorescence imaging techniques ensures the appropriate biodistribution of a PET 
imaging candidate. However, acridinium 148 showed a higher liver uptake than the 
phosphonium cation 147. This feature makes acridinium 148 a bad PET imaging agent in 
comparison with phosphonium 147 despite the fact that phosphonium 147 does not 
contain the DNA-intercalating feature that the acridine moiety in 148 has. An 
intercalating agent with a high selectivity for mitochondria in cells affected by cancer 
could be a useful tool for the development of anticancer therapies. 
 
Figure 4.5 Structures of complexes 147 and 148 proposed by Zhou394 developed in order to compare 
their properties as PET agents. 
 
4.3 BODIPY-derived ligand target 
The LJH research group has experience in the field of phosphines and phosphonium 
salts;107 the findings reported by Zhou389, 394 were therefore of interest.395 As explained 
above, radiotracers based on phosphonium cations display a high selectivity for 
mitochondria in cancer cells. In addition, these compounds seem to have different 
selectivity according to their physicochemical features. The radiotracers reported 
included either fluorescence or a phosphonium moiety but not both. The natural next step 
was for our group to develop a molecule which could contain the useful fluorescent 
moiety without sacrificing the highly selective phosphonium moiety (Figure 4.6). 
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Figure 4.6 General depiction of the radiotracer proposed by the LJH group. This molecule contains 
the radionuclide 64Cu and a fluorescent moiety to exploit both techniques, PET and fluorescence 
imaging, using the same agent. 
 
The synthesis of this proposed radiotracer will include a BODIPY core that will act as the 
fluorescent moiety. The fluorescent moiety creates the possibility of determining the 
presence of the radiotracer even when the cold analogue is used in cells, using 
fluorescence microscopy techniques. Developing a phosphonium salt based on a 
BODIPY core is a synthetic challenge that can be overcome using previous 
methodologies developed by our group. A tertiary phosphine in the meso position of the 
BODIPY core will be synthesised and a linker will be attached to it to form the required 
phosphonium cation. The chosen linker is the commercially available α,α′-dibromo-p-
xylene. The addition of this phenyl ring to the radiotracer decreases its tumour uptake 
more than an alkyl chain. However, there are radiotracer tests of phosphonium cations 
bearing this linker.389, 390, 394, 396 Using this commercial linker in the proposed radiotracer 
155 will allow us to contrast it with other cations reported in the literature. 
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Figure 4.7 Synthesis of the proposed radiotracer 155. The colours show the different functions that 
each part of the molecule exerts. 
 
The coupling of 1,4-bis(bromomethyl)benzene with the tertiary phosphine 151 produces 
the phosphonium salt 152 which will couple with the chelator agent 153 in order to add 
the chelating moiety that will interact with the metal of interest. Finally, [Cu(OAc)2] will 
be reacted with the chelating agent 154 to generate the novel radiotracer 155. 
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4.4 Synthesis of BODIPY-Cu(II) complex derived from a phosphonium 
cation 
The first reaction required to achieve the proposed novel radiotracer 155 is the one pot 
condensation of the aryl bromide BODIPY derivative 149. Commercially available 3-
ethyl-2,4-dimethyl-1H-pyrrole was dissolved with 4-bromobenzaldehyde in 
dichloromethane in the presence of trifluoroacetic acid, yielding the bromide 149 in a 55% 
yield. Then an oxidation took place by the addition of BF2. This procedure has been 
previously reported by the LJH group.397 
 
Figure 4.8 Synthesis of bromide 149 by pyrrole condensation. 
 
Research on substitution of the fluorine atoms of the BODIPY core for alkyl and aryl 
groups has been accomplished using organolithium and Grignard reagents producing 
BODIPY dyes with alkyl and aryl groups on the boron atom,398, 399 subsequently allowing 
more versatile chemistry to be carried out on the meso position of the BODIPY core.108-
110 The difluorine-BODIPY 149 was reacted with MeMgBr in order to produce the 
dimethylated BODIPY 150. C−Boron bonds are less likely to undergo an attack by 
nucleophiles or reducing agents, in comparison to boron-fluoride bonds.  
 
Figure 4.9 Synthesis of the tertiary phosphine 151.395 
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This step locks down the BODIPY core, allowing a bromine-lithium exchange reaction 
to be performed in the next step with buthyl lithium, obtaining a nucleophilic species that 
attacks ClPCy2, displacing the chloride atom and yielding the tertiary phosphine 151. 
The reaction to obtain the tertiary phosphine was shown to have some technical 
difficulties. Tertiary phosphines can be oxidised to their phosphine oxide form. The 
oxidation seems to be facilitated when the phosphine is in solution.35, 36 The first attempts 
to synthesise this molecule led to the phosphine oxide 156. The reaction was carefully 
monitored using the 31P{1H} NMR technique. It was found that after 8 hours the desired 
tertiary phosphine was formed and the formation of the oxide was minimal. It was 
possible to separate the oxide using column chromatography. The 31P{1H} NMR analysis 
of other reported phosphine oxides had shown values of around 50 ppm for this kind of 
compound ((CH3)3PO and (C2H5)3PO).
400 Therefore, at this point it was sensible to infer 
that the compound producing a singlet at 45.7 ppm in 31P{1H} NMR belongs to an 
phosphine oxide. 
 
Figure 4.10 31P{1H} NMR of the desired tertiary phosphine 151 (2.2 ppm) and the side product 
phosphine oxide 156 (45.7 ppm). 
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Tertiary phosphine 151 can act as a nucleophile due to its lone pair of electrons. This is 
highly significant since it will be useful when adding a linker group to the phosphine 
functional group, as has been shown by Zhou to synthesise the different ligands made by 
his group.389 
 
Figure 4.11 Synthesis of phosphonium 152. 
 
The linker added was 1,4-bis(bromomethyl)benzene. This molecule has 2 bromide atoms 
which can act as leaving groups. However, the symmetry of the molecule makes both 
bromide atoms equivalent. In order to avoid the addition of two tertiary phosphines to the 
same linker molecule, it is important to control the number of equivalents of tertiary 
phosphine 151 that will be reacted. This reaction has been extensively reported using 
triphenylphosphine390, 401-403 and is usually carried out in toluene since its polarity is quite 
low. The low polarity of this solvent forces the triphenyl phosphonium ion to precipitate 
from the solution which avoids the reaction of 2 molecules of triphenylphosphine with 1 
molecule of 1,4-bis(bromomethyl)benzene. The synthesis of BODIPY phosphonium 152 
was performed in toluene following the procedure reported for its triphenylphosphine 
analogue. However, no solid precipitated from the solution which might explain the low 
yield obtained for compound 152 (55%) in comparison with the reported triphenyl 
phosphonium 157 (approximately 80%218). 
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Figure 4.12 Novel BODIPY phosphonium 152 and the reported triphenyl phosphonium salt 157. 
 
Figure 4.12 shows the greater degree of non-polar substituent in the novel BODIPY 
phosphonium 152 in comparison with triphenyl phosphonium 157. This difference is 
likely to explain their different solubility in toluene. 
This reaction was monitored by 31P{1H} NMR until completion. The main proof that the 
compound proposed was obtained was provided by this NMR technique since there was 
a shift in the signal of the reaction. The 31P{1H} NMR signal corresponding to the tertiary 
phosphine is detected at 2.8 ppm; the presence of a new signal at 30.2 ppm indicated that 
the starting material had been consumed. In addition, it suggests that the product obtained 
is not the phosphine oxide 156, which was a significant concern since the tertiary 
phosphine 151 had prove to be readily oxidised in solution. 
The 1H NMR analysis of 152 shows that there is a new set of two aryl doublets that 
integrate for two protons each. In addition, the protons on the methylene groups of the 
starting material 1,4-bis(bromomethyl)benzene are a good indicator for determining a 
coupling of a nucleophile to this molecule. In the starting material, both methylene groups 
are equivalent; therefore, the 1H NMR spectroscopy of both sets of protons produce a 
singlet with a chemical shift of 4.4 ppm.404 The 1H NMR spectrum of the BODIPY 
phosphonium salt 152 suggests that the two sets of methylene protons are different in this 
molecule. 
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Figure 4.13 1H NMR of BODIPY-phosphonium salt 152 showing the two different sets of aryl 
doublets. 
 
The two signals, 4.92 (d, 2JHP = 8.1 Hz, 2H) ppm and 4.34 (s, 2H) ppm, differ not only in 
chemical shift but also in multiplicity. This must be due to the effect exerted by 
phosphorus. The signal at 4.92 ppm belongs to protons on a methylene group that are 
coupling to the phosphorus atom and the singlet at 4.34 ppm belongs to the methylene 
that bears the bromide atom. This correlates with the reported spectrum for 
triphenylphosphonium 157.405 The presence of phosphonium 152 was also corroborated 
by HRMS. 
Tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate 153 was synthesised using 
the procedure described by Zhou.389 Once prepared, the chelating agent 153 was coupled 
to the BODIPY phosphonium salt 152. The free amine in 153 act as a nucleophile and 
attacks the benzylic carbon that bears the bromide atom that will act as a leaving group, 
producing the BODIPY-substituted macrocycle ligand 154. 
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Figure 4.14 Synthesis of BODIPY-substituted macrocyclic ligand 154. 
 
This reaction could not be monitored using 31P{1H} NMR spectroscopy, since the 
coupling of the macrocyclic ligand 154 did not produce a major impact on the chemical 
environment of the phosphorus atom. The phosphonium 152 produces a signal at 30.2 
ppm, whereas the phosphonium ligand 154 produces a signal at 30.3 ppm – the compound 
was thus initially identified primarily by its 1H NMR spectrum. In the novel ligand 154, 
the methylene group that bears the nitrogen atom underwent a change in its chemical 
environment, since the bromide atom has been displaced and substituted for the 
macrocycle ligand. Similar compounds report the signal of the expected singlet as part of 
the multiplet produced by the ethyl protons that form the macrocycle.402 The same 
displacement occurred with the novel ligand 154. The protons on the methylene group 
that couple to the phosphorus atom suffer no change in their chemical shift. Therefore, 
they were not particularly useful for identifying the newly formed ligand 154. The tert-
butyl groups were important for identifying the coupling of macrocycle 153 and the 
BODIPY-phosphonium salt 152. The tert-butyl groups attached to the nitrogen atoms, 
which are two bonds away from the nitrogen in the benzylic position, are equivalent. The 
remaining tert-butyl group in the macrocycle is in a different environment. Therefore, the 
1H NMR spectrum of this molecule would be expected to present 2 singlets in the alkyl 
NMR region. The integration ratio of the singlets should be 2:1 due to the total amount 
of proton atoms on these groups, 18:9. This was obtained in the 1H NMR spectrum of 
compound 154 confirming the formation of the expected compound. The tert-butyl 
groups of the free macrocyclic ligand 153 are also different. However, they are similar 
enough to form a multiplet that integrates 27 protons at 1.47 ppm as was reported by Cao 
et al.406 The formation of two identifiable singlets was led us to think that the coupling 
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took place as expected. In addition, the formation of phosphonium ligand 154 was also 
corroborated by HRMS. 
 
Figure 4.15 1H NMR showing the types of tert-butyl groups in the macrocycle of the BODIPY-
substituted ligand 154. 
 
Once it was established that the ligand 154 had been synthesised, it was decided that a 
Cu-complex analogous to those reported by Zhou389 should be prepared. Following the 
procedure carried out by his group, the fluorescent ligand 154 was reacted with 
[Cu(OAc)2]. Since 
63Cu and 65Cu, the most abundant Cu isotopes, have large nuclear 
quadrupole moments, the reaction could not be monitored by NMR techniques. Therefore, 
the proof that a product had been formed at this point was provided by the lack of 1H 
NMR signals of the starting material. This proved that the starting material was consumed 
but it provided no evidence regarding the nature of the complex formed. 
 
Figure 4.16 Synthesis of Cu(II) complex 156. The ethyl acetate groups of [Cu(OAc)2] are displaced 
by the nitrogen atoms of the BODIPY-substituted macrocyclic ligand 154. 
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The TLC showed different fractions that were separated via column chromatography. The 
HRMS analysis of these fractions suggested complexes with different R groups to acetate 
on the copper centre. Figure 4.17 shows the structures that correlate with the HRMS 
findings of the fractions analysed. The M/Z value of the expected complex 156 is 1248.77; 
but HRMS showed at 664.8417, 639.8755 and 653.8908. In addition, the mass 
fragmentation patterns observed corresponded to those produced by compounds 
containing Cu isotopes (63Cu with an abundance of 69.17% and 65Cu with an abundance 
of 30.83%). Those values M/Z are approximately half of the value expected for the 
complex 156. This result led us to assume that there was another positive charge on the 
complexes, with the Cu the most plausible atom to have this charge. The structures that 
fit best to the M/Z value are shown in Figure 4.17. The possible substituents on the 
metallic core that we proposed are bromide (664.8417 M/Z), methoxy (639.8755 M/Z) 
and acetate (653.8908 M/Z). Zhou et al.389 identified their Cu complexes by comparing 
their HPLC retention times against Gd and In complexes with their ligands 143-146 
(Figure 4.4). They did not report any extra ligands attached to their metallic core besides 
the main chelating agent. They proposed that the free carboxylate groups would stabilise 
the Cu atom avoiding the positive charge we saw in the HRMS of our sample. This might 
be due to the fact that the BODIPY ligand 154 has the tert-butyl groups. Therefore, the 
carboxylate groups are not available to interact in the same fashion as proposed by Zhou. 
The bromide anion in complex 155 must have been obtained from other molecules of the 
ligand 154, since this phosphonium cation has bromide as its counter ion. In complex 157, 
a methoxide group occupies a position on the metallic core. This group likely originates 
from the methanol used during the reaction as solvent. Since the starting material was 
[Cu(OAc)2], it is not surprising that in complex 158, an acetate group is found attached 
to metallic core as was suggested by the HRMS data. 
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Figure 4.17 Probable structure, suggested by HRMS analysis, of complexes 155, 156 and 158, 
obtained from reacting ligand 154 with [Cu(OAc)2]. 
 
Different fractions were separated using column chromatography. Several attempts to 
recrystallize the purified fractions were set-up until success was achieved. This revealed 
the structure 155 where the geometry of the metallic centre is a distorted square pyramidal 
molecular geometry (Figure 4.18).  
 
Figure 4.18 X-ray crystal structure view of [CuBr(154)][Br]2 155 (50% probability ellipsoids with 
interesting copper, phosphorus, boron, nitrogen, oxygen and carbon atoms labelled. Carbon atoms 
in grey). Hydrogen atoms have been omitted for clarity Br1–Cu1 2.4744(7), Cu1–N3 2.073(3), Cu1–
N4 2.098(3), Cu1–N5 2.085(3), Cu1–N6 2.085(3), P1–C22 1.796(4), P1–C27 1.832(4), P1–C39 
1.800(4), P1–C33A 1.856(7); N3–Cu1–Br1 104.38(10), N3–Cu1–N4 85.72(12), N3–Cu1–N5 
148.96(13), N3–Cu1–N6 85.04(12), N4–Cu1–Br1 104.75(9), N5–Cu1–Br1 106.65(8), N5–Cu1–N4 
85.66(11), N5–Cu1–N6 86.50(11), N6–Cu1–Br1 107.55(8), N6–Cu1–N4 147.66(12). 
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The different groups that are suggested by the HRMS indicate that different products are 
produced in this reaction. This would explain why the yield of complex 155 does not 
seem to be high (44%). 
Springborg et al.407 reported the complex 159 which is an example of a Cu(II) complex 
that is similar to the BODIPY-Cu(II) complex 155. This complex contains the same 
macrocycle, a bromine atom and a penta-coordinated geometry, as our BODIPY-complex 
155. The bromine atom is not in the axial position in the complex 159 (Br1−Cu1−N2 
153.3(3)). This is different in our complex 155 where the bromine atom is in the axial 
position (N5–Cu1–Br1 106.65(8)). This difference might be due to the effect exerted by 
the ethyl group that connects the two nitrogen atoms in the complex 159. The Cu−N bond 
lengths are similar in both molecules, having a length of 2.09±0.03 Å. The nitrogen atoms 
that are attached to the ethyl chain have Cu−N bond lengths below 2.00 Å (Cu1−N1 
1.985(6) Å and Cu1−N3 1.995(9)).   
 
Figure 4.19 Cu(II) complex 159 reported by Springborg et al.407 The ethyl group connecting two 
nitrogen atoms in this ligand creates some differences in terms of some angles and bond lengths 
found for the BODIPY-Cu(II) complex 155  
  
The phosphonium-Cu(II) complexes reported by Zhou394 were not identified using X-ray 
crystal analysis. On the other hand, the BODIPY-Cu(II) complex 155 was identified using 
that technique, which allowed us to determine its molecular geometry. The complexes 
reported by Zhou394 contain tert-butyl groups protecting the carboxylate functions; 
therefore, the molecular geometry might be different. Riesen et al.408 synthesised the 
macrocyclic-Cu(II) complex 160 whose ligand resembles the chelating moiety of 
BODIPY-Cu(II) complex 155 with one principal difference: the tert-butyl groups are not 
present in the ligand used by Riesen. This allows them to interact with the metallic core 
resulting in octahedral molecular geometry around the central metallic core. This suggests 
that the distorted square pyramidal molecular geometry observed in the BODIPY-Cu(II) 
complex 155 is given by the lack of interaction between the carboxylate groups with the 
metallic core. Since these groups cannot stabilise the metallic core, the chelating effect of 
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the bromine, acetate and methoxide groups must be facilitated. Unprotecting the 
carboxylate groups would possibly decrease the formation of side products. 
 
Figure 4.20 Macrocyclic-Cu(II) complex 160 synthesised by Riesen et al.408 
 
Complexes of Co and Zn have also shown interesting biological properties;409, 410 
synthesising complexes with these metals and ligand 154 has thus been attempted. 
However, it has not been possible to properly identify or obtain a crystal for X-ray 
analysis of the obtained compounds at the time of writing. 
4.5 Photophysical Data 
Once the synthesis of complex 155 was accomplished, it was necessary to determine the 
photophysical properties of this compound to verify whether it can be a candidate for 
fluorescent cell imaging. It is interesting to investigate the photophysical properties of the 
different functional groups added during the synthesis of the ligand 154. The 
phosphonium cation 152 does not possess the lone pair of electrons that the tertiary 
phosphine 151 contains.395  
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Compound λabs (nm)a λem (nm)a ε (cm−1/M)a Δνst (nm)a 
152 519 545 24,000 26 
154 518 544 50,000 26 
155 518 545 40,000 27 
a Measured in dry degassed tetrahydrofuran at room temperature. Dyes were excited at 485 nm. 
Table 4.1 Photophysical data for the Cu(II) complex 155 and its precursors. 
 
The chelating moiety also contains pairs of electrons on the nitrogen atoms that form the 
main 12-membered macrocycle. Lone pair of electrons from both nitrogen or phosphorus 
atoms and heavy atoms, such as copper, have shown to have a quenching effect in 
fluorophores.121, 124, 125, 337-339, 411, 412 Photophysical data were collected for the Cu(II) 
complex 155 and its precursors in dry degassed tetrahydrofuran to minimise 
photobleaching (Table 4.1). 
The Stokes shifts in compounds 152, 154 and 155 do not display any significant change 
in their values. The quantum yield (ΦF) of compounds 152, 154 and 155 were measured 
in different solvents in order to investigate the effect exerted by the solvent on their ΦF. 
The S0-S1 excitation of the fluorophore usually leads to an excited vibrational level of S1 
followed by a loss of some vibrational energy to the solvent. This excess of energy is 
stabilized by the effect of polar solvent molecules, since typically, the fluorophore has a 
larger dipole moment in the excited state (S1) than in the ground state (S0).
40 Following 
this excitation, E can produce a reorientation or relaxation of polar solvent molecules 
around it to lower the energy S1. This reduction of energy is seen in the emission in its 
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increased wavelength; longer wavelengths are less energetic since the energy of emission 
is inversely proportional to the wavelength as Equation 1 on page 21 illustrates.40 
ΦF were measured with respect to 4,4-difluoro-8-phenyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene (ΦF = 0.76, in tetrahydrofuran)413. Dyes were excited at 480 nm. 
Table 4.2 ΦF of compounds 152, 154 and 155 in solvents with different polarities. 
 
The results show a constant trend where the ligand 154 has the highest ΦF value, followed 
by the phosphonium cation 152 and finally the Cu(II) complex, 155. The ΦF of the tertiary 
phosphine 151 has been reported by this group previously;395 the value is 0.44 using the 
same fluorescent standard. That value was corroborated by the measurements obtained 
during the development of this project. This result is interesting since the opposite would 
be expected considering that the lone pair of electrons in the tertiary phosphine 151 could 
potentially interact with the fluorophore producing Photoinduced Electron Transfer that 
could provoke fluorescence quenching. Calculated molecular orbital surfaces already 
reported by this group show that the tertiary phosphine 151 has no phosphorus character 
in the HOMO, HOMO−1 or HOMO−2 of this molecule.395 This suggests that there would 
be little interaction between the lone pair of electrons on the phosphorus atom and the 
fluorescent core. The lower ΦF of the phosphonium ion 152 relative to the tertiary 
phosphine 151 may be explained by its interaction with the solvent. Tetrahydrofuran 
seems to be the solvent where the highest ΦF values were recorded. This is interesting 
since this solvent has an intermediate polarity value in between methanol and 
dichloromethane. Even more interesting is the fact that the ΦF values recorded in 
dichloromethane were intermediate and those recorded in methanol were the lowest. This 
could mean that the high polarity of methanol decreases emission for these compounds 
because of solvent-E interactions. The values recorded in dichloromethane are lower 
than those recorded in tetrahydrofuran, even though, the latter solvent has a higher 
polarity. This might be due to dynamic fluorescence quenching given by the fluorophore 
colliding with a halogen containing substance, such as dichloromethane. During the 
Compound ΦF in DCM ΦF in MeOH ΦF in THF 
152 0.20 0.15 0.29 
154 0.26 0.24 0.34 
155 0.03 0.07 0.08 
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lifetime of the excited state, this collision provokes the return of the fluorophore to the 
ground state without emission of a photon.414 
 
Figure 4.21 Emission spectra of the phosphonium cation 152, ligand 154 and the complex 
[CuBr(154)][Br]2 155, in tetrahydrofuran (excitation at 480 nm). 
 
 
Figure 4.22 Emission spectra of the complex [CuBr(154)Br][Br]2 155 in tetrahydrofuran (excitation 
at 480 nm). The intensity of the emission of complex 155 is much lower than that one of compounds 
152 and 154. 
 
The addition of the chelating moiety to the phosphonium cation 152 decreases the polarity 
of the product since the resulting ligand 154 contains three tert-butyl groups. This might 
reduce the interactions of the E of ligand 154 with the solvent, which could increase the 
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emission. This can explain the higher ΦF ligand 154 in comparison with its precursor, 
phosphonium salt 152. It was not entirely unexpected to observe a reduction of the ΦF of 
the Cu(II) complex 155. The presence of the Cu atom may generate the heavy atom effect 
mentioned in the Section 1.4.1, causing spin-orbit coupling and giving rise to intersystem 
crossing to a triplet state, which is usually spin forbidden. From the excited triplet state, 
relaxation predominately happens via non-radiative decay over radiative 
phosphorescence.415 The BODIPY-Cu(II) complex 155 has a lower ΦF than compounds 
152 and 154 as can be seen in Figure 4.21 and Figure 4.22. However, its ΦF value proves 
that it is fluorescent, and it can, therefore, be a candidate for fluorescent microscopy. 
4.6 Summary 
Previous reports in the literature show that radiolabelled phosphonium cations can be 
traced into cancerous tissue since the mitochondria of the cells that form this tissue have 
a higher Δψm103, 373, 374. Positively charged cations can diffuse into living cells and 
accumulate in the mitochondria.375-377 This characteristic makes the mitochondria a 
natural target for drug candidate molecules. Radiolabelled phosphonium cations are 
traceable in cancerous tissue using PET techniques if they contain a suitable radiolabel.388, 
383, 386 Research on Cu(II) complexes based on phosphonium cations389, 394 showed that 
this is an area to be exploited for the development of radiotracers. In this chapter, the 
synthesis of a fluorescent Cu(II) complex based on a BODIPY phosphonium cation linked 
to a chelating moiety is reported allowing in vivo and in vitro imaging. The required 
phosphonium cation was obtained by reacting 1,4-bis(bromomethyl)benzene with the 
tertiary phosphine 151. The resulting phosphonium cation 152 contains a bromide in a 
benzylic position, which makes it a good leaving group, thereby facilitating the attack of 
the free amine of the macrocyclic chelating agent 154. The resulting ligand 154 was then 
reacted with [Cu(OAc)2] producing different complexes identified by HRMS. It was 
possible to obtain crystals of the main product of this reaction, which were of a high 
enough quality to be analysed by X-ray crystallography, revealing the structure of the 
complex obtained. The metallic core of this complex is a penta-coordinated copper centre. 
The ΦF values of the novel compounds show that the reported ΦF of tertiary phosphine 
151395 is higher than the phosphonium cation 152, which could be related to the positive 
charge on the phosphorus atom (polarity of the salt). Cu(II) complex 155 has the lowest 
ΦF value, which is likely related to the heavy atom effect prompted by the Cu atom. 
Nonetheless, the synthesis of a fluorescent Cu(II) complex containing a phosphonium 
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cation was successfully achieved as suggested by the emission spectrum of complex 155, 
shown in Figure 4.22. 
4.7 Experimental 
4.7.1 General procedure 
All air- and/or water-sensitive reactions were performed under a dinitrogen atmosphere 
using standard Schlenk line techniques. Tetrahydrofuran and toluene were dried over 
sodium/benzophenone and sodium respectively, dichloromethane was dried over calcium 
hydride; all solvents used for reactions were distilled prior to use. All starting materials 
were purchased from Aldrich, Acros Organics, Alfa Aesar or Strem and used as received. 
Compounds 149,397 150,397 and 151397 were prepared according to literature procedures. 
Flash chromatography was performed on silica gel from Fluorochem (silica gel, 40-63u, 
60A). Thin-layer chromatography was carried out on Fisher aluminium-based plates with 
silica gel and fluorescent indicator (254 nm). Melting points were determined in open 
glass capillary tubes on a Stuart SMP3 melting point apparatus. 1H, 13C{1H}, 31P{1H}, 
19F{1H} and 11B{1H} NMR spectra were recorded on a JEOL Lambda 500 (1H 500.16 
MHz) or JEOL ECS-400 (1H 399.78 MHz) spectrometer at room temperature (21°C); 1H 
and 13C shifts were relative to tetramethylsilane, 31P relative to 80% H3PO4, 
11B relative 
to BF3.Et2O and 
19F relative to CFCl3. Infrared spectra were recorded on a Varian 800 
FT-IR spectrometer. UV-Vis absorption and emission spectra were recorded on a UV-
1800 Shimadzu spectrophotometer and RF-6000 Shimadzu spectrofluorometer 
respectively. Mass spectrometry was carried out by the EPSRC National Mass 
Spectrometry Service Centre, Swansea. 
4.7.2 8-(4-Bromophenyl)-4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 149 
 
TFA (3 drops) was added dropwise to a solution of 4-bromobenzaldehyde (15.0 g, 81.0 
mmol) and 3-ethyl-2,4-dimethyl-1H-pyrrole (21.9 mL, 162 mmol) in anhydrous 
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dichloromethane (1500 mL). The reaction was stirred at room temperature under 
dinitrogen in a darkened flask overnight. DDQ (20.2 g, 81.0 mmol) was added in a single 
portion, and the reaction was stirred at room temperature for 2 hours. Anhydrous N,N-
diisopropylethylamine (84.7 mL, 486 mmol) and BF3·Et2O (80.0 mL, 648 mmol) were 
added, and the reaction was stirred at room temperature for 4 hours. The reaction mixture 
was washed with water (3 x 100 mL) and brine (3 x 100 mL). The separated organic 
fractions were dried over magnesium sulphate, filtered and the solvent removed in vacuo 
yielding a dark-violet solid with a green tint. Purification was achieved using column 
chromatography on silica gel (toluene, Rf = 0.5) and afforded a purple solid (20.5 g, 55%). 
MP: 240–244 °C. 1H NMR (400 MHz, CDCl3) δ 7.61 (d, 3JHH = 8.2 Hz, 2H), 7.16 (d, 
3JHH = 8.2 Hz, 2H), 2.51 (s, 6H), 2.29 (q, 
3JHH = 7.8 Hz, 4H), 1.29 (s, 6H), 0.96 (t, 
3JHH = 
7.8 Hz, 6H) ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 154.7, 138.9, 138.4, 138.2, 135.4, 
133.5, 132.3, 130.1, 123.4, 17.0, 14.6, 12.6, 11.9 ppm. 19F{1H} NMR (376 MHz, CDCl3) 
δ −145.6 (q (equal intensity), 1JFB = 31.8 Hz, 2F) ppm. 11B{1H} NMR (128 MHz, CDCl3) 
δ −0.2 (t, 1JFB = 31.8 Hz, 1B) ppm. IR (neat): 𝜈  = 2971 (w), 2901 (w), 1532 (s), 1473 
(m), 1405 (s), 1316 (w), 1259 (m), 1182 (s), 1065 (m), 973 (s), 754 (s), 623 (m) cm−1. 
4.7.3 8-(4-Bromophenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 150  
 
8-(4-Bromophenyl)-4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene (149) (2.50 g, 5.46 mmol) was dissolved in anhydrous tetrahydrofuran (100 mL). 
Methylmagnesium bromide (3.8 mL, 11.50 mmol, 3.0M solution in dibutyl ether) was 
added to this solution dropwise, which caused the solution to turn darker with an orange 
tint; the solution was stirred at room temperature until complete consumption of the 
starting material was observed by TLC. The reaction was quenched with water (20 mL) 
and the solution was extracted with dichloromethane (2 x 100 mL); the combined organic 
fractions were washed with water (40 mL) and brine (40 mL), and dried over magnesium 
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sulphate. Purification was performed by column chromatography on silica gel (petroleum 
ether/toluene 4:1, Rf = 0.6) yielding an orange solid (1.00 g, 40%). MP: 201-204 °C. 1H 
NMR (400 MHz, CDCl3) δ 7.60 (d, 3JHH = 8.2 Hz, 2H), 7.36 (d, 3JHH = 8.2 Hz, 2H), 2.19 
(q, 3JHH = 7.3 Hz, 4H), 1.74 (s, 6H), 1.32 (s, 6H), 0.88 (t, 
3JHH = 7.3 Hz, 6H), 0.22 (s, 6H) 
ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 150.9, 138.8, 136.3, 133.6, 132.6, 132.0, 130.6, 
128.8, 122.4, 17.4, 14.7, 14.3, 12.0, 10.4 (br) ppm. 11B{1H}NMR (128 MHz, CDCl3) δ 
−1.2 ppm. IR (neat): 𝜈 = 2960 (w), 1548 (s), 1472 (m), 1385 (s), 1303 (w), 1169 (s), 1140 
(m), 1111 (m), 968 (s), 772 (s) cm−1. 
4.7.4 8-((4-Dicyclohexylphosphino)phenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-
diethyl-4-bora-3a,4a-diaza-s-indacene 151 
 
8-(4-Bromophenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene (150) (0.50 g, 1.11 mmol) was dissolved in anhydrous diethyl ether (40 mL) and 
cooled to −78 °C. n-BuLi (0.49 mL, 1.22 mmol, 2.5M in hexane) was added dropwise 
over five minutes and the reaction was allowed to warm to room temperature over 45 
minutes. The solution was cooled back to −78 °C and chlorodiphenylphosphine (0.27 mL, 
1.22 mmol) was added dropwise. The reaction was allowed to warm to room temperature 
and was stirred overnight. The reaction mixture was washed with water and extracted 
with diethyl ether (3 x 30 mL). The combined organic fractions were washed with brine 
(30 mL) and dried over magnesium sulphate. The solvent was removed in vacuo yielding 
a red/orange solid. The compound was purified using column chromatography on silica 
gel (chloroform/hexane 1:4, Rf = 0.4) and produced an orange solid (0.35 g, 60%). 1H 
NMR (400 MHz, CDCl3) δ 7.47 (m, 2H), 7.21 (d, 3JHH = 8.2 Hz, 2H), 2.37 (s, 6H), 2.23 
(q, 3JHH = 7.3 Hz, 4H), 1.90-1.56 (m, 12H), 1.36-1.22 (m, 3H), 1.19 (s, 6H), 1.12-0.95 (m, 
10H), 0.90 (t, 3JHH = 7.3 Hz, 6H), 0.21 (s, 6H) ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 
150.6, 140.2, 137.9, 135.0 (d, JCP = 19.2 Hz), 134.7 (d, JCP = 19.2 Hz), 133.8, 132.5, 129.1, 
128.3 (d, JCP = 7.7 Hz), 32.1 (d, JCP = 12.5 Hz), 28.7 (d, JCP = 6.7 Hz), 27.1 (d, JCP = 6.7 
Hz), 26.7, 17.6, 14.8, 14.4, 11.9, 10.5 (br) ppm. 31P{1H} NMR (162 MHz, CDCl3) δ 2.8 
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ppm. 11B{1H} NMR (128 MHz, CDCl3) δ −2.1 ppm. IR (neat): 𝜈 = 2927 (w), 2856 (w), 
1551 (s), 1448 (m), 1321 (m), 1171 (s), 1145 (s), 946 (s) cm−1. HRMS (AP+) calcd. for 
C37H55B1N2P1 [M+H]
+ requires m/z 569.4198, found m/z 568.4202 (0.1 ppm). 
4.7.5 9-(4-(Bromomethyl)benzyl)-8-((4-dicyclohexyl)phenyl)-4,4-dimethyl-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene phosphonium bromide 
152 
 
8-((4-Dicyclohexylphosphino)phenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-
bora-3a,4a-diaza-s-indacene (151) (0.60 g, 1.31 mmol) was dissolved in anhydrous 
toluene (30 mL) and added to a stirred solution of 1,4-bis(bromomethyl)benzene (0.35 g, 
1.31 mmol) in anhydrous toluene (30 mL); the resulting red solution was heated to 110 °C 
overnight. The reaction was monitored by 31P{1H} NMR showing the presence of a 
phosphonium ion. The reaction was allowed to cool to room temperature and the solvent 
was removed in vacuo. The compound was purified using column chromatography on 
silica gel (chloroform/methanol 9.5:0.5, Rf = 0.6) and produced a red solid (0.61 g, 55%). 
1H NMR (400 MHz, CDCl3) δ 8.07 (m, 2H), 7.59 (d, 3JHH = 8.1 Hz, 2H), 7.23 (d, 3JHH = 
8.1 Hz, 2H), 7.13 (d, 3JHH = 8.1 Hz, 2H), 4.92 (d, 
2JHP = 8.1 Hz, 2H), 4.34 (s, 2H), 2.39 
(s, 6H), 2.24 (q, 3JHH = 7.3 Hz, 4H), 2.07-1.91 (m, 5H), 1.83-1.62 (m, 7H), 1.47-1.21 (m, 
10H), 1.14 (s, 6H), 0.92 (t, 3JHH = 7.3 Hz, 6H), 0.22 (s, 6H) ppm. 13C{1H} NMR (100 
MHz, CDCl3) δ 151.6, 151.0, 143.9 (d, JCP = 3.4 Hz), 138.5 (d, JCP = 3.4 Hz), 137.3, 
134.2 (d, JCP = 8.7 Hz), 133.3, 133.1, 130.9-130.8 (overlapping signals), 129.8, 129.4, 
115.6, 114.9, 32.7, 30.9, 30.5, 26.3-26.7 (overlapping signals), 25.5, 17.3, 14.5, 12.0, 10.0 
(br) ppm. 31P{1H} NMR (162 MHz, CDCl3) δ 30.2 ppm. 11B{1H} NMR (128 MHz, 
CDCl3) δ −1.9 ppm. IR (neat): 𝜈 = 2929 (m), 2856 (m), 2360 (w), 1549 (s), 1447 (m), 
1319 (s), 1171 (s), 1027 (w), 947 (s), 796 (m), 745 (s), 671 (w) cm−1. HRMS (AP+) calcd. 
for C45H62B1Br1N2P1 [M+H]
+ requires m/z 751.3926, found m/z 751.3917 (0.1 ppm). 
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4.7.6 9-(4-((4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-
1-yl)methyl)benzyl)-8-((4-dicyclohexyl)phenyl)-4,4-dimethyl-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene phosphonium bromide 
154 
 
9-(4-(Bromomethyl)benzyl)-8-((4-dicyclohexyl)phenyl)-4,4-dimethyl-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene phosphonium bromide (152) 
(0.10 g, 0.12 mmol), tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7-triacetate (153) 
(0.06g, 0.12 mmol) and Na2CO3 (0.04 g, 0.36 mmol) were dissolved in anhydrous 
acetonitrile (6 mL) and the resulting red suspension was heated to 80 °C overnight. The 
reaction was allowed to cool to room temperature and the solvent was removed in vacuo. 
The compound was purified using column chromatography on silica gel 
(chloroform/methanol 9:1, Rf = 0.3) and produced a red solid (0.09 g, 60%). 1H NMR 
(400 MHz, CDCl3) δ 8.14 (m, 2H), 7.65 (d, 3JHH = 8.6 Hz, 2H), 7.27 (d, 3JHH = 7.1 Hz, 
2H), 7.18 (d, 3JHH = 7.1 Hz, 2H), 4.75 (d, 
2JHP = 13.6 Hz, 2H), 3.32-3.21 (m, 2H), 3.01-
2.95 (m, 2H), 2.88 (s, 2H), 2.84 (s, 2H), 2.39 (s, 6H), 2.24 (q, 3JHH = 7.5 Hz, 4H), 2.11-
2.01 (m, 5H), 1.98-1.88 (m, 5H), 1.85-1.63 (m, 10H), 1.61-1.47 (m, 6H), 1.43 (s, 18H), 
1.39 (s, 9H), 1.29-1.21 (m, 4H), 1.16 (s, 6H), 1.09-0.98 (m, 3H), 0.92 (t, 3JHH = 7.5 Hz, 
6H), 0.82-0.75 (m, 5H), 0.21 (s, 6H) ppm ppm. 13C{1H} NMR (100 MHz, CDCl3) δ 173.7, 
172.6, 151.6, 144.0, 137.2, 136.5, 134.3 (d, JCP = 8.5 Hz), 133.2, 132.8, 131.1-130.9 
(overlapping signals), 128.7 (d, JCP = 7.7 Hz), 128.4, 115.7, 114.9, 83.2, 82.7, 58.5, 56.8, 
55.9, 50.6-49.6 (overlapping signals), 30.7, 30.2, 28.1, 28.0, 26.2, 25.7, 20.6, 19.5, 17.6, 
14.9, 14.5, 12.2, 11.5, 10.5 (br) ppm. 31P{1H} NMR (162 MHz, CDCl3) δ 30.3 ppm; 
11B{1H} NMR (128 MHz, CDCl3) δ −1.0 ppm. IR (neat): 𝜈 = 2933 (m), 2860 (m), 2360 
(m), 1723 (s), 1550 (m), 1163 (s), 801 (m), 751 (m), 610 (m) cm−1. HRMS (AP+) calcd. 
for C71H112B1N6O6P1 [M+H]
+ requires m/z 593.4237, found m/z 593.4231 (0.4 ppm). 
  
171 
 
4.7.7 [CuBr(154)][Br]2 155 
 
9-(4-((4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-
yl)methyl)benzyl)-8-((4-dicyclohexyl)phenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-
diethyl-4-bora-3a,4a-diaza-s-indacene phosphonium bromide (154) (0.12 g, 0.09 mmol) 
was dissolved in anhydrous methanol (3 mL) and added to a stirred solution of Cu(OAc)2 
(0.02 g, 0.09 mmol) in anhydrous methanol (3 mL). The mixture was stirred at 65 °C for 
2 hours and the solvent was removed giving a dark red solid. Purification using column 
chromatography on silica gel (chloroform/methanol 9:1, Rf = 0.3) yielded a red solid (0.06 
g, 44%). A sample suitable for X-ray crystallographic analysis was obtained from 
chloroform. IR (neat): 𝜈 = 2931 (m), 2867 (m), 1732 (s), 1558 (s), 1461 (s), 1369 (m), 
1322 (m), 1173 (s), 1147 (s), 982 (s), 946 (m) cm−1. 
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5 Future Work 
The present work shows important developments have been made: 
 In chapter 2, the synthesis of the phosphindoles 73-79 proved that it is possible to 
create analogues with substituents in the C3 position. It was not possible to create 
a fluorescent derivative using anthracene, naphthalene or benzene as substituents; 
therefore, it would be interesting to use either a different fluorophore or to add a 
linker in between the two cyclic functionalities (the phosphindole and the 
fluorophore). This work also proved that it is possible to add substituents to the 
phenyl ring of the phosphindole core. To avoid the mixture of regioisomers that 
was encountered, it would be prudent to use an arene like phenyl that doesn’t give 
rise to this problem. Clearly the mechanism of this reaction – as shown by the 
tolyl derivative – is vulnerable to the generation of undesirable regioisomers. 
 In chapter, the synthesis of a pyrene-functionalised tridentate ligand from an air-
stable alkyl primary phosphine was described, which opens up the possibility of 
synthesising primary phosphines featuring different PAHs. The coordination 
chemistry of 109 was studied since the square planar Pt(II) complex 116 presented 
here has shown promising anticancer activity against bone osteosarcoma (U2OS) 
and transformed mammary cancer (HMLER) cells, the next step would be to 
compare it against similar compounds in order to explain its mechanism of action. 
Currently, the palladium analogue [PdCl(109)][Cl] 120 is being tested in the same 
cells assays as 116 to determine if the latter’s mode of action is platinum 
dependant. Similarly, [(Triphos)PtCl] is also being investigated to establish what 
role the pyrene plays in the cytotoxicity of 116. 
 Chapter 4 shows that the BODIPY-Cu(II) phosphonium complex 155, as 
confirmed by X-ray crystallography was achieved. Further work on this 
compound wil focus on stablishing that 155 is a useful probe for cell studies by 
fluorescence microscopy. Studies will take place to determine if 155 localises in 
mitochondria. Finally, the free ligand 154 will be used to obtain the BODIPY-
64Cu(II) radiotracer to facilitate imaging studies. Developments are also possible 
with this novel macrocyclic phosphonium ligand – it should also allow for the 
synthesis of complexes containing different radioactive metals such as 68Ga 111In, 
82Rb, 86Y and 89Zr. These metals have different radioactive devay profiles. 
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In general, this work has led us to synthesise and characterise molecules containing a 
fluorescent moiety and a second function of biological interest. The BODIPY derivatives 
in particular appear to be judicious option for producing fluorescent probes due to their 
relatively high quantum yield. Although the pyrene derivative were, they can interact with 
DNA. As such, two classes of fluorescent transition metal probes have been developed: 
a BODIPY-Cu(II) phosphonium complex for fluorescence and PET applications and a 
pyrene-derived Pt complex for DNA intercalation. 
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Appendix 
Crystallography 
Crystal structure of 69 
Table 1 Crystal data and structure refinement for 69. 
Empirical formula C31H24NZrBr0.5Cl0.5 
Formula weight 559.41 
Temperature/K 150.15 
Crystal system monoclinic 
Space group P21/c 
a/Å 7.71380(10) 
b/Å 18.1990(3) 
c/Å 17.3229(3) 
α/° 90 
β/° 96.714(2) 
γ/° 90 
Volume/Å3 2415.17(7) 
Z 4 
ρcalcg/cm3 1.538 
μ/mm-1 1.358 
F(000) 1132.0 
Crystal size/mm3 0.45 × 0.2 × 0.15 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.77 to 57.02 
Index ranges -10 ≤ h ≤ 10, -23 ≤ k ≤ 20, -17 ≤ l ≤ 22 
Reflections collected 14345 
Independent reflections 5158 [Rint = 0.0226, Rsigma = 0.0308] 
Data/restraints/parameters 5158/0/314 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0259, wR2 = 0.0639 
Final R indexes [all data] R1 = 0.0346, wR2 = 0.0653 
Largest diff. peak/hole / e Å-3 0.43/-0.54 
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Crystal structure of 73 
Table 2 Crystal data and structure refinement for 73. 
Empirical formula C25H22NPS 
Formula weight 399.46 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group Pbca 
a/Å 14.47762(13) 
b/Å 13.63301(11) 
c/Å 21.14832(15) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 4174.12(6) 
Z 8 
ρcalcg/cm3 1.271 
μ/mm-1 2.163 
F(000) 1680.0 
Crystal size/mm3 0.23 × 0.15 × 0.09 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.362 to 133.824 
Index ranges -17 ≤ h ≤ 17, -15 ≤ k ≤ 16, -25 ≤ l ≤ 18 
Reflections collected 28327 
Independent reflections 3713 [Rint = 0.0348, Rsigma = 0.0190] 
Data/restraints/parameters 3713/0/256 
Goodness-of-fit on F2 1.027 
Final R indexes [I>=2σ (I)] R1 = 0.0304, wR2 = 0.0807 
Final R indexes [all data] R1 = 0.0345, wR2 = 0.0840 
Largest diff. peak/hole / e Å-3 0.25/-0.27 
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Crystal structure of 74 
Table 3 Crystal data and structure refinement for 74. 
Empirical formula C21H20NPS 
Formula weight 349.41 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21/c 
a/Å 11.1317(2) 
b/Å 14.2985(2) 
c/Å 12.3847(2) 
α/° 90 
β/° 111.841(2) 
γ/° 90 
Volume/Å3 1829.74(6) 
Z 4 
ρcalcg/cm3 1.268 
μ/mm-1 2.388 
F(000) 736.0 
Crystal size/mm3 0.2 × 0.16 × 0.1 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.558 to 133.874 
Index ranges -13 ≤ h ≤ 12, -17 ≤ k ≤ 16, -14 ≤ l ≤ 14 
Reflections collected 13100 
Independent reflections 3248 [Rint = 0.0383, Rsigma = 0.0312] 
Data/restraints/parameters 3248/0/220 
Goodness-of-fit on F2 1.021 
Final R indexes [I>=2σ (I)] R1 = 0.0324, wR2 = 0.0812 
Final R indexes [all data] R1 = 0.0412, wR2 = 0.0873 
Largest diff. peak/hole / e Å-3 0.29/-0.22 
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Crystal structure of 75 
Table 4 Crystal data and structure refinement for 75. 
Empirical formula C17H18NPS 
Formula weight 299.35 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21/c 
a/Å 11.02573(16) 
b/Å 20.3758(3) 
c/Å 7.04987(11) 
α/° 90 
β/° 99.1072(14) 
γ/° 90 
Volume/Å3 1563.84(4) 
Z 4 
ρcalcg/cm3 1.271 
μ/mm-1 2.702 
F(000) 632.0 
Crystal size/mm3 0.36 × 0.18 × 0.11 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.122 to 134.06 
Index ranges -13 ≤ h ≤ 13, -24 ≤ k ≤ 24, -8 ≤ l ≤ 7 
Reflections collected 42773 
Independent reflections 2795 [Rint = 0.0503, Rsigma = 0.0157] 
Data/restraints/parameters 2795/0/184 
Goodness-of-fit on F2 1.063 
Final R indexes [I>=2σ (I)] R1 = 0.0288, wR2 = 0.0740 
Final R indexes [all data] R1 = 0.0325, wR2 = 0.0763 
Largest diff. peak/hole / e Å-3 0.31/-0.25 
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Crystal structure of 76 
Table 5 Crystal data and structure refinement for 76. 
Empirical formula C33H32NOPS 
Formula weight 521.63 
Temperature/K 150(2) K 
Crystal system triclinic 
Space group P1 
a/Å 10.4544(5) 
b/Å 12.6185(7) 
c/Å 12.7281(7) 
α/° 67.862(5) 
β/° 69.229(4) 
γ/° 67.350(4) 
Volume/Å3 1391.56(13) 
Z 2 
ρcalcg/cm3 1.245 
μ/mm-1 0.200 
F(000) 552 
Crystal size/mm3 0.42  0.40  0.35 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 3.1 to 28.4 
Index ranges 13 to 12, k 16 to 15, l 14 to 16 
Reflections collected 11486 
Independent reflections 5748 (Rint = 0.0149) 
Data/restraints/parameters 5748 / 0 / 355 
Goodness-of-fit on F2 1.065 
Final R indexes [I>=2σ (I)] R1 = 0.0409, wR2 = 0.1090 
Final R indexes [all data] R1 = 0.0603, wR2 = 0.1164 
Largest diff. peak/hole / e Å-3 0.30 and 0.50 
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Crystal structure 77 
Table 6 Crystal data and structure refinement for 77. 
Empirical formula C25H22NPSe 
Formula weight 446.36 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group Pbca 
a/Å 14.46942(11) 
b/Å 13.83807(10) 
c/Å 21.17154(15) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 4239.15(5) 
Z 8 
ρcalcg/cm3 1.399 
μ/mm-1 3.173 
F(000) 1824.0 
Crystal size/mm3 0.24 × 0.17 × 0.06 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.352 to 133.772 
Index ranges -17 ≤ h ≤ 17, -12 ≤ k ≤ 16, -25 ≤ l ≤ 25 
Reflections collected 57128 
Independent reflections 3774 [Rint = 0.0460, Rsigma = 0.0160] 
Data/restraints/parameters 3774/0/256 
Goodness-of-fit on F2 1.047 
Final R indexes [I>=2σ (I)] R1 = 0.0300, wR2 = 0.0809 
Final R indexes [all data] R1 = 0.0353, wR2 = 0.0850 
Largest diff. peak/hole / e Å-3 0.58/-0.57 
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Crystal structure 78 
Table 7 Crystal data and structure refinement for 78. 
Empirical formula C21H20NPSe 
Formula weight 396.31 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21/c 
a/Å 11.25631(18) 
b/Å 14.45813(18) 
c/Å 12.3901(2) 
α/° 90 
β/° 112.1141(19) 
γ/° 90 
Volume/Å3 1868.10(5) 
Z 4 
ρcalcg/cm3 1.409 
μ/mm-1 3.523 
F(000) 808.0 
Crystal size/mm3 0.24 × 0.17 × 0.15 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.48 to 133.91 
Index ranges -13 ≤ h ≤ 12, -16 ≤ k ≤ 17, -14 ≤ l ≤ 14 
Reflections collected 13781 
Independent reflections 3317 [Rint = 0.0320, Rsigma = 0.0233] 
Data/restraints/parameters 3317/0/220 
Goodness-of-fit on F2 1.033 
Final R indexes [I>=2σ (I)] R1 = 0.0251, wR2 = 0.0610 
Final R indexes [all data] R1 = 0.0322, wR2 = 0.0656 
Largest diff. peak/hole / e Å-3 0.29/-0.26 
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Crystal structure 79 
Table 8 Crystal data and structure refinement for 79. 
Empirical formula C17H18NPSe 
Formula weight 346.25 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21 
a/Å 8.5322(3) 
b/Å 8.2843(3) 
c/Å 11.2269(4) 
α/° 90 
β/° 94.181(3) 
γ/° 90 
Volume/Å3 791.44(5) 
Z 2 
ρcalcg/cm3 1.453 
μ/mm-1 2.463 
F(000) 352.0 
Crystal size/mm3 0.2079 × 0.1842 × 0.0913 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.798 to 54.952 
Index ranges -10 ≤ h ≤ 11, -10 ≤ k ≤ 10, -14 ≤ l ≤ 14 
Reflections collected 12450 
Independent reflections 3427 [Rint = 0.0470, Rsigma = 0.0501] 
Data/restraints/parameters 3427/1/184 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0326, wR2 = 0.0553 
Final R indexes [all data] R1 = 0.0418, wR2 = 0.0582 
Largest diff. peak/hole / e Å-3 0.52/-0.29 
Flack parameter -0.009(6) 
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Crystal structure 80 
Table 9 Crystal data and structure refinement for 80. 
Empirical formula C25H23NPSCl 
Formula weight 435.92 
Temperature/K 150.01(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 14.8440(2) 
b/Å 17.6553(3) 
c/Å 17.6310(3) 
α/° 90 
β/° 107.5083(17) 
γ/° 90 
Volume/Å3 4406.59(13) 
Z 8 
ρcalcg/cm3 1.314 
μ/mm-1 3.182 
F(000) 1824.0 
Crystal size/mm3 0.2442 × 0.1045 × 0.0842 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.846 to 132.742 
Index ranges -8 ≤ h ≤ 17, -20 ≤ k ≤ 20, -20 ≤ l ≤ 20 
Reflections collected 33799 
Independent reflections 7703 [Rint = 0.0458, Rsigma = 0.0351] 
Data/restraints/parameters 7703/480/529 
Goodness-of-fit on F2 1.022 
Final R indexes [I>=2σ (I)] R1 = 0.0337, wR2 = 0.0844 
Final R indexes [all data] R1 = 0.0432, wR2 = 0.0894 
Largest diff. peak/hole / e Å-3 0.46/-0.36 
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Crystal structure 81 
Table 10 Crystal data and structure refinement for 81. 
Empirical formula C26H25NPSCl 
Formula weight 449.95 
Temperature/K 150.00(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 10.0581(5) 
b/Å 22.5806(10) 
c/Å 10.3541(5) 
α/° 90 
β/° 93.929(4) 
γ/° 90 
Volume/Å3 2346.07(18) 
Z 4 
ρcalcg/cm3 1.274 
μ/mm-1 0.333 
F(000) 944.0 
Crystal size/mm3 0.3256 × 0.1642 × 0.1448 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.754 to 59.018 
Index ranges -13 ≤ h ≤ 13, -29 ≤ k ≤ 30, -13 ≤ l ≤ 14 
Reflections collected 76161 
Independent reflections 6037 [Rint = 0.0552, Rsigma = 0.0290] 
Data/restraints/parameters 6037/309/286 
Goodness-of-fit on F2 1.212 
Final R indexes [I>=2σ (I)] R1 = 0.0639, wR2 = 0.1237 
Final R indexes [all data] R1 = 0.0835, wR2 = 0.1306 
Largest diff. peak/hole / e Å-3 0.41/-0.39 
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Crystal structure 94 
Table 11 Crystal data and structure refinement for 94. 
Empirical formula C17H13P 
Formula weight 248.24 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21/n 
a/Å 11.2924(2) 
b/Å 8.81898(12) 
c/Å 13.4847(3) 
α/° 90 
β/° 113.882(2) 
γ/° 90 
Volume/Å3 1227.92(4) 
Z 4 
ρcalcg/cm3 1.343 
μ/mm-1 1.765 
F(000) 520.0 
Crystal size/mm3 0.25 × 0.17 × 0.1 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.662 to 134.01 
Index ranges -13 ≤ h ≤ 13, -10 ≤ k ≤ 10, -16 ≤ l ≤ 16 
Reflections collected 32162 
Independent reflections 2185 [Rint = 0.0380, Rsigma = 0.0119] 
Data/restraints/parameters 2185/0/169 
Goodness-of-fit on F2 1.047 
Final R indexes [I>=2σ (I)] R1 = 0.0608, wR2 = 0.1799 
Final R indexes [all data] R1 = 0.0693, wR2 = 0.1901 
Largest diff. peak/hole / e Å-3 0.39/-0.70 
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Crystal structure 95 
Table 12 Crystal data and structure refinement for 95. 
Empirical formula C20H19P 
Formula weight 290.32 
Temperature/K 150.00(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 7.5163(4) 
b/Å 29.1986(9) 
c/Å 7.5464(3) 
α/° 90 
β/° 114.466(6) 
γ/° 90 
Volume/Å3 1507.46(13) 
Z 4 
ρcalcmg/mm3 1.279 
m/mm-1 1.510 
F(000) 616.0 
Crystal size/mm3 0.263 × 0.115 × 0.051 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection 6.054 to 133.462° 
Index ranges -8 ≤ h ≤ 8, -33 ≤ k ≤ 34, -8 ≤ l ≤ 8 
Reflections collected 7524 
Independent reflections 2451 [Rint = 0.0328, Rsigma = 0.0314] 
Data/restraints/parameters 2451/6/199 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0394, wR2 = 0.1040 
Final R indexes [all data] R1 = 0.0469, wR2 = 0.1106 
Largest diff. peak/hole / e Å-3 0.33/-0.23 
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Crystal structure of 100 
Table 13 Crystal data and structure refinement for 100. 
Empirical formula C21H21O3P 
Formula weight 352.35 
Temperature/K 150.01(10) 
Crystal system triclinic 
Space group P-1 
a/Å 8.6981(3) 
b/Å 9.7858(4) 
c/Å 11.3382(4) 
α/° 90.893(3) 
β/° 102.740(3) 
γ/° 112.373(4) 
Volume/Å3 865.15(6) 
Z 2 
ρcalcg/cm3 1.353 
μ/mm-1 1.547 
F(000) 372.0 
Crystal size/mm3 0.22 × 0.19 × 0.12 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.044 to 132.52 
Index ranges -10 ≤ h ≤ 10, -11 ≤ k ≤ 11, -13 ≤ l ≤ 13 
Reflections collected 23420 
Independent reflections 3030 [Rint = 0.0339, Rsigma = 0.0151] 
Data/restraints/parameters 3030/258/249 
Goodness-of-fit on F2 1.044 
Final R indexes [I>=2σ (I)] R1 = 0.0404, wR2 = 0.1044 
Final R indexes [all data] R1 = 0.0448, wR2 = 0.1081 
Largest diff. peak/hole / e Å-3 0.39/-0.33 
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Crystal structure 102 
Table 14 Crystal data and structure refinement for 102. 
Empirical formula C20H17Br 
Formula weight 337.24 
Temperature/K 150.01(10) 
Crystal system triclinic 
Space group P-1 
a/Å 6.99019(14) 
b/Å 7.7048(2) 
c/Å 15.4327(3) 
α/° 81.785(2) 
β/° 84.5942(17) 
γ/° 65.973(2) 
Volume/Å3 750.77(3) 
Z 2 
ρcalcmg/mm3 1.492 
m/mm-1 2.728 
F(000) 344.0 
Crystal size/mm3 0.313 × 0.196 × 0.132 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection 5.828 to 52.742° 
Index ranges -8 ≤ h ≤ 8, -9 ≤ k ≤ 9, -19 ≤ l ≤ 19 
Reflections collected 36958 
Independent reflections 3071 [Rint = 0.0393, Rsigma = 0.0145] 
Data/restraints/parameters 3071/0/190 
Goodness-of-fit on F2 1.107 
Final R indexes [I>=2σ (I)] R1 = 0.0185, wR2 = 0.0492 
Final R indexes [all data] R1 = 0.0200, wR2 = 0.0500 
Largest diff. peak/hole / e Å-3 0.29/-0.31 
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Crystal structure 103. 
Table 15 Crystal data and structure refinement for 103. 
Empirical formula C24H27O3P 
Formula weight 394.42 
Temperature/K 150.01(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 8.1515(4) 
b/Å 26.7594(10) 
c/Å 9.5127(5) 
α/° 90 
β/° 106.984(5) 
γ/° 90 
Volume/Å3 1984.50(17) 
Z 4 
ρcalcmg/mm3 1.320 
m/mm-1 0.161 
F(000) 840.0 
Crystal size/mm3 0.232 × 0.182 × 0.152 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection 6 to 52.73° 
Index ranges -10 ≤ h ≤ 10, -33 ≤ k ≤ 33, -11 ≤ l ≤ 11 
Reflections collected 16477 
Independent reflections 4045 [Rint = 0.0342, Rsigma = 0.0299] 
Data/restraints/parameters 4045/0/255 
Goodness-of-fit on F2 1.020 
Final R indexes [I>=2σ (I)] R1 = 0.0391, wR2 = 0.0949 
Final R indexes [all data] R1 = 0.0502, wR2 = 0.1011 
Largest diff. peak/hole / e Å-3 0.27/-0.47 
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Crystal structure 116 
Table 16 Crystal data and structure refinement for 116. 
Empirical formula C48H45Cl2P3Pt 
Formula weight 980.74 
Temperature/K 150.0(2) 
Crystal system triclinic 
Space group P-1 
a/Å 9.3188(3) 
b/Å 16.0163(7) 
c/Å 16.0188(8) 
α/° 114.587(4) 
β/° 95.249(3) 
γ/° 106.127(3) 
Volume/Å3 2028.99(16) 
Z 2 
ρcalcg/cm3 1.605 
μ/mm-1 9.055 
F(000) 980.0 
Crystal size/mm3 0.09 × 0.08 × 0.02 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.246 to 134.194 
Index ranges -10 ≤ h ≤ 9, -19 ≤ k ≤ 19, -19 ≤ l ≤ 18 
Reflections collected 29025 
Independent reflections 7166 [Rint = 0.0775, Rsigma = 0.0688] 
Data/restraints/parameters 7166/158/499 
Goodness-of-fit on F2 0.987 
Final R indexes [I>=2σ (I)] R1 = 0.0348, wR2 = 0.0619 
Final R indexes [all data] R1 = 0.0547, wR2 = 0.0685 
Largest diff. peak/hole / e Å-3 1.25/-0.66 
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Crystal structure 120 
Table 17 Crystal data and structure refinement for 120. 
Empirical formula C48H45Cl2P3Pd 
Formula weight 892.05 
Temperature/K 150.0(2) 
Crystal system triclinic 
Space group P-1 
a/Å 9.3424(3) 
b/Å 15.9663(7) 
c/Å 15.9893(5) 
α/° 114.613(4) 
β/° 95.230(3) 
γ/° 106.190(3) 
Volume/Å3 2022.80(16) 
Z 2 
ρcalcg/cm3 1.465 
μ/mm-1 0.744 
F(000) 916.0 
Crystal size/mm3 0.25 × 0.16 × 0.12 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.878 to 57.46 
Index ranges -12 ≤ h ≤ 12, -19 ≤ k ≤ 19, -19 ≤ l ≤ 21 
Reflections collected 32276 
Independent reflections 8975 [Rint = 0.0416, Rsigma = 0.0458] 
Data/restraints/parameters 8975/599/523 
Goodness-of-fit on F2 1.036 
Final R indexes [I>=2σ (I)] R1 = 0.0373, wR2 = 0.0749 
Final R indexes [all data] R1 = 0.0528, wR2 = 0.0820 
Largest diff. peak/hole / e Å-3 0.53/-0.44 
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Crystal structure 121 
Table 18 Crystal data and structure refinement for 121. 
Empirical formula C48H45Cl2NiP3 
Formula weight 844.36 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21/n 
a/Å 19.5203(3) 
b/Å 7.39919(9) 
c/Å 28.7444(4) 
α/° 90 
β/° 107.6135(14) 
γ/° 90 
Volume/Å3 3957.04(9) 
Z 4 
ρcalcg/cm3 1.417 
μ/mm-1 3.359 
F(000) 1760.0 
Crystal size/mm3 0.27 × 0.18 × 0.08 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 4.868 to 133.962 
Index ranges -22 ≤ h ≤ 23, -8 ≤ k ≤ 8, -34 ≤ l ≤ 32 
Reflections collected 29006 
Independent reflections 7017 [Rint = 0.0494, Rsigma = 0.0377] 
Data/restraints/parameters 7017/0/487 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0344, wR2 = 0.0835 
Final R indexes [all data] R1 = 0.0472, wR2 = 0.0920 
Largest diff. peak/hole / e Å-3 0.43/-0.23 
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Crystal structure 155 
Table 19 Crystal data and structure refinement for 155. 
Empirical formula C71H111BBr3CuN6O6P 
Formula weight 1489.70 
Temperature/K 150.0(2) 
Crystal system triclinic 
Space group P-1 
a/Å 12.7536(3) 
b/Å 16.2685(3) 
c/Å 22.2666(4) 
α/° 103.401(2) 
β/° 93.393(2) 
γ/° 102.018(2) 
Volume/Å3 4367.51(16) 
Z 2 
ρcalcg/cm3 1.133 
μ/mm-1 2.478 
F(000) 1562.0 
Crystal size/mm3 0.27 × 0.08 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.132 to 133.77 
Index ranges -15 ≤ h ≤ 15, -19 ≤ k ≤ 19, -26 ≤ l ≤ 26 
Reflections collected 61659 
Independent reflections 15402 [Rint = 0.0495, Rsigma = 0.0406] 
Data/restraints/parameters 15402/1111/1010 
Goodness-of-fit on F2 1.032 
Final R indexes [I>=2σ (I)] R1 = 0.0611, wR2 = 0.1668 
Final R indexes [all data] R1 = 0.0746, wR2 = 0.1790 
Largest diff. peak/hole / e Å-3 1.97/-1.22 
 
